<SEC-DOCUMENT>0001171843-19-002946.txt : 20190506
<SEC-HEADER>0001171843-19-002946.hdr.sgml : 20190506
<ACCEPTANCE-DATETIME>20190503190534
ACCESSION NUMBER:		0001171843-19-002946
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190506
DATE AS OF CHANGE:		20190503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		19797709

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_050319p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 12pt"><b>UNITED
STATES</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 12pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 12pt"><b>FORM&nbsp;10-Q</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&nbsp;</font></td>
    <td style="width: 96%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the quarterly period ended March
31, 2019</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</font></td>
    <td style="width: 96%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number 000-21326</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 11pt"><b>Anika
Therapeutics,&nbsp;Inc.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></font></td>
    <td style="width: 50%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>04-3145961</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation or Organization)</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32 Wiggins Avenue, Bedford, Massachusetts</b></font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>01730</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(781)&nbsp;457-9000</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name, Former Address and Former
Fiscal Year, if Changed Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Securities registered pursuant to Section 12(b) of the Act:</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I></I></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Title of Each Class</I></P></TD>
    <TD STYLE="width: 34%">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I></I></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Trading Symbol</I></P></TD>
    <TD STYLE="width: 33%">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I></I></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Name of Each Exchange on Which Registered</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Common Stock, par value $0.01 per share</P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">ANIK</P></TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">NASDAQ Global Select Market</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15 (d)&nbsp;of the
Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required
to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days. Yes </font><font style="font-family: Wingdings">x</font>
<font style="font-family: Times New Roman, Times, Serif">&nbsp;No </font><font style="font-family: Wingdings">o</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule&nbsp;405
of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes </font><font style="font-family: Wingdings">x</font> <font style="font-family: Times New Roman, Times, Serif">No
</font><font style="font-family: Wingdings">o</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 15%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&nbsp; &#9744;</font></td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 13%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;&#9746;</font></td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer&nbsp;&#9744;</font></td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 18%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Smaller reporting</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">company&nbsp;&#9744;</p></td>
    <td style="vertical-align: top; width: 18%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Emerging growth</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">company&nbsp;&#9744;</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule&nbsp;12b-2 of the Exchange Act). Yes&nbsp; &#9744; &nbsp;No&nbsp; &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APPLICABLE ONLY TO CORPORATE ISSUERS:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 22, 2019, there were 14,206,920 outstanding shares
of Common Stock, par value $.01&nbsp;per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p><p style="margin: 0pt"></p><p style="margin: 0pt"></p><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANIKA THERAPEUTICS,&nbsp;INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></td>
    <td style="width: 87%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></td>
    <td style="width: 5%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Page</b></p></td></tr>
<tr style="vertical-align: top">
    <td><a href="#a_001"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part&nbsp;I</font></a></td>
    <td><a href="#a_001"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</font></a></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_002"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.</font></a></td>
    <td><a href="#a_002"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements (unaudited):</font></a></td>
    <td style="text-align: center"><a href="#a_002"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_003"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets as of
    March 31, 2019 and December 31, 2018 </font></a></td>
    <td style="text-align: center"><a href="#a_003"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_004"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations
    and Comprehensive Income for the three-months ended March 31, 2019 and 2018</font></a></td>
    <td style="text-align: center"><a href="#a_004"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_005"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Stockholders&#8217;
    Equity for the three-months ended March 31, 2019 and 2018</font></a></td>
    <td style="text-align: center"><a href="#a_005"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_006"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows
    for the three-months ended March 31, 2019 and 2018</font></a></td>
    <td style="text-align: center"><a href="#a_006"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_007"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements</font></a></td>
    <td style="text-align: center"><a href="#a_007"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_008"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;2.</font></a></td>
    <td><a href="#a_008"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of
    Financial Condition and Results of Operations</font></a></td>
    <td style="text-align: center"><a href="#a_008"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_009"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;3.</font></a></td>
    <td><a href="#a_009"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About
    Market Risk</font></a></td>
    <td style="text-align: center"><a href="#a_009"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_010"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;4.</font></a></td>
    <td><a href="#a_010"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</font></a></td>
    <td style="text-align: center"><a href="#a_010"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td><a href="#a_011"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part&nbsp;II</font></a></td>
    <td><a href="#a_011"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</font></a></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_012"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.</font></a></td>
    <td><a href="#a_012"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</font></a></td>
    <td style="text-align: center"><a href="#a_012">19</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_013"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1A.</font></a></td>
    <td><a href="#a_013"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</font></a></td>
    <td style="text-align: center"><a href="#a_013"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_014"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</font></a></td>
    <td><a href="#a_014"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and
    Use of Proceeds</font></a></td>
    <td style="text-align: center"><a href="#a_014"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 10pt"><a href="#a_015"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;6.</font></a></td>
    <td><a href="#a_015"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</font></a></td>
    <td style="text-align: center"><a href="#a_015"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></a></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><a href="#a_016"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</font></a></td>
    <td style="text-align: center"><a href="#a_016"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">References in this Quarterly Report on
Form 10-Q to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; and other similar references refer
to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ANIKA, ANIKA THERAPEUTICS, CINGAL, HYAFF, MONOVISC, and ORTHOVISC
are our registered trademarks. This Quarterly Report on Form 10-Q also contains registered marks, trademarks, and trade names that
are the property of other companies and licensed to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p><p style="margin: 0pt"></p><p style="margin: 0pt"></p><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_001"></a>PART I:</b></font></td>
    <td style="width: 90%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INFORMATION</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%"><a name="a_002"></a><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1.</b></font></td>
    <td style="width: 90%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL STATEMENTS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><a name="a_003"></a>Condensed Consolidated Balance Sheets</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except per share data)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">ASSETS</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br> 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br> 2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current assets:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">95,514</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">89,042</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Investments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">71,222</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">69,972</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts receivable, net of reserves of $1,210 and $1,525 at March 31, 2019 and December 31, 2018, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18,265</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20,775</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Inventories, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,617</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">21,300</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,077</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,854</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Total current assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">209,695</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">202,943</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Property and equipment, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">53,051</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">54,111</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23,748</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other long-term assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,003</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,897</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Intangible assets, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,467</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,191</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Goodwill</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,695</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,851</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">306,659</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">278,993</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -10pt; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,571</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,143</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,031</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,146</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total current liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,602</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,289</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other long-term liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">366</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">550</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred tax liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,388</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,542</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Lease liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,232</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Commitments and contingencies (Note 13)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&#8217; equity:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred stock, $.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $.01 par value; 60,000 shares authorized, 14,214 and 14,210 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">142</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">142</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in-capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">52,030</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">50,763</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated other comprehensive loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(5,841</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(5,526</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Retained earnings</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">222,740</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">218,233</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">269,071</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">263,612</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">306,659</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">278,993</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><a name="a_004"></a>Condensed Consolidated Statements of Operations and Comprehensive Income</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except per share data)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product revenue</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">24,717</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,258</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Licensing, milestone and contract revenue</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Total revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">24,723</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">21,264</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Cost of product revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,311</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,845</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Research&nbsp;&amp; development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,258</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,161</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Selling, general&nbsp;&amp; administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,672</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,090</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,241</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,096</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Income (loss) from operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,482</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,832</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Interest and other income, net</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">498</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">95</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Income (loss) before income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,980</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,737</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Provision for (benefit from) income taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,473</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,051</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,507</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,686</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Basic net income (loss) per share:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net income (loss)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.32</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.46</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Basic weighted average common shares outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,185</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,679</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Diluted net income (loss) per share:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net income (loss)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.31</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.46</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Diluted weighted average common shares outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,314</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,679</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net income (loss)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,507</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,686</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(315</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">620</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Comprehensive income (loss)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,192</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,066</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><a name="a_005"></a>Condensed Consolidated Statements of Stockholders' Equity</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(in thousands)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="23" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended March 31, 2019</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">$.01 Par</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Additional Paid</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Retained</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Comprehensive</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Stockholders'</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">in Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Earnings</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, January 1, 2019</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">14,210</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">142</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">50,763</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">218,233</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">(5,526</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">263,612</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Issuance of common stock for equity awards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Retirement of common stock for minimum tax withholdings</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(124</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(124</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,386</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,386</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net income</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,507</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,507</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other comprehensive loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(315</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(315</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2019</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,214</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,030</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222,740</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,841</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,071</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="23" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended March 31, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">$.01 Par</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Additional Paid</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Retained</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Comprehensive</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Stockholders'</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">in Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Earnings</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, January 1, 2018</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">14,688</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">147</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">68,617</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">199,511</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">(4,784</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 7%; border-bottom: Black 2.5pt double; text-align: right">263,491</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Issuance of common stock for equity awards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">89</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">511</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">512</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Retirement of common stock for minimum tax withholdings</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(32</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,735</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,736</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,565</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,565</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(6,686</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(6,686</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other comprehensive income</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">620</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">620</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance, March 31, 2018</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,745</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,958</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">192,825</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,164</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">263,766</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><a name="a_006"></a>Condensed Consolidated Statements of Cash Flows</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(in thousands)</p>

<p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows from operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net income (loss)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,507</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(6,686</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,477</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,473</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Amortization of right-of-use assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">297</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Loss on disposal of fixed assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">721</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">142</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Loss on impairment of intangible asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">281</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Stock-based compensation expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,386</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,565</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Deferred income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(124</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(75</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Provision for inventory</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">381</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,246</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Accretion to amortized cost of investments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(363</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Changes in operating assets and liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Accounts receivable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,489</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,730</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Inventories</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,617</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3,924</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Prepaid expenses, other current and long-term assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(182</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">509</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Accounts payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">496</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(180</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Lease liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(269</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 40pt">Accrued expenses, other current and long-term liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,928</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,270</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Income taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">910</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,478</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net cash provided by operating activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,462</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,592</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows from investing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from maturity of investments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">58,094</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">15,250</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchase of investments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(58,981</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,500</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,030</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,543</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net cash (used in) provided by investing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,917</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">207</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows from financing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash paid for tax withheld on vested restricted stock awards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(124</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,735</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Proceeds from exercise of equity awards</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">512</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net cash (used in) financing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(119</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,223</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Exchange rate impact on cash</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">46</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Increase in cash and cash equivalents</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,472</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,541</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,042</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">133,256</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95,514</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,797</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt">Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">24,110</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Non-cash investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; text-indent: -10pt">Purchases of property and equipment included in accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">246</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">207</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE></div>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;The accompanying notes are an
integral part of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANIKA THERAPEUTICS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><a name="a_007"></a><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(amounts in thousands, except share and
per share amounts or as otherwise noted)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<b>unaudited</b>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></font></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of Business</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Anika Therapeutics, Inc. (the &#8220;Company&#8221;)
is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative
pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing,
and commercializing products based on its proprietary Hyaluronic Acid (&#8220;HA&#8221;) technology. The Company&#8217;s orthopedic
medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company is subject to risks common to
companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing
and new products, and compliance with U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulations and approval
requirements, as well as the ability to grow the Company&#8217;s business through appropriate commercial strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></font></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited
condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&nbsp;and
regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and in accordance with accounting principles generally
accepted in the United States (&#8220;US GAAP&#8221;). The financial statements include the accounts of Anika Therapeutics, Inc.
and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures
normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to
SEC rules and regulations relating to interim financial statements. The December 31, 2018 balances reported herein are derived
from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited
condensed consolidated financial statements and related notes should be read in conjunction with the Company&#8217;s annual financial
statements filed with its Annual Report on Form&nbsp;10-K for the year ended December 31, 2018. The results of operations for the
three-month period ended March 31, 2019 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31,
2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recent Accounting Pronouncements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards
Update (&ldquo;ASU&rdquo;) No. 2016-02, <I>Leases</I> (Topic 842), which, among other things, results in the recognition of lease
assets and lease liabilities by lessees on the Company&rsquo;s balance sheets for virtually all leases. ASU 2016-02 supersedes
most previous lease accounting guidance and is effective for interim and annual periods beginning after December 15, 2018. The
Company adopted the new guidance as of January 1, 2019 using the modified retrospective adoption method in which it did not restate
prior periods. The adoption of this standard did not have a material impact on the condensed consolidated statement of operations.
See Note 12 for further details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In August 2018, the FASB issued ASU No. 2018-15,&nbsp;<I>Intangibles
&ndash; Goodwill and Other &ndash; Internal-Use Software&nbsp;(Subtopic 350-40)</I>, which amends ASU No. 2015-05,&nbsp;Customers
Accounting for Fees in a Cloud Computing Agreement,&nbsp;to help entities evaluate the accounting for fees paid by a customer in
a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software
license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement
that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use
software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU 2018-15 require
an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation
costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal
years and interim periods beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period
for all entities. The Company is assessing ASU 2018-15 and the impact that adopting this new accounting standard will have on its
consolidated financial statements and footnote disclosures.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></font></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company receives
payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as
deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company
performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to
consideration is unconditional. As of March 31, 2019, deferred revenue was $67 thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has agreements
with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (&#8220;Mitek&#8221;) that include the grant of
certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent
72% and 76% of total Company revenues for the three-month periods ended March 31, 2019 and March 31, 2018, respectively. The Company
has agreements with other customers that may include the delivery of a license and supply of product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables
provide the disaggregated revenue by major product group and primary geographical market. Product revenue by product group was
as follows:&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Orthobiologics</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,748</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">19,489</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Surgical</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,392</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,245</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dermal</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">129</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(539</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,448</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,063</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Product Revenue</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,717</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,258</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Total revenue by geographic
location was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Revenue</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br> Revenue</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br> Revenue</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br> Revenue</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Geographic Location:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left; padding-left: 10pt">United States</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,089</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">81</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,910</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">80</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Europe</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,526</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,391</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,108</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,963</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Revenue</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,723</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,264</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 2, 2018, the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products,
HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that
the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication
of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary
measure. During the three-month period ended March 31, 2018, the Company recorded a revenue reserve for this voluntary recall of
$1.1 million of which $0.9 million was related to revenue recorded in prior periods. The adjustments related to the initial revenue
reserve subsequent to March 31, 2018 were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and
all geographic locations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></font></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investments</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All of the Company&rsquo;s investments are carried
at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related
income taxes. The Company held investments, including U.S. treasury bills totaling $71.2 million and $70.0 million as of March
31, 2019 and December 31, 2018, respectively. Unrealized gains and losses as well as the associated tax impact on the Company&rsquo;s
available-for-sale securities were immaterial as of March 31, 2019 and December 31, 2018.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></font></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company&rsquo;s investments are all classified
within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents,
current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity
of these instruments, and therefore fair value information is not included in the table below.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy
of the Company's cash equivalents and investments at fair value was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br> Active Markets<br> &nbsp;for Identical Assets&nbsp;<br> &nbsp;(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br> &nbsp;Observable Inputs&nbsp;<br> &nbsp;(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br> &nbsp;Unobservable Inputs&nbsp;<br> &nbsp;(Level 3)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash equivalents:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,147</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,147</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,147</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Investments:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,221</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,221</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,221</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br> Active Markets<br> &nbsp;for Identical Assets&nbsp;<br> &nbsp;(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br> &nbsp;Observable Inputs&nbsp;<br> &nbsp;(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br> &nbsp;Unobservable Inputs&nbsp;<br> &nbsp;(Level 3)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash equivalents:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,984</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,984</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8211;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,984</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Investments:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,972</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,972</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,972</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><b>6.</b></td>
    <td style="width: 7px"><b>&nbsp;</b></td>
    <td style="text-align: justify"><b>Equity Incentive Plan</b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates
the fair value of stock options and stock appreciation rights (&#8220;SARs&#8221;) using the Black-Scholes valuation model. Fair
value of restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) are measured by the grant-date
price of the Company&#8217;s shares. Fair value of performance restricted stock units (&#8220;PSUs&#8221;) is measured by the grant-date
price of the Company&#8217;s shares with corresponding compensation cost recognized over the requisite service period. Compensation
cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment
and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in
the period of the change. If the performance targets are not achieved, no compensation cost is recognized and any previously recognized
compensation cost is reversed.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of each
stock option award during the three-month periods ended March 31, 2019 and 2018 was estimated on the grant date using the Black-Scholes
option-pricing model with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&nbsp;</td>
    <td style="text-align: right">2.44%</td><td style="text-align: center"> - </td><td style="white-space: nowrap; text-align: left">2.54%</td><td>&nbsp;</td>
    <td style="text-align: right">2.15%</td><td style="text-align: center"> - </td><td style="white-space: nowrap; text-align: left">2.37%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&nbsp;</td>
    <td style="text-align: right">44.34%</td><td style="text-align: center"> - </td><td style="white-space: nowrap; text-align: left">44.41%</td><td>&nbsp;</td>
    <td style="text-align: right">38.74%</td><td style="text-align: center"> - </td><td style="white-space: nowrap; text-align: left">40.81%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Expected life (years)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 4%; text-align: right">&nbsp;</td><td style="width: 5%; text-align: center">3.5</td><td style="white-space: nowrap; width: 5%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 5%; text-align: right">&nbsp;</td><td style="width: 4%; text-align: center">4.5</td><td style="white-space: nowrap; width: 5%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td style="text-align: center">0.00%</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td style="text-align: center">0.00%</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
$1.4 million and $7.6 million of stock-based compensation expense for the three-month periods ended March 31, 2019 and 2018, respectively.
Upon the retirement of the Company&#8217;s former Chief Executive Officer on March 9, 2018, all of his outstanding stock-based
compensation awards vested in full and became exercisable in accordance with their terms, resulting in a one-time expense of $6.2
million that was fully recognized during the three-month period ended March 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company presents
the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its
employees as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Cost of product revenue</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">92</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(216</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research&nbsp;&amp; development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">177</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">210</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Selling, general&nbsp;&amp; administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,117</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,571</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,386</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,565</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth share information for stock-based compensation awards granted and exercised during the three-month periods ended March
31, 2019 and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grants:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left; padding-left: 10pt">Stock Options</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">104,292</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">192,300</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">RSAs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">64,578</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">RSUs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">165,507</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,130</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">PSUs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">114,500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercises:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock Options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,425</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">SARs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">During the three-month period ended March 31, 2019, the Company granted stock-based compensation awards in the
form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable
or vest ratably over a three-year period. The PSUs granted to employees contained performance conditions with business and financial
targets. The business target, amounting to 30% of the total performance conditions, will be measured based on achievement in the
2019 fiscal year, while the financial targets, amounting to 70% of the total performance conditions, will ultimately be measured
with respect to the Company&rsquo;s operating results in the 2021 fiscal year. The Company recorded $0.1 million of stock-based
compensation expense associated with PSUs for the three-month period ended March 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p><div data-td-statement-type="note"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify; width: 47px"><b>7.</b></td>
    <TD STYLE="width: 7px"><b>&nbsp;</b></td>
    <TD STYLE="text-align: justify"><b>Earnings
Per Share (&#8220;EPS&#8221;)</b></td></tr>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic EPS is calculated
by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although
legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS
is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of
outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">The
following table provides share information used in the calculation of the Company's basic and diluted earnings (loss) per share
(in thousands):</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Shares used in the calculation of basic earnings per share</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">14,185</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">14,679</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of dilutive securities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options, SARs, RSAs, RSUs and PSUs</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted shares used in the calculation of earnings per share</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,314</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,679</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Stock options to purchase 1.0 million shares
for the three-month period ended March 31, 2019 were excluded from the computation of diluted EPS as their effect would have been
anti-dilutive. For the three months ended March 31, 2018, the net loss available to common stockholders is divided by the weighted
average number of common shares outstanding during the period to calculate basic earnings per share. The assumed exercise of stock
options at March 31, 2018 would have been anti-dilutive.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></font></td></tr></table><div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventories</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventories consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br> 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br> 2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Raw materials</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,751</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13,688</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work-in-process</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,972</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,626</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,536</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,819</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,259</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,133</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Inventories</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,617</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,300</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other long-term assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,642</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,833</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other long-term assets
include $3.6 million and $3.8 million of inventory expected to remain on hand beyond one year as of March 31, 2019 and December
31, 2018, respectively.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intangible Assets</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets as
of March 31, 2019 and December 31, 2018 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">March 31, 2019</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">December 31, 2018</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Gross Value</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <BR>
Currency <BR>
Translation<BR>
 Adjustment</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Impairment</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <BR>
Amortization</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <BR>
Value</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <BR>
Currency <BR>
Translation<BR>
 Adjustment</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <BR>
Amortization</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <BR>
Value</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">Useful Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 21%">Developed technology</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">17,100</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">(2,929</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">(281</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">(8,927</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">4,963</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">(2,824</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">(8,672</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">5,604</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt; text-align: center">15</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">In-process research &amp; development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,406</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,232</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,174</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,168</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,238</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Indefinite</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Distributor relationships</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(415</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,285</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(415</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,285</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Patents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(176</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(494</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">330</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(169</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(482</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">349</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">16</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Elevess trade name</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,206</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,752</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(281</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(14,706</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,467</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,576</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(14,439</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,191</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-taggable-table=""></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate amortization
expense related to intangible assets was $0.3 million for the three-month periods ended March 31, 2019 and 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
a $0.3 million impairment charge for the HYALOSPINE developed technology asset in the three-month period ended March 31, 2019.
HYALOSPINE was an adhesion prevention gel for use after spinal surgery, and received initial CE Mark approval in January 2015.
In March 2019, the Company made the decision not to renew the CE Mark as the product was not aligned with the Company&#8217;s core
strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general &amp; administrative
expenses on our condensed consolidated statements of operations.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Through March 31, 2019, except as set forth in this paragraph, there have not been any other events or changes
in circumstances that indicate that the carrying value of the other acquired intangible assets may not be recoverable. The Company
was notified by the distributor of MEROGEL INJECTIBLE that it would not continue to order the product from the Company or market
the product. As a result, the depreciation schedule of the remaining $0.1 million of net book value was accelerated. The Company
continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions,
to assess the potential for the fair value of the reporting unit to decline below its recorded amount.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p><div data-td-statement-type="note"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify; width: 47px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill</b></font></td></tr>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company completed
its annual impairment review as of November 30, 2018 and concluded that no impairment in the carrying value of goodwill exists
as of that date. Through March 31, 2019, there have been no events or changes in circumstances that indicate that the carrying
value of goodwill may not be recoverable. Changes in the carrying value of goodwill were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br> 2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">Balance at January 1, 2019</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,851</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(156</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2019</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,695</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued Expenses</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Accrued expenses consist of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br> 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br> 2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Compensation and related expenses</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,563</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,446</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,810</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,989</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research grants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">392</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">400</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Clinical trial costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">419</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">577</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,296</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">385</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability - current</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,075</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">476</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">349</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,031</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,146</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included in Compensation
and related expenses as of March 31, 2019 are the accrued and unpaid costs related to the retirement of the Company&#8217;s former
Chief Executive Officer as of March 9, 2018. On the same date, the Company and the former Chief Executive Officer entered into
a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive
Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of $1.7 million over the 18-month
period subsequent to March 9, 2018, among other benefits. The unpaid amounts under these agreements are included in accrued expenses.
As more fully described in Note 6, all of the former Chief Executive Officer&#8217;s outstanding equity awards vested in full and
became exercisable upon his retirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div data-td-statement-type="note"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify; width: 47px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Leases</b></font></td></tr>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company adopted Topic 842 as of January
1, 2019 using the modified retrospective adoption method, which did not require it to restate prior periods. The Company has elected
the transition relief package of practical expedients permitted within Topic 842. Accordingly, the Company has not reassessed the
classification of its existing leases as of the transition date, whether existing contracts at the transition date contain a lease,
or whether unamortized initial direct costs before the transition adjustments would have met the definition of initial direct costs
at lease commencement. The Company also applied practical expedients to not separate lease and nonlease components for all new
leases as well as leases commencing before the effective date if certain criteria are met, and does not record leases on its balance
sheet with terms of twelve months or less. Lease expense associated with leases with terms of twelve months or less are immaterial
and recognized as incurred. The Company has included options to extend in the terms of its leases where it is reasonably certain
that it will exercise these options.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the inception of an arrangement the
Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term
greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable,
long-term lease liabilities. Lease liabilities and the corresponding right-of-use assets are recorded based on the present
values of lease payments over the expected lease terms. The interest rate implicit in lease contracts is typically not
readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that
would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar
economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are
recognized as incurred. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs
paid or incentives received. If significant events, changes in circumstances, or other events indicate that the lease term or
other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised
inputs as of the reassessment date, and adjust the right-of-use asset.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company leases approximately 134,000 square
feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts, and approximately 33,000 square
feet of office, research and development, training, and warehousing space in Padova, Italy. The current term of the Bedford lease
extends to 2022 with several extension options, and the current term of the Padova lease extends to 2026.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company identified and assessed significant
assumptions in recognizing the right-of-use asset and lease liability on January 1, 2019 as follows:</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Incremental borrowing
rate</i>. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining
the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would
have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company&#8217;s
lease agreements do not provide implicit rates. As the Company did not have any external borrowings at the transition date with
comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line
of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based
on the impact of collateral over the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Lease and nonlease components. </I>The Company
is required to pay variable fees for operating expenses in addition to monthly base rent for certain operating leases. The amounts
of additional rent associated with these fees are considered nonlease components. The Company has elected the practical expedient
which allows nonlease components in a contract to be accounted for as part of a single lease component to which they relate. Any
variable components of these operating costs are excluded from lease payments and are recognized in the period incurred.</P>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Extension Options.</i>
The terms of the Company&#8217;s leases include options to extend the lease term. As of the transition date to Topic 842 the Company
has included extension options reasonably certain to be exercised in the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense and other
information are as follows:&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ending <br>
March 31, 2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">522</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease cost</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Variable Lease Cost</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">52</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">576</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other information</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flows from operating leases</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">497</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">17.6</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4.1</td><td style="white-space: nowrap; text-align: left">%</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Future minimum commitments due under these
lease agreements as of March 31, 2019 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; padding-left: 10pt; text-indent: -10pt">Years ending December 31,</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Operating Lease Obligation</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left; padding-left: 10pt; text-indent: -10pt">2019 (remaining 9 months)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,490</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,025</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,024</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">2022</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,981</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">2023</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,965</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Thereafter</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23,530</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Present value adjustment</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,708</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Present value of lease payments</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td><TD STYLE="text-align: right">23,307</td><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Less current portion included in Accrued expenses and other current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,075</TD><TD STYLE="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,232</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments and Contingencies</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain of its contracts,
the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the
time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate,
or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any
third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in
any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by
the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure
to these risks. Based on the Company&#8217;s historical activity, in combination with its liability insurance coverage, the Company
believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties as of
March 31, 2019 or December 31, 2018, and has no history of claims paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also
involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these
legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings
to have a material adverse effect on its financial position, results of operations, or cash flow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></font></td></tr></table><div data-td-statement-type="note"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 47px; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The provision for income taxes was $1.5 million
for the three-month period ended March 31, 2019, based on an effective tax rate of 24.6%.&nbsp;The benefit from income taxes was
$1.1 million for the three-month period ended March 31, 2018, based on an effective tax benefit rate of (13.6%). The net increase
in the effective tax rate for the three-month period ended March 31, 2019, as compared to the same period in 2018, was primarily
due to the windfall tax benefit the Company realized in March 2018 due to limitations on the deductibility of executive compensation
for accelerated stock vesting upon the retirement of its former Chief Executive Officer on March 9, 2018. The Company realized
an immaterial shortfall for the three-month period ended March 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company files income
tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.&nbsp; The associated tax filings remain
subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings
relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the preparation of the financial statements, the Company assesses whether it was more likely than not that it would be able to
utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded
that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets not otherwise subject to a valuation
allowance are realizable on a &#8220;more likely than not&#8221; basis. As such, the Company did not record a valuation allowance
as of March 31, 2019 or December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_008"></a>ITEM 2.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (amounts in thousands, except per share amounts or as otherwise noted)</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read the
following discussion in conjunction with our financial statements and related notes appearing elsewhere in this report. In addition
to historical information, this report contains "forward-looking statements" within the meaning of Section&nbsp;27A of
the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934 concerning our business, consolidated financial
condition, and results of operations. The Securities and Exchange Commission ("SEC") encourages companies to disclose
forward-looking statements so that investors can better understand a company&#8217;s prospects and make informed investment decisions.
Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual
results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements can be identified by such words as "will," "likely," "may," "believe,"
"expect," "anticipate," "intend," "seek," "designed," "develop," "would,"
"future," "can," "could," and other expressions that are predictions of or indicate future events
and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this
report regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements.
Examples of forward-looking statements include, among others, statements regarding expected future operating results, expectations
regarding the timing and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect
on our financial condition of claims, litigation, and governmental and regulatory proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Please also refer to those factors described
in Part II, Item 1A &ldquo;Risk Factors&rdquo; of our Annual Report on Form 10-K for the year ended December 31, 2018 for important
factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking
statement made by us in this report is based only on information currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a global, integrated
orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases
and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative
tissue repair. We have over two decades of global expertise developing, manufacturing, and commercializing our products based on
our proprietary hyaluronic acid (&#8220;HA&#8221;) technology. Our orthopedic medicine portfolio includes ORTHOVISC, MONOVISC,
and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold
to aid cartilage repair and regeneration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our therapeutic offerings
consist of products in the following areas: Orthobiologics, Dermal, Surgical, and Other, which includes our ophthalmic and veterinary
products. All of our products are based on HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its
unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection
and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules
to and within cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technologies
for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. Our patented technology
chemically modifies HA to allow for longer residence time in the body. We also offer products made from HA based on two other technologies:
HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.&nbsp;Our technologies are protected by an extensive
portfolio of owned and licensed patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception
in 1992, we have utilized a commercial partnership model for the distribution of our products to end-users. Our strong, worldwide
network of distributors has historically provided, and continues to provide, a solid foundation for our revenue growth and territorial
expansion. For near-term and long-term opportunities in the U.S. market, especially with respect to surgical products utilized
in an operating room environment, we have evaluated a potential hybrid commercial approach that would see us balance a small direct
model with an optimal form of strategic partnership, an approach we intend to utilize for the commercialization of our injectable,
HA-based surgical bone repair product. For longer-term future products in the U.S. market, we intend to evaluate the appropriate
commercial model for each instance on a case-by-case basis, based on market dynamics, product type and other factors. These models
could include direct sales, distribution partnerships, or a hybrid of those forms. We believe that the combination of the direct
and distribution commercial models will maximize the revenue potential from our current and future product portfolio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see the section
captioned &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Management
Overview&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2018, for a description of each of the above
therapeutic areas, including the individual products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 2, 2018, we
publicly disclosed a voluntary recall of certain production lots of our HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX.
We communicated with all affected distributors in advance of that announcement, and we are taking all required or otherwise appropriate
actions with respect to applicable regulatory bodies. We initiated the recall following internal quality testing, which indicated
that the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication
of any safety or efficacy issue related to the products, we are committed to the highest standards of quality and removed the products
from the field as a precautionary measure. During the fourth quarter of 2018, we resolved this matter and resumed shipment of these
products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts primarily consist of the development of new medical applications for our HA-based technology, the management of clinical
trials for certain product candidates, the preparation and processing of applications for regulatory approvals or clearances at
all relevant stages of product development, and process development and scale-up manufacturing activities for our existing and
new products. Our development focus is orthopedic and regenerative medicine and includes products for tissue protection, repair,
and regeneration. We anticipate that we will continue to commit significant resources in the near future to research and development
activities, including in relation to preclinical activities and clinical trials. These activities are aimed at the delivery of
a steady cascade of new product development and launches over the next several years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our third generation, single-injection osteoarthritis
product under development in the United States, CINGAL, which is composed of our proprietary cross-linked HA material combined
with an approved steroid and is designed to provide both short- and long-term pain relief to patients, is a main pipeline product
and a component of our growth strategy. We completed an initial CINGAL Phase III clinical trial, including the associated statistical
analysis for 368 enrolled patients, during the fourth quarter of 2014 with data indicating that the product met all primary and
secondary endpoints relative to placebo set forth for the trial. During the first half of 2015, we completed a CINGAL retreatment
study with 242 patients who had participated in the Phase III clinical trial and reported safety data related to the retreatment
study. This initial Phase III clinical trial and the associated retreatment study supported the Health Canada and CE Mark approval
of the product, and the commercial launch of the product in both Canada and the European Union occurred in the second quarter of
2016. In the United States, after discussions with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) related to the regulatory
pathway for CINGAL, we conducted a formal meeting with the FDA&rsquo;s Office of Combination Products (&ldquo;OCP&rdquo;) to present
and discuss our data in September 2015, and we submitted a formal request for designation with OCP a month later. In its response
to our formal request for designation, OCP assigned the product to the FDA&rsquo;s Center for Drug Evaluation and Research (&ldquo;CDER&rdquo;)
as the lead agency center for premarket review and regulation. We then held discussions with CDER to understand the requirements
for submitting a New Drug Application (&ldquo;NDA&rdquo;) for CINGAL. We held a meeting with CDER in September 2016 to align on
an approval framework and on submission requirements for this NDA for CINGAL, including the execution of an additional Phase III
clinical trial to supplement our existing CINGAL pivotal study data. We submitted an IND in late 2016, and discussions with CDER
indicated that they did not have objections to our clinical protocol design. As a result, we commenced work on this second Phase
III clinical trial (&ldquo;CINGAL 16-02 Study&rdquo;) in the first quarter of 2017, and the first patient was treated in the second
quarter of 2017. Enrollment of the 576 patients in this second Phase III clinical trial was completed during October 2017, and
we completed the six-month patient follow-up in April 2018. We received and analyzed the data from the CINGAL 16-02 Study during
the second quarter of 2018, and, while substantial pain reduction associated with CINGAL was evident at each measurement point,
we determined based on statistical analysis that it did not meet the primary study endpoint of demonstrating a statistically significant
difference in pain reduction between CINGAL and the approved steroid component of CINGAL at the six-month time point. In the third
quarter of 2017, we initiated an additional three-month extended follow-up study in conjunction with the CINGAL 16-02 Study to
investigate the efficacy of CINGAL over this longer period. The first patients were enrolled in this follow-up study in the fourth
quarter of 2017 and we completed the nine-month patient follow-up in the third quarter of 2018. We recently met with the FDA to
discuss the potential approval pathway for CINGAL in the United States moving forward in light of the work we have previously done.
In the meeting, the FDA indicated that an additional Phase III clinical trial would be necessary to support U.S. marketing approval
for CINGAL, and we are continuing to align with the FDA on the parameters and requirements for this additional clinical trial.
Concurrently, we are refreshing our primary market research in advance of making our final decision on how to proceed with respect
to seeking U.S. marketing approval for CINGAL from the FDA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have several research
and development programs underway for new products, including for HYALOFAST (in the United States), an innovative product for cartilage
tissue repair, and other early stage regenerative medicine development programs. HYALOFAST, which received CE Mark approval in
September 2009, is commercially available in Europe and certain international countries. During the first quarter of 2015, we submitted
an Investigational Device Exemption (&#8220;IDE&#8221;) for HYALOFAST to the FDA, which was approved in July 2015. We commenced
patient enrollment in a clinical trial in December 2015, and we are advancing site initiations and patient enrollment activities.
In the second quarter of 2016, a supplement to the HYALOFAST IDE was approved to expand the inclusion criteria for the clinical
study, which was aimed at decreasing the time needed to complete the clinical trial. The previously-described voluntary recall
of certain production lots of our HYAFF-based products did not impact the HYALOFAST clinical trial, as the product used in the
clinical trial is not sourced from the affected production lots. Given the changing medical landscape with respect to the randomization
arm for this trial, the microfracture procedure, we are actively pursuing alternative strategies to accelerate patient enrollment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the third quarter of 2017, we submitted an
application to the FDA for 510(k) clearance of an injectable, HA-based surgical bone repair product that is reabsorbed by the body
and replaced by the growth of new bone during the healing process. The 510(k) clearance was received from the FDA in December 2017,
and we expect to make this bone repair product commercially available in the United States during the second half of 2019 utilizing
the previously-described hybrid commercial approach. In addition to other early stage research and development initiatives we are
currently undertaking, we are working to expand our regenerative medicine pipeline with a new product candidate in the form of
an implant for rotator cuff repair utilizing our proprietary solid HA, which could be used to repair partial and full-thickness
rotator cuff tears. We finalized development of an initial product prototype during the fourth quarter of 2018, and we are performing
preclinical testing of and developing the surgical instrumentation for the potential product.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are also currently proceeding with other
research and development programs, one of which utilizes our proprietary HA technology to treat pain associated with common repetitive
overuse injuries, such as lateral epicondylitis, also known as tennis elbow. We submitted a CE Mark application for this treatment
during the first quarter of 2016 and received a CE Mark for the treatment of pain associated with tennis elbow in December 2016.
We began work towards a post-market clinical study in relation to the CE Mark for this product in the fourth quarter of 2018. Outside
of the United States, this product is marketed under the trade name ORTHOVISC-T. Additionally, in the second quarter of 2016, we
submitted an IDE to the FDA to conduct a Phase III clinical trial for this treatment, which was approved by the FDA in June 2016.
Notwithstanding that approval and in light of recent changes to the regulatory environment for HA-based products, in the first
quarter of 2019, the FDA requested that we submit this product to OCP for designation, which we did early in the second quarter
of 2019. We also have several other research and development programs underway focused on expanding the indications of our current
products, including MONOVISC. During 2019, we will also be performing post-market clinical work in relation to the CE Mark for
MONOVISC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we
entered into an agreement with the University of Liverpool to develop an injectable mesenchymal stem cell therapy for the treatment
of age-related osteoarthritis with the goal of bringing a therapeutics candidate through clinical trials to market to meet an
unmet therapeutic need. We are currently in the preclinical phase of this program and aim to finalize proof of concept during
the second quarter of 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Three Months Ended March 31, 2019 Compared to Three Months Ended March 31, 2018</p>

<p style="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Product revenue</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">24,717</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,258</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,459</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">16</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Licensing, milestone and contract revenue</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">24,723</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">21,264</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,459</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">16</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cost of product revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,311</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,845</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(534</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7</td><td style="white-space: nowrap; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research&nbsp;&amp; development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,258</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,161</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(903</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(17</td><td style="white-space: nowrap; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Selling, general&nbsp;&amp; administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,672</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,090</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,418</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,241</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,096</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,855</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(34</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income (loss) from operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,482</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,832</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13,314</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">170</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest and other income, net</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">498</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">95</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">403</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">424</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income (loss) before income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,980</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,737</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13,717</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">177</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Provision for (benefit from) income taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,473</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,051</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,524</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,507</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,686</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,193</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">167</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product gross profit</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,406</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,413</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,993</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Product gross margin</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">70</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">63</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Product Revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product revenue for
the three-month period ended March 31, 2019 was $24.7 million, an increase of 16%, or $3.5 million, as compared to $21.3 million
for the three-month period ended March 31, 2018. For the three-month period ended March 31, 2019, the increase in product revenue
was mainly driven by growth in viscosupplement revenue domestically and internationally, as well as higher sales of our HYAFF-based
products.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables
present product revenue by product group:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Orthobiologics</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,748</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">19,489</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,259</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">12</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Surgical</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,392</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,245</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">147</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dermal</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">129</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(539</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">668</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">124</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,448</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,063</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">385</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,717</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,258</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,459</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">16</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Orthobiologics</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our orthobiologics
franchise consists of orthopedic pain management and regenerative therapies. Overall, sales increased by 12%, or $2.3 million,
for the three-month period ended March 31, 2019, as compared to the same period in 2018, largely as a result of increased revenue
from our viscosupplement products both domestically and internationally. Domestically, the increased viscosupplement revenue was
primarily driven by order timing. Growth in our international viscosupplement revenue largely resulted from a year-over-year increase
in sales of our single-injections products during the quarter. Despite the increase in the quarter ended March 31, 2019 as compared
to same period in the prior year, we expect orthobiologics product revenue in 2019 to decrease as compared to 2018, primarily
due to the ORTHOVISC and MONOVISC pricing declines in the U.S. viscosupplement market, offset in part by growth in international
CINGAL revenue and the commercial launch of our injectable, HA-based surgical bone repair product in the U.S. via the previously-described
hybrid commercial approach.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Surgical</i>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our surgical franchise consists of products
used to prevent surgical adhesions and to treat ear, nose, and throat (&ldquo;ENT&rdquo;) disorders. Sales of our surgical&nbsp;products
increased by 12%, or $0.1 million, during the three-month period ended March 31, 2019, as compared to the same period in 2018.
The increase in surgical product revenue for the three-month period was primarily due to an increase in sales&nbsp;to our worldwide
ENT commercial partner,&nbsp;which was partially offset&nbsp;by a decrease in sales of our&nbsp;surgical anti-adhesion products.
We expect surgical product revenue to increase in 2019 as compared to 2018 primarily due to increased worldwide revenue associated
with sales of our surgical anti-adhesion product and ENT sales.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dermal</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our dermal franchise&nbsp;<FONT STYLE="background-color: white">consists
of advanced wound care products, which are </FONT>based on our HYAFF technology, and aesthetic dermal fillers. Our advanced wound
care products treat complex skin wounds ranging from burns to diabetic ulcers, with HYALOMATRIX and HYALOFILL as the lead products.
For the three-month period ended March 31, 2019, dermal product sales increased by $0.7 million as compared to the same quarter
in 2018 as we resumed shipment of HYALOMATRIX products following the previously-described voluntary recall of certain production
lots of our HYAFF-based products in 2018. We expect dermal sales to increase in 2019 as a result of resuming HYALOMATRIX shipments
which was impacted by the previously mentioned voluntary recall in 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Other product revenue includes revenues from
our ophthalmic and veterinary franchises. Other product revenue increased by 36%, or $0.4 million, as compared to the same period
in 2018, primarily due to increased sales of our veterinary product. We expect other revenue to decrease modestly in 2019 as compared
to 2018,&nbsp;primarily as a result of decreased sales to one of our ophthalmic distributors offset in part by increased revenue
from veterinary products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Licensing, Milestone and Contract Revenue&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Licensing, milestone
and contract revenue for the three-month periods ended March 31, 2019 and 2018 was $6 thousand. We expect licensing, milestone
and contract revenue to be at an equivalent level in 2019 as compared to 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Product Gross Profit and Margin</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Product gross profit for the three-month period
ended March 31, 2019 was $17.4 million, representing 70% of product revenue. Product gross profit for the three-month period ended
March 31, 2018 was $13.4 million, or 63% of&nbsp;product revenue for the period. The increase in product gross margin for the three-month
period ended March 31, 2019, as compared to the same period in 2018, was due primarily to previously-described voluntary recall.
During the first quarter of 2018, product gross margin was negatively impacted by an increase in inventory reserves, including
those related to the recall.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&nbsp;&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Research and development expenses for the three-month
period ended March 31, 2019 were $4.3 million, or 17% of total revenue for the period, a decrease of $0.9 million as compared to
the same period in 2018. The decrease in research and development expense was primarily due to lower clinical trial expenses related
to CINGAL for the three-month period ended March 31, 2019, as compared to March 31, 2018, offset in part by higher pre-clinical
product development activities with respect to certain product candidates in our research and development pipeline and additional
expenses associated with compliance activities related to the European Union Medical Device Regulation. Research and development
spending is expected to potentially increase in 2019, as compared to 2018, as we further develop new products and initiate clinical
trials based on our development activities, perform required post-market clinical follow-ups for our MONOVISC and ORTHOVISC-T products
in the European Union, and as a result of current or future changes to the regulatory environments in the jurisdictions in which
we do business.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Selling, General and Administrative</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Selling, general and administrative expenses
for the three-month period ended March 31, 2019 were $7.7 million, representing 31% of total revenue for the period, a decrease
of $8.4 million as compared to the same period in 2018. The decrease was primarily due to non-cash stock-based compensation expense
related to the retirement of our former Chief Executive Officer within the three-month period ending March 31, 2018. We expect
selling, general and administrative expenses for 2019 to decrease in comparison to 2018 due to the above mentioned one-time charge.
The decrease will be partially offset by investments in our commercial capabilities and the implementation of improved business
and financial technology platforms required to grow our business both domestically and internationally.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 199.85pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The provision for income taxes was $1.5 million
for the three-month period ended March 31, 2019, based on an effective tax rate of 24.6%.&nbsp;The benefit from income taxes was
$1.1 million for the three-month period ended March 31, 2018, based on an effective tax benefit rate of (13.6%). The net increase
in the effective tax rate for the three-month period ended March 31, 2019, as compared to the same period in 2018, was primarily
due to the windfall tax benefit the Company realized in March 2018 due to limitations on the deductibility of executive compensation
for accelerated stock vesting upon the retirement of its former Chief Executive Officer on March 9, 2018. We realized an immaterial
shortfall for the three-month period ended March 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>How
We Evaluate Our Operations</I></B></FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We present information below with respect to
adjusted EBITDA, which we define as our net income excluding interest expense (net), income tax benefit (expense), depreciation
and amortization, and stock-based compensation. This financial measure is not based on any standardized methodology prescribed
by accounting principles generally accepted in the United States (&ldquo;GAAP&rdquo;) and are not necessarily comparable to similarly
titled measures presented by other companies.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We have presented adjusted EBITDA because it
is a key measure used by our management and board of directors to understand and evaluate our operating performance and to develop
operational goals for managing our business. We believe this financial measure helps identify underlying trends in our business
that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of the
expenses eliminated in calculating adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating
performance. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding
and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing
for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Adjusted EBITDA is not prepared in accordance
with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There
are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest GAAP equivalent.
Some of these limitations are:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses,
the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected
in adjusted EBITDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and
will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation
strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense
included in operating expenses would be higher, which would affect our cash position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from
the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adjusted EBITDA does not reflect provision for (benefit from) income taxes or the cash requirements
to pay taxes; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital
expenditures or contractual commitments.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following is a reconciliation of net income
to adjusted EBITDA for the three-month periods ended March 31, 2019 and 2018, respectively:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" align="CENTER" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,507</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,686</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest and other income, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(498</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(95</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Provision for income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,473</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,051</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,477</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,473</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,386</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,565</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,345</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,206</td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Adjusted EBITDA in the three months ended March
31, 2019, as compared with the comparable period in 2018, reflected an increase of $4.0 million in gross profit and a decrease
of $9.3 million in other operating expenses, in addition to the changes in interest and other income, net, provision for (benefit
from) income taxes, depreciation and amortization, and stock-based compensation shown in the preceding table.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity and Capital Resources </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require cash to
fund our operating expenses and to make capital expenditures. We expect that our requirements for cash to fund these uses will
increase as our operations expand. Historically we have generated positive cash flow from operations, which, together with our
available cash, investments, and debt, have met our cash requirements. Cash, cash equivalents, and investments aggregated $166.7
million and $159.0 million, and working capital totaled $198.1 million and $191.7 million as of March 31, 2019 and December 31,
2018, respectively.&nbsp;In addition, as of March 31, 2019, we have $50.0 million of available credit under our senior revolving
credit facility with Bank of America, N.A. We believe that we have adequate financial resources to support our business for at
least the twelve months from the issuance date of our financial statements. As of March 31, 2019, we were in compliance with the
terms of our credit agreement with Bank of America, N.A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash provided by operating
activities was $8.5 million for the three-month period ended March 31, 2019, as compared to cash provided by operating activities
of&nbsp;$9.6 million&nbsp;for the same&nbsp;period in 2018.&nbsp;The decrease in cash provided by operations for the three-month
period ended March 31, 2019, as compared to the same period in 2018, was primarily related to a decrease in collections of our
accounts receivable due to timing of receipts and a decrease in accrued expenses. These factors were partially offset by a decrease
in prepayments of income taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in investing
activities was $1.9 million for the three-month period ended March 31, 2019, as compared to cash provided by investing activities
of $0.2 million for the same period in 2018.&nbsp;The change was due to increased purchases of investments, partially offset by
lower capital expenditures as compared to the same period in 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used by financing
activities was $0.1 million for the three-month period ended March 31, 2019, as compared to cash used by financing activities of
$1.2 million for the same period in 2018. The decrease in cash used in financing activities for the three-month period ended March
31, 2019, was primarily attributable to decreased utilization of cash for employee tax withholding in exchange for shares surrendered
by equity award holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Critical Accounting Policies
and Estimates </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There were no other significant changes in our
critical accounting policies or estimates during the three months ended March 31, 2019 to augment the critical accounting estimates
disclosed under the heading &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
in our Annual Report on Form&nbsp;10-K for the fiscal year ended December 31, 2018, other than those described in the Notes to
the condensed consolidated financial statements included in this report, including the adoption of&nbsp;the Financial Accounting
Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards Codification, <I>Leases</I>, (ASC 842) effective January 1, 2019.
As a result of our adoption of the new lease standard, we re-assessed the estimates, assumptions, and judgments that are most critical
in our recognition of leases.&nbsp; For information regarding the impact
of recently adopted accounting standards, refer to Notes 2 and 12 to the condensed financial statements included in this report.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A discussion of Recent Accounting Pronouncements
is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and is updated in the Notes to the condensed
consolidated financial statements included in this report.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contractual Obligations and Other
Commercial Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="background-color: white">Our contractual
obligations and other commercial commitments are summarized in the section captioned &ldquo;Part II, Item 7, Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&mdash;Liquidity and Capital Resources&mdash;Contractual
Obligations and Other Commercial Commitments&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2018. We
had no material changes outside the ordinary course to our contractual obligations reported in our 2018 Annual Report on Form
10-K during the three months ended March 31, 2019. For additional discussion, see Note 13 to the condensed consolidated financial
statements included in this report.</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent
that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements,
we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and
others, or through other sources. No assurance can be given that any additional financing will be made available to us or will
be available on acceptable terms should such a need arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Off-balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not use special
purpose entities or other off-balance sheet financing techniques that we believe have, or are reasonably likely to have, a current
or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, or capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_009"></a>ITEM 3.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our market risks and
the ways we manage them are summarized in the section captioned &#8220;Part&nbsp;II, Item&nbsp;7A, Quantitative and Qualitative
Disclosures About Market Risk&#8221; in our&nbsp;Annual Report on&nbsp;Form&nbsp;10-K for the year ended December 31, 2018. There
have been no material changes in the first&nbsp;three&nbsp;months of&nbsp;2019&nbsp;to our market risks or to our management of
such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_010"></a>ITEM 4.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTROLS AND PROCEDURES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of disclosure controls and procedures.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Rule&nbsp;13a-15
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), we carried out an evaluation under the
supervision and with the participation of our management, including our chief executive officer and chief financial officer, of
the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by
this report. Based upon that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure
controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under
the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules&nbsp;and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by our company in the reports it files or submits under the Exchange Act is accumulated and communicated to our
management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding
required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control
over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our
systems evolve with our business.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in internal controls over financial reporting.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes
in our internal control over financial reporting during the three-month period ended March 31, 2019 that have materially affected,
or that are reasonably likely to materially affect, our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><a name="a_011"></a>PART&nbsp;II: OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_012"></a>ITEM 1.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL PROCEEDINGS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are involved from
time-to-time in various legal proceedings arising in the normal course of business.&nbsp;Although the outcomes of these legal proceedings
are inherently difficult to predict, we do not expect the resolution of these occasional legal proceedings to have a material adverse
effect on our financial position, results of operations, or cash flow. There have been no material changes to the information provided
in the section captioned &#8220;Part I, Item 3, Legal Proceedings&#8221; in our Annual Report on Form 10-K for the year ended December
31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 6%; text-align: justify"><a name="a_013"></a><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1A.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK FACTORS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no
material changes to the risk factors described in the section captioned &#8220;Part I, Item 1A, Risk Factors&#8221; in our Annual
Report on Form&nbsp;10-K for the year ended December 31, 2018. In addition to the other information set forth in this report, you
should carefully consider the factors discussed in the section captioned &#8220;Part&nbsp;I, Item 1A, Risk Factors&#8221; in our
Annual Report on Form&nbsp;10-K for the year ended December 31, 2018, which could materially affect our business, financial condition,
or future results. The risks described in our Annual Report on Form&nbsp;10-K and our Quarterly Reports on Form 10-Q are not the
only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial
also may have a material adverse effect on our business, financial condition, and/or operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_014"></a>ITEM 2.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Unregistered Sales of Equity Securities and Use of Proceeds</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under our equity compensation plans, and subject to the specific approval of the Compensation Committee of our
Board of Directors, grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise
by allowing us to withhold shares of stock otherwise issuable to the grantee. During the three months ended March 31, 2019, we
withheld 2,625 shares to satisfy grantee tax withholding obligations on restricted stock award vesting events. On May 2, 2019,
we announced that the Board of Directors had approved a $50.0 million stock repurchase program to include a $30.0 million accelerated
share repurchase program and up to an additional $20.0 million of our common stock to be purchased on the open market.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Total&nbsp;Number<BR>
of Shares<BR>
Purchased</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Average<BR>
Price Paid <BR>
per Share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Total&nbsp;Number&nbsp;of<BR> Shares Purchased as <BR>
Part of Publicly <BR>
Announced Plans or <BR>
Programs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Maximum&nbsp;Number&nbsp;(or <BR>
Approximate Dollar <BR>
Value) of Shares that May <BR>
Yet be Purchased Under <BR>
the Plans or Programs</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; width: 36%">January 1 to 31, 2019</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%">-</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%">-</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%">-</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%">-</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">February 1 to 28, 2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">38.07</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">March 1 to 31, 2019</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">2,625</TD><TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_015"></a>ITEM 6.</b></font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; border-bottom: black 1pt solid; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&nbsp;No.</b></font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_101.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</font></a></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_101.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No. 2, dated April 9, 2019, to Employment Agreement, dated July 27, 2017, as amended March 8, 2018, by and between Anika Therapeutics,
    Inc. and Joseph G. Darling</font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_102.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</font></a></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_102.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No. 2, dated April 9, 2019, to Employment Agreement, dated March 22, 2010, as amended December 8, 2010, by and between Anika
    Therapeutics, Inc. and Sylvia Cheung</font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_103.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</font></a></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_103.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Retention Agreement, dated April 9, 2019, by and between Anika Therapeutics, Inc. and Thomas Finnerty</font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_104.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</font></a></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/898437/000117184319002383/exh_104.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Retention Agreement, dated April 9, 2019, by and between Anika Therapeutics, Inc. and Edward S. Ahn</font></a></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31)</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule&nbsp;13a-14(a)/15d-14(a)&nbsp;Certifications</font></td></tr>
<tr>
    <td style="vertical-align: top; width: 9%; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</td>
    <td style="width: 3%; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; width: 87%; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><A HREF="exh_311.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*31.1</font></A></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><A HREF="exh_311.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Joseph G. Darling, pursuant to Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e), as adopted pursuant to Section&nbsp;302 of the
    Sarbanes-Oxley Act of 2002.</font></A></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><A HREF="exh_312.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*31.2</font></A></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><A HREF="exh_312.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Sylvia Cheung, pursuant to Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e), as adopted pursuant
to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></A></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1350
    Certifications</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><A HREF="exh_321.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**32.1</font></A></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><A HREF="exh_321.htm"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Joseph G. Darling, and Sylvia Cheung, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906
    of the Sarbanes-Oxley Act of 2002.</font></A></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(101)</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*101</font></td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following materials from Anika Therapeutics, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019
    as filed with the SEC on May 3, 2019, formatted in XBRL (eXtensible Business Reporting Language), as follows:</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Balance Sheets as of March 31, 2019 (unaudited) and December 31, 2018 (unaudited)</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2019 and March
    31, 2018 (unaudited)</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2019 and March 31, 2018 (unaudited)</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and March 31, 2018 (unaudited)</font></td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</font></td>
    <td style="vertical-align: top; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Condensed Consolidated Financial Statements (unaudited)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></td>
    <td style="width: 95%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**&nbsp;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<br style="clear: both"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><a name="a_016"></a>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANIKA THERAPEUTICS,&nbsp;INC.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="3" style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 52%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 3, 2019</font></td>
    <td style="width: 2%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ SYLVIA CHEUNG</font></td>
    <td style="width: 20%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sylvia Cheung</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Financial Officer</i></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Authorized Officer and Principal Financial Officer)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>



<p style="margin: 0"></p>

<p style="margin-top: 0; text-align: center; margin-bottom: 0">22</p>

<p style="margin-top: 0; text-align: center; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; text-align: center; margin-bottom: 0"></p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Certification of Principal Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Joseph G. Darling, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt">1.</TD>
    <TD STYLE="width: 85%">
        <P STYLE="font-size: 10pt; margin: 0pt 0">I have reviewed this report on Form&nbsp;10-Q for the quarterly period ended March 31,
        2019 of Anika Therapeutics,&nbsp;Inc.;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">3.</TD>
    <TD STYLE="width: 85%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">4.</TD>
    <TD STYLE="width: 85%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(a)</TD>
    <TD STYLE="width: 81%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(b)</TD>
    <TD STYLE="width: 81%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(c)</TD>
    <TD STYLE="width: 81%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(d)</TD>
    <TD STYLE="width: 81%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">5.</TD>
    <TD STYLE="width: 85%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(a)</TD>
    <TD STYLE="width: 81%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(b)</TD>
    <TD STYLE="width: 81%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Date: May 3, 2019</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid">/s/ JOSEPH G. DARLING</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Joseph G. Darling</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"> </P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp; </P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp; </P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>





<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Certification of Principal Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Sylvia Cheung, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt">1.</TD>
    <TD STYLE="width: 85%">
        <P STYLE="font-size: 10pt; margin: 0pt 0">I have reviewed this report on Form&nbsp;10-Q for the quarterly period ended March 31,
        2019 of Anika Therapeutics,&nbsp;Inc.;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">3.</TD>
    <TD STYLE="width: 85%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">4.</TD>
    <TD STYLE="width: 85%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(a)</TD>
    <TD STYLE="width: 81%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(b)</TD>
    <TD STYLE="width: 81%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(c)</TD>
    <TD STYLE="width: 81%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(d)</TD>
    <TD STYLE="width: 81%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 8%">5.</TD>
    <TD STYLE="width: 85%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(a)</TD>
    <TD STYLE="width: 81%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">(b)</TD>
    <TD STYLE="width: 81%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; white-space: nowrap">Date: &nbsp;May 3, 2019</TD>
    <TD STYLE="width: 34%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; white-space: nowrap">/s/ SYLVIA CHEUNG</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Sylvia Cheung</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Principal Financial Officer</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<BR>&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>





<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Certification of Principal Executive Officer and Principal Financial Officer Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">The undersigned officers of Anika Therapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;)
hereby certify to their knowledge and in their respective capacities that the Company&rsquo;s quarterly report on Form&nbsp;10-Q
to which this certification is attached (the &ldquo;Report&rdquo;), as filed with the Securities and Exchange Commission on the
date hereof, fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and that the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; white-space: nowrap">Date: May 3, 2019</TD>
    <TD STYLE="width: 34%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; white-space: nowrap">/s/ JOSEPH G. DARLING</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Joseph G. Darling.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Principal Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">Date: May 3, 2019</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">/s/ SYLVIA CHEUNG</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Sylvia Cheung</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Principal Financial Officer</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">This certification shall not be deemed &ldquo;filed&rdquo; for any
purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>anik-20190331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:55PM UTC 2019-05-03--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:anik="http://www.anikatherapeutics.com/20190331" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="anik-20190331.xsd" xlink:type="simple"/>
  <anik:AccruedClinicalTrialCostsCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380152" unitRef="iso4217-usd">419000</anik:AccruedClinicalTrialCostsCurrent>
  <anik:AccruedClinicalTrialCostsCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380153" unitRef="iso4217-usd">577000</anik:AccruedClinicalTrialCostsCurrent>
  <anik:AccruedResearchGrantsCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380150" unitRef="iso4217-usd">392000</anik:AccruedResearchGrantsCurrent>
  <anik:AccruedResearchGrantsCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380151" unitRef="iso4217-usd">400000</anik:AccruedResearchGrantsCurrent>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380082" unitRef="iso4217-usd">2929000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380086" unitRef="iso4217-usd">2824000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c46380091" unitRef="iso4217-usd">1232000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c46380095" unitRef="iso4217-usd">1168000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c46380100" unitRef="iso4217-usd">415000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c46380104" unitRef="iso4217-usd">415000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380109" unitRef="iso4217-usd">176000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380113" unitRef="iso4217-usd">169000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c46380118" unitRef="iso4217-usd" xs:nil="true"/>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c46380122" unitRef="iso4217-usd" xs:nil="true"/>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2019-03-31" decimals="-3" id="c46380127" unitRef="iso4217-usd">4752000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2018-12-31" decimals="-3" id="c46380131" unitRef="iso4217-usd">4576000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379943" unitRef="iso4217-usd">2147000</anik:CashEquivalentsFairValueDisclosure>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379944" unitRef="iso4217-usd">2147000</anik:CashEquivalentsFairValueDisclosure>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379945" unitRef="iso4217-usd">2147000</anik:CashEquivalentsFairValueDisclosure>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379951" unitRef="iso4217-usd">4984000</anik:CashEquivalentsFairValueDisclosure>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379952" unitRef="iso4217-usd">4984000</anik:CashEquivalentsFairValueDisclosure>
  <anik:CashEquivalentsFairValueDisclosure contextRef="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379953" unitRef="iso4217-usd">4984000</anik:CashEquivalentsFairValueDisclosure>
  <anik:IncreaseDecreaseInLeaseLiabilities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379821" unitRef="iso4217-usd">-269000</anik:IncreaseDecreaseInLeaseLiabilities>
  <anik:IncreaseDecreaseInLeaseLiabilities contextRef="d_2018-01-01_2018-03-31" id="c46379822" unitRef="iso4217-usd" xs:nil="true"/>
  <anik:InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal contextRef="i_2019-03-31" decimals="-3" id="c46380063" unitRef="iso4217-usd">26259000</anik:InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal>
  <anik:InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal contextRef="i_2018-12-31" decimals="-3" id="c46380064" unitRef="iso4217-usd">25133000</anik:InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal>
  <anik:PercentageOfNetRevenue contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-US" decimals="2" id="c46379919" unitRef="xbrli-pure">0.81</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-US" decimals="2" id="c46379921" unitRef="xbrli-pure">0.8</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-EuropeMember" decimals="2" id="c46379923" unitRef="xbrli-pure">0.1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-EuropeMember" decimals="2" id="c46379925" unitRef="xbrli-pure">0.11</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c46379927" unitRef="xbrli-pure">0.09</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c46379929" unitRef="xbrli-pure">0.09</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2019-01-01_2019-03-31" decimals="2" id="c46379931" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2018-01-01_2018-03-31" decimals="2" id="c46379933" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-RSUsGrantedToEmployeesMember" decimals="1" id="c46379975" unitRef="xbrli-pure">0.3</anik:PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear>
  <anik:PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-RSUsGrantedToEmployeesMember" decimals="1" id="c46379977" unitRef="xbrli-pure">0.7</anik:PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear>
  <anik:RevenueFromContractWithCustomerPercentage contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-OrthobiologicsMember" decimals="2" id="c46379908" unitRef="xbrli-pure">194.89</anik:RevenueFromContractWithCustomerPercentage>
  <anik:RevenueFromContractWithCustomerPercentage contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-SurgicalMember" decimals="2" id="c46379910" unitRef="xbrli-pure">12.45</anik:RevenueFromContractWithCustomerPercentage>
  <anik:RevenueFromContractWithCustomerPercentage contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-DermalMember" decimals="2" id="c46379912" unitRef="xbrli-pure">-5.39</anik:RevenueFromContractWithCustomerPercentage>
  <anik:RevenueFromContractWithCustomerPercentage contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ManufacturedProductOtherMember" decimals="2" id="c46379914" unitRef="xbrli-pure">10.63</anik:RevenueFromContractWithCustomerPercentage>
  <anik:RevenueFromContractWithCustomerPercentage contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ProductMember" decimals="2" id="c46379916" unitRef="xbrli-pure">212.58</anik:RevenueFromContractWithCustomerPercentage>
  <anik:RevenuesFromAgreementsAsPercentOfTotalRevenue contextRef="d_2019-01-01_2019-03-31_CounterpartyNameAxis-DepuyMitekIncMember" decimals="2" id="c46379897" unitRef="xbrli-pure">0.72</anik:RevenuesFromAgreementsAsPercentOfTotalRevenue>
  <anik:RevenuesFromAgreementsAsPercentOfTotalRevenue contextRef="d_2018-01-01_2018-03-31_CounterpartyNameAxis-DepuyMitekIncMember" decimals="2" id="c46379898" unitRef="xbrli-pure">0.76</anik:RevenuesFromAgreementsAsPercentOfTotalRevenue>
  <anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;December 31, 2018&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Gross Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Currency &lt;br /&gt; Translation&lt;br /&gt; Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Impairment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Net Book &lt;br /&gt; Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Currency &lt;br /&gt; Translation&lt;br /&gt; Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Net Book &lt;br /&gt; Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;Useful Life&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 21%"&gt;Developed technology&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,929&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(281&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,927&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,963&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,824&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,672&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,604&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;In-process research &amp;amp; development&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,406&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,232&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,174&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,168&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,238&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Indefinite&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Distributor relationships&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,700&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(415&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,285&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(415&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,285&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Patents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(176&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(494&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(169&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(482&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Elevess trade name&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,206&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,752&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(281&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,706&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,467&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,576&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,439&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,191&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock>
  <anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage of&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage of&lt;br /&gt; Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 52%; text-align: left; padding-left: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,089&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,910&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;Europe&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,526&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,391&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,108&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,963&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total Revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,723&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,264&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock>
  <anik:SeveranceBenefitFollowingRetirement contextRef="d_2018-03-08_2018-03-08_TitleOfIndividualAxis-FormerChiefExecutiveOfficerMember" decimals="-5" id="c46380143" unitRef="iso4217-usd">1700000</anik:SeveranceBenefitFollowingRetirement>
  <anik:SeveranceBenefitFollowingRetirementTerm contextRef="d_2018-03-08_2018-03-08_TitleOfIndividualAxis-FormerChiefExecutiveOfficerMember" id="c46380144">P1Y180D</anik:SeveranceBenefitFollowingRetirementTerm>
  <dei:AmendmentFlag contextRef="d_2019-01-01_2019-03-31" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2019-01-01_2019-03-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2019-01-01_2019-03-31" id="c-13">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2019-01-01_2019-03-31" id="c-12">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2019-01-01_2019-03-31" id="c-11">2019-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2019-01-01_2019-03-31" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2019-01-01_2019-03-31" id="c-2">0000898437</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2019-04-22" decimals="INF" id="c-9" unitRef="xbrli-shares">14206920</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2019-01-01_2019-03-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="d_2019-01-01_2019-03-31" id="c-7">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="d_2019-01-01_2019-03-31" id="c-5">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2019-01-01_2019-03-31" id="c-1">Anika Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntitySmallBusiness contextRef="d_2019-01-01_2019-03-31" id="c-8">false</dei:EntitySmallBusiness>
  <dei:TradingSymbol contextRef="d_2019-01-01_2019-03-31" id="c-3">anik</dei:TradingSymbol>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184343">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Accrued expenses consist of the following:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;br /&gt; 2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Compensation and related expenses&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,563&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,446&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,810&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,989&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Research grants&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;392&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Clinical trial costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;419&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;577&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Income taxes payable&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,296&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;385&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Lease liability - current&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,075&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;476&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,031&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,146&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Included in Compensation and related expenses as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;are the accrued and unpaid costs related to the retirement of the Company&amp;#x2019;s former Chief Executive Officer as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 9, 2018. &lt;/div&gt;On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.7&lt;/div&gt; million over the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;-month period subsequent to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 9, 2018, &lt;/div&gt;among other benefits. The unpaid amounts under these agreements are included in accrued expenses. As more fully described in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,&lt;/div&gt; all of the former Chief Executive Officer&amp;#x2019;s outstanding equity awards vested in full and became exercisable upon his retirement.&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379619" unitRef="iso4217-usd">3571000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379620" unitRef="iso4217-usd">3143000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379595" unitRef="iso4217-usd">18265000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379596" unitRef="iso4217-usd">20775000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380154" unitRef="iso4217-usd">1296000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380155" unitRef="iso4217-usd">385000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="i_2019-03-31" decimals="-3" id="c46379621" unitRef="iso4217-usd">8031000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="i_2018-12-31" decimals="-3" id="c46379622" unitRef="iso4217-usd">8146000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380148" unitRef="iso4217-usd">1810000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380149" unitRef="iso4217-usd">1989000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2019-03-31" decimals="-3" id="c46379657" unitRef="iso4217-usd">-5841000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2018-12-31" decimals="-3" id="c46379658" unitRef="iso4217-usd">-5526000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2019-03-31" decimals="-3" id="c46379655" unitRef="iso4217-usd">52030000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2018-12-31" decimals="-3" id="c46379656" unitRef="iso4217-usd">50763000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46380962" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380963" unitRef="iso4217-usd">124000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46380964" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46380965" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380966" unitRef="iso4217-usd">124000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46381004" unitRef="iso4217-usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46381005" unitRef="iso4217-usd">1735000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46381006" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46381007" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46381008" unitRef="iso4217-usd">1736000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46380968" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380969" unitRef="iso4217-usd">1386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46380970" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46380971" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380972" unitRef="iso4217-usd">1386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46381010" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46381011" unitRef="iso4217-usd">7565000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46381012" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46381013" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46381014" unitRef="iso4217-usd">7565000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379963" unitRef="iso4217-usd">1386000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379964" unitRef="iso4217-usd">7565000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-03-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="-5" id="c46379968" unitRef="iso4217-usd">6200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-CostOfSalesMember" decimals="-3" id="c46380017" unitRef="iso4217-usd">92000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-CostOfSalesMember" decimals="-3" id="c46380018" unitRef="iso4217-usd">-216000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c46380019" unitRef="iso4217-usd">177000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c46380020" unitRef="iso4217-usd">210000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="c46380021" unitRef="iso4217-usd">1117000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="c46380022" unitRef="iso4217-usd">7571000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379597" unitRef="iso4217-usd">1210000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379598" unitRef="iso4217-usd">1525000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2019-01-01_2019-03-31" decimals="-5" id="c46380070" unitRef="iso4217-usd">300000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2019-01-01_2019-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="-6" id="c46380042" unitRef="xbrli-shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AreaOfRealEstateProperty contextRef="i_2019-03-31_LeaseArrangementTypeAxis-AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" decimals="INF" id="c46380171" unitRef="utr-sqft">134000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty contextRef="i_2019-03-31_LeaseArrangementTypeAxis-OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" decimals="INF" id="c46380172" unitRef="utr-sqft">33000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:Assets contextRef="i_2019-03-31" decimals="-3" id="c46379615" unitRef="iso4217-usd">306659000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2018-12-31" decimals="-3" id="c46379616" unitRef="iso4217-usd">278993000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379603" unitRef="iso4217-usd">209695000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379604" unitRef="iso4217-usd">202943000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2019-03-31_InvestmentTypeAxis-USTreasuryBillSecuritiesMember" decimals="-5" id="c46379935" unitRef="iso4217-usd">71200000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2018-12-31_InvestmentTypeAxis-USTreasuryBillSecuritiesMember" decimals="-5" id="c46379936" unitRef="iso4217-usd">70000000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184323">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&amp;nbsp;and regulations of the Securities and Exchange Commission (the &amp;#x201c;SEC&amp;#x201d;) and in accordance with accounting principles generally accepted in the United States (&amp;#x201c;US GAAP&amp;#x201d;). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company&amp;#x2019;s annual financial statements filed with its Annual Report on Form&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-K for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018. &lt;/div&gt;The results of operations for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily indicative of the results to be expected for the year ending &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases&lt;/div&gt; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;), which, among other things, results in the recognition of lease assets and lease liabilities by lessees on the Company&amp;#x2019;s balance sheets for virtually all leases. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; supersedes most previous lease accounting guidance and is effective for interim and annual periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;The Company adopted the new guidance as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019 &lt;/div&gt;using the modified retrospective adoption method in which it did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; restate prior periods. The adoption of this standard did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the condensed consolidated statement of operations. See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; for further details.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic;"&gt;Intangibles &amp;#x2013; Goodwill and Other &amp;#x2013; Internal-Use Software&amp;nbsp;(Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;350&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;)&lt;/div&gt;, which amends ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;05,&lt;/div&gt;&amp;nbsp;Customers Accounting for Fees in a Cloud Computing Agreement,&amp;nbsp;to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;350&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt; to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; is effective for fiscal years and interim periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2019. &lt;/div&gt;Early adoption is permitted, including adoption in any interim period for all entities. The Company is assessing ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379855" unitRef="iso4217-usd">246000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379856" unitRef="iso4217-usd">207000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2019-03-31" decimals="-3" id="c46379591" unitRef="iso4217-usd">95514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2018-12-31" decimals="-3" id="c46379592" unitRef="iso4217-usd">89042000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2017-12-31" decimals="INF" id="c46379850" unitRef="iso4217-usd">133256000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2018-03-31" decimals="INF" id="c46379852" unitRef="iso4217-usd">141797000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184327">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;All of the Company&amp;#x2019;s investments are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held investments, including U.S. treasury bills totaling &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$71.2&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$70.0&lt;/div&gt; million as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;respectively. Unrealized gains and losses as well as the associated tax impact on the Company&amp;#x2019;s available-for-sale securities were immaterial as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379847" unitRef="iso4217-usd">6472000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379848" unitRef="iso4217-usd">8541000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2019-03-31" id="c46379632" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2018-12-31" id="c46379633" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184348">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;also warrant that the products it manufactures do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company&amp;#x2019;s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; &lt;/div&gt;accrued warranties as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;and has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; history of claims paid.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2019-03-31" decimals="INF" id="c46379647" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2018-12-31" decimals="INF" id="c46379648" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2019-03-31" decimals="-3" id="c46379649" unitRef="xbrli-shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2018-12-31" decimals="-3" id="c46379650" unitRef="xbrli-shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2019-03-31" decimals="-3" id="c46379651" unitRef="xbrli-shares">14214000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2018-12-31" decimals="-3" id="c46379652" unitRef="xbrli-shares">14210000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2019-03-31" decimals="-3" id="c46379653" unitRef="xbrli-shares">14214000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2018-12-31" decimals="-3" id="c46379654" unitRef="xbrli-shares">14210000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2019-03-31" decimals="-3" id="c46379645" unitRef="iso4217-usd">142000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2018-12-31" decimals="-3" id="c46379646" unitRef="iso4217-usd">142000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379704" unitRef="iso4217-usd">4192000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379705" unitRef="iso4217-usd">-6066000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractWithCustomerLiability contextRef="i_2019-03-31" decimals="-3" id="c46379896" unitRef="iso4217-usd">67000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379672" unitRef="iso4217-usd">7311000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379673" unitRef="iso4217-usd">7845000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostsAndExpenses contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379678" unitRef="iso4217-usd">19241000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379679" unitRef="iso4217-usd">29096000</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379804" unitRef="iso4217-usd">-124000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379805" unitRef="iso4217-usd">-75000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2019-03-31" decimals="-3" id="c46380216" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2018-12-31" decimals="-3" id="c46380217" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c46379627" unitRef="iso4217-usd">3388000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c46379628" unitRef="iso4217-usd">3542000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DepreciationAndAmortization contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379794" unitRef="iso4217-usd">1477000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379795" unitRef="iso4217-usd">1473000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184331">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equity Incentive Plan&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company estimates the fair value of stock options and stock appreciation rights (&amp;#x201c;SARs&amp;#x201d;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&amp;#x201c;RSAs&amp;#x201d;) and restricted stock units (&amp;#x201c;RSUs&amp;#x201d;) are measured by the grant-date price of the Company&amp;#x2019;s shares. Fair value of performance restricted stock units (&amp;#x201c;PSUs&amp;#x201d;) is measured by the grant-date price of the Company&amp;#x2019;s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; achieved, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; compensation cost is recognized and any previously recognized compensation cost is reversed.&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of each stock option award during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.44%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.54%&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.15%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.37%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44.34%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44.41%&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;38.74%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40.81%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Expected life (years)&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 5%; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 5%; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.00%&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.00%&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recorded &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.4&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7.6&lt;/div&gt; million of stock-based compensation expense for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; respectively. Upon the retirement of the Company&amp;#x2019;s former Chief Executive Officer on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 9, 2018, &lt;/div&gt;all of his outstanding stock-based compensation awards vested in full and became exercisable in accordance with their terms, resulting in a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-time expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.2&lt;/div&gt; million that was fully recognized during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Cost of product revenue&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(216&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Research&amp;nbsp;&amp;amp; development&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;177&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;210&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling, general&amp;nbsp;&amp;amp; administrative&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,117&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,571&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,386&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,565&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table sets forth share information for stock-based compensation awards granted and exercised during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Grants:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 68%; text-align: left; padding-left: 10pt"&gt;Stock Options&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104,292&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;192,300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;RSAs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;64,578&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;RSUs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;165,507&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,130&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;PSUs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Exercises:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock Options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,425&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;SARs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the Company granted stock-based compensation awards in the form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable or vest ratably over a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year period. The PSUs granted to employees contained performance conditions with business and financial targets. The business target, amounting to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt; of the total performance conditions, will be measured based on achievement in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; fiscal year, while the financial targets, amounting to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70%&lt;/div&gt; of the total performance conditions, will ultimately be measured with respect to the Company&amp;#x2019;s operating results in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2021&lt;/div&gt; fiscal year. The Company recorded &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.1&lt;/div&gt; million of stock-based compensation expense associated with PSUs for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Grants:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 68%; text-align: left; padding-left: 10pt"&gt;Stock Options&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104,292&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;192,300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;RSAs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;64,578&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;RSUs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;165,507&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,130&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;PSUs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Exercises:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock Options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,425&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;SARs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379691" unitRef="iso4217-usd-per-xbrli-shares">0.32</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379692" unitRef="iso4217-usd-per-xbrli-shares">-0.46</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379696" unitRef="iso4217-usd-per-xbrli-shares">0.31</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379697" unitRef="iso4217-usd-per-xbrli-shares">-0.46</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184335">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 47px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Earnings Per Share (&amp;#x201c;EPS&amp;#x201d;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;div style="display: inline; background-color: white"&gt;The following table provides share information used in the calculation of the Company's basic and diluted earnings (loss) per share (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Shares used in the calculation of basic earnings per share&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Effect of dilutive securities:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock options, SARs, RSAs, RSUs and PSUs&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted shares used in the calculation of earnings per share&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,314&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;Stock options to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.0&lt;/div&gt; million shares for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;were excluded from the computation of diluted EPS as their effect would have been anti-dilutive. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;the net loss available to common stockholders is divided by the weighted average number of common shares outstanding during the period to calculate basic earnings per share. The assumed exercise of stock options at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;would have been anti-dilutive.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379845" unitRef="iso4217-usd">46000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379846" unitRef="iso4217-usd">-35000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2019-01-01_2019-03-31" decimals="3" id="c46380206" unitRef="xbrli-pure">0.246</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2018-01-01_2018-03-31" decimals="3" id="c46380209" unitRef="xbrli-pure">0.136</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380146" unitRef="iso4217-usd">2563000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380147" unitRef="iso4217-usd">4446000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Quoted Prices in&lt;br /&gt; Active Markets&lt;br /&gt; &amp;nbsp;for Identical Assets&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 1)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant Other&lt;br /&gt; &amp;nbsp;Observable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 2)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant&amp;nbsp;&lt;br /&gt; &amp;nbsp;Unobservable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 3)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized Cost&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Investments:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;U.S. treasury bills&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2018&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Quoted Prices in&lt;br /&gt; Active Markets&lt;br /&gt; &amp;nbsp;for Identical Assets&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 1)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant Other&lt;br /&gt; &amp;nbsp;Observable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 2)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant&amp;nbsp;&lt;br /&gt; &amp;nbsp;Unobservable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 3)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized Cost&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Investments:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;U.S. treasury bills&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184328">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;The Company&amp;#x2019;s investments are all classified within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity of these instruments, and therefore fair value information is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the table below.&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value hierarchy of the Company's cash equivalents and investments at fair value was as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Quoted Prices in&lt;br /&gt; Active Markets&lt;br /&gt; &amp;nbsp;for Identical Assets&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 1)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant Other&lt;br /&gt; &amp;nbsp;Observable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 2)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant&amp;nbsp;&lt;br /&gt; &amp;nbsp;Unobservable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 3)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized Cost&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,147&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Investments:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;U.S. treasury bills&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2018&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Quoted Prices in&lt;br /&gt; Active Markets&lt;br /&gt; &amp;nbsp;for Identical Assets&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 1)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant Other&lt;br /&gt; &amp;nbsp;Observable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 2)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Significant&amp;nbsp;&lt;br /&gt; &amp;nbsp;Unobservable Inputs&amp;nbsp;&lt;br /&gt; &amp;nbsp;(Level 3)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized Cost&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,984&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Investments:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;U.S. treasury bills&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#x2013;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;69,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379796" unitRef="iso4217-usd">297000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
  <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="d_2018-01-01_2018-03-31" id="c46379797" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" id="c46380089">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" id="c46380107">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" id="c46380116">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c46380125">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380084" unitRef="iso4217-usd">8927000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380087" unitRef="iso4217-usd">8672000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c46380102" unitRef="iso4217-usd">4285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c46380105" unitRef="iso4217-usd">4285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380111" unitRef="iso4217-usd">494000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380114" unitRef="iso4217-usd">482000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c46380120" unitRef="iso4217-usd">1000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c46380123" unitRef="iso4217-usd">1000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2019-03-31" decimals="-3" id="c46380129" unitRef="iso4217-usd">14706000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31" decimals="-3" id="c46380132" unitRef="iso4217-usd">14439000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379798" unitRef="iso4217-usd">-721000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379799" unitRef="iso4217-usd">-142000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:Goodwill contextRef="i_2019-03-31" decimals="-3" id="c46379613" unitRef="iso4217-usd">7695000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2018-12-31" decimals="-3" id="c46379614" unitRef="iso4217-usd">7851000</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184339">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intangible Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Intangible assets as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;consisted of the following:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;December 31, 2018&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Gross Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Currency &lt;br /&gt; Translation&lt;br /&gt; Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Impairment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Net Book &lt;br /&gt; Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Currency &lt;br /&gt; Translation&lt;br /&gt; Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Accumulated &lt;br /&gt; Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap"&gt;Net Book &lt;br /&gt; Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"&gt;Useful Life&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 21%"&gt;Developed technology&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,929&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(281&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,927&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,963&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,824&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,672&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,604&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;In-process research &amp;amp; development&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,406&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,232&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,174&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,168&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,238&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Indefinite&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Distributor relationships&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,700&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(415&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,285&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(415&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,285&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Patents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(176&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(494&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(169&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(482&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Elevess trade name&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,000&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: 0pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,206&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,752&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(281&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,706&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,467&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,576&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14,439&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,191&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate amortization expense related to intangible assets was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.3&lt;/div&gt; million for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recorded a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.3&lt;/div&gt; million impairment charge for the HYALOSPINE developed technology asset in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019. &lt;/div&gt;HYALOSPINE was an adhesion prevention gel for use after spinal surgery, and received initial CE Mark approval in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2015. &lt;/div&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2019, &lt;/div&gt;the Company made the decision &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to renew the CE Mark as the product was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; aligned with the Company&amp;#x2019;s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general &amp;amp; administrative expenses on our condensed consolidated statements of operations.&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;Through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;except as set forth in this paragraph, there have &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.1&lt;/div&gt; million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184341">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 47px"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company completed its annual impairment review as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 30, 2018 &lt;/div&gt;and concluded that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment in the carrying value of goodwill exists as of that date. Through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;there have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; events or changes in circumstances that indicate that the carrying value of goodwill &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. Changes in the carrying value of goodwill were as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 82%"&gt;Balance at January 1, 2019&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,851&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Effect of foreign currency adjustments&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(156&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,695&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
  <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380140" unitRef="iso4217-usd">-156000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
  <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="i_2018-11-30" decimals="-3" id="c46380136" unitRef="iso4217-usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-HYALOSPINEDevelopedTechnologyAssetMember" decimals="-5" id="c46380073" unitRef="iso4217-usd">300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379800" unitRef="iso4217-usd">281000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="d_2018-01-01_2018-03-31" id="c46379801" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380083" unitRef="iso4217-usd">281000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379684" unitRef="iso4217-usd">5980000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379685" unitRef="iso4217-usd">-7737000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184349">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;The provision for income taxes was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.5&lt;/div&gt; million for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;based on an effective tax rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24.6%.&lt;/div&gt;&amp;nbsp;The benefit from income taxes was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;based on an effective tax benefit rate of (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.6%&lt;/div&gt;). The net increase in the effective tax rate for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;as compared to the same period in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; was primarily due to the windfall tax benefit the Company realized in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2018 &lt;/div&gt;due to limitations on the deductibility of executive compensation for accelerated stock vesting upon the retirement of its former Chief Executive Officer on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 9, 2018. &lt;/div&gt;The Company realized an immaterial shortfall for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.&amp;nbsp; The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the preparation of the financial statements, the Company assesses whether it was more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; otherwise subject to a valuation allowance are realizable on a &amp;#x201c;more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&amp;#x201d;&lt;/div&gt; basis. As such, the Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; &lt;/div&gt;record a valuation allowance as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380204" unitRef="iso4217-usd">1473000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46380207" unitRef="iso4217-usd">-1051000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379819" unitRef="iso4217-usd">496000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379820" unitRef="iso4217-usd">-180000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379813" unitRef="iso4217-usd">-2489000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379814" unitRef="iso4217-usd">-5730000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379825" unitRef="iso4217-usd">910000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379826" unitRef="iso4217-usd">-1478000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379823" unitRef="iso4217-usd">-1928000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379824" unitRef="iso4217-usd">3270000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379815" unitRef="iso4217-usd">1617000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379816" unitRef="iso4217-usd">3924000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379817" unitRef="iso4217-usd">182000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379818" unitRef="iso4217-usd">-509000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380081" unitRef="iso4217-usd">17100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c46380090" unitRef="iso4217-usd">4406000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c46380099" unitRef="iso4217-usd">4700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380108" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c46380117" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2019-03-31" decimals="-3" id="c46380126" unitRef="iso4217-usd">28206000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-MEROGELINJECTIBLEAssetsMember" decimals="-5" id="c46380080" unitRef="iso4217-usd">100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31" decimals="-3" id="c46379611" unitRef="iso4217-usd">8467000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31" decimals="-3" id="c46379612" unitRef="iso4217-usd">9191000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380085" unitRef="iso4217-usd">4963000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c46380088" unitRef="iso4217-usd">5604000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c46380094" unitRef="iso4217-usd">3174000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c46380097" unitRef="iso4217-usd">3238000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" id="c46380103" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" id="c46380106" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380112" unitRef="iso4217-usd">330000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c46380115" unitRef="iso4217-usd">349000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c46380121" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c46380124" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379682" unitRef="iso4217-usd">498000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379683" unitRef="iso4217-usd">95000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InventoryDisclosureTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184337">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Inventories consist of the following:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;br /&gt; 2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Raw materials&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,751&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,688&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Work-in-process&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,626&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,536&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,819&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,259&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,133&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Inventories&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,617&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Other long-term assets&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,642&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,833&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Other long-term assets include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.6&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.8&lt;/div&gt; million of inventory expected to remain on hand beyond &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;respectively.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2019-03-31" decimals="-3" id="c46380061" unitRef="iso4217-usd">7536000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2018-12-31" decimals="-3" id="c46380062" unitRef="iso4217-usd">6819000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="i_2019-03-31" decimals="-3" id="c46379599" unitRef="iso4217-usd">22617000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2018-12-31" decimals="-3" id="c46379600" unitRef="iso4217-usd">21300000</us-gaap:InventoryNet>
  <us-gaap:InventoryNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c46380054" unitRef="iso4217-usd">3642000</us-gaap:InventoryNoncurrent>
  <us-gaap:InventoryNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c46380055" unitRef="iso4217-usd">3833000</us-gaap:InventoryNoncurrent>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="i_2019-03-31" decimals="-3" id="c46380057" unitRef="iso4217-usd">12751000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="i_2018-12-31" decimals="-3" id="c46380058" unitRef="iso4217-usd">13688000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRecallExpense contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379904" unitRef="iso4217-usd">1100000</us-gaap:InventoryRecallExpense>
  <us-gaap:InventoryRecallExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c46379905" unitRef="iso4217-usd">900000</us-gaap:InventoryRecallExpense>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2019-03-31" decimals="-3" id="c46380059" unitRef="iso4217-usd">5972000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2018-12-31" decimals="-3" id="c46380060" unitRef="iso4217-usd">4626000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379808" unitRef="iso4217-usd">381000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379809" unitRef="iso4217-usd">3246000</us-gaap:InventoryWriteDown>
  <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379810" unitRef="iso4217-usd">363000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
  <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="d_2018-01-01_2018-03-31" id="c46379811" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LeaseCost contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380183" unitRef="iso4217-usd">576000</us-gaap:LeaseCost>
  <us-gaap:LeaseCostTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;For the three months ending &lt;br /&gt; March 31, 2019&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 20%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Variable Lease Cost&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;576&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Other information&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;497&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17.6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; padding-left: 10pt; text-indent: -10pt"&gt;Years ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Operating Lease Obligation&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 80%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2019 (remaining 9 months)&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,490&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2020&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,025&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2021&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,024&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2022&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,981&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2023&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Thereafter&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,530&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Present value adjustment&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(9,708&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Present value of lease payments&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,307&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Less current portion included in Accrued expenses and other current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,075&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Lease liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,232&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="i_2019-03-31" decimals="-3" id="c46380193" unitRef="iso4217-usd">23530000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="i_2019-03-31" decimals="-3" id="c46380192" unitRef="iso4217-usd">1965000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="i_2019-03-31" decimals="-3" id="c46380191" unitRef="iso4217-usd">1981000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="i_2019-03-31" decimals="-3" id="c46380190" unitRef="iso4217-usd">2024000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="i_2019-03-31" decimals="-3" id="c46380189" unitRef="iso4217-usd">2025000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="i_2019-03-31" decimals="-3" id="c46380188" unitRef="iso4217-usd">1490000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="i_2019-03-31" decimals="-3" id="c46380194" unitRef="iso4217-usd">9708000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184345">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 47px"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Operating Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;The Company adopted Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019 &lt;/div&gt;using the modified retrospective adoption method, which did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; require it to restate prior periods. The Company has elected the transition relief package of practical expedients permitted within Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842.&lt;/div&gt; Accordingly, the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reassessed the classification of its existing leases as of the transition date, whether existing contracts at the transition date contain a lease, or whether unamortized initial direct costs before the transition adjustments would have met the definition of initial direct costs at lease commencement. The Company also applied practical expedients to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; separate lease and nonlease components for all new leases as well as leases commencing before the effective date if certain criteria are met, and does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; record leases on its balance sheet with terms of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months or less. Lease expense associated with leases with terms of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months or less are immaterial and recognized as incurred. The Company has included options to extend in the terms of its leases where it is reasonably certain that it will exercise these options.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the expected lease terms. The interest rate implicit in lease contracts is typically &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; depend on a rate or index are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the lease liability and are recognized as incurred. Certain adjustments to the right-of-use assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be required for items such as initial direct costs paid or incentives received. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised inputs as of the reassessment date, and adjust the right-of-use asset.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;The Company leases approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134,000&lt;/div&gt; square feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts, and approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,000&lt;/div&gt; square feet of office, research and development, training, and warehousing space in Padova, Italy. The current term of the Bedford lease extends to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2022&lt;/div&gt; with several extension options, and the current term of the Padova lease extends to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2026.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;The Company identified and assessed significant assumptions in recognizing the right-of-use asset and lease liability on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019 &lt;/div&gt;as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Incremental borrowing rate&lt;/div&gt;. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company&amp;#x2019;s lease agreements do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; provide implicit rates. As the Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have any external borrowings at the transition date with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease and nonlease components. &lt;/div&gt;The Company is required to pay variable fees for operating expenses in addition to monthly base rent for certain operating leases. The amounts of additional rent associated with these fees are considered nonlease components. The Company has elected the practical expedient which allows nonlease components in a contract to be accounted for as part of a single lease component to which they relate. Any variable components of these operating costs are excluded from lease payments and are recognized in the period incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Extension Options.&lt;/div&gt; The terms of the Company&amp;#x2019;s leases include options to extend the lease term. As of the transition date to Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; the Company has included extension options reasonably certain to be exercised in the lease term.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense and other information are as follows:&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;For the three months ending &lt;br /&gt; March 31, 2019&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 20%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Variable Lease Cost&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;576&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Other information&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;497&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17.6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Future minimum commitments due under these lease agreements as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;are as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; padding-left: 10pt; text-indent: -10pt"&gt;Years ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Operating Lease Obligation&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 80%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2019 (remaining 9 months)&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,490&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2020&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,025&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2021&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,024&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2022&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,981&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;2023&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,965&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Thereafter&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,530&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Present value adjustment&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(9,708&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Present value of lease payments&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,307&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Less current portion included in Accrued expenses and other current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,075&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Lease liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,232&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2019-03-31" decimals="-3" id="c46379663" unitRef="iso4217-usd">306659000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2018-12-31" decimals="-3" id="c46379664" unitRef="iso4217-usd">278993000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379623" unitRef="iso4217-usd">11602000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379624" unitRef="iso4217-usd">11289000</us-gaap:LiabilitiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379593" unitRef="iso4217-usd">71222000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379594" unitRef="iso4217-usd">69972000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379947" unitRef="iso4217-usd">71221000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379948" unitRef="iso4217-usd">71221000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379949" unitRef="iso4217-usd">71221000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379955" unitRef="iso4217-usd">69972000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379956" unitRef="iso4217-usd">69972000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="c46379957" unitRef="iso4217-usd">69972000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:NatureOfOperations contextRef="d_2019-01-01_2019-03-31" id="s1184322">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Nature of Business&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;Anika Therapeutics, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (&amp;#x201c;HA&amp;#x201d;) technology. The Company&amp;#x2019;s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;The Company is subject to risks common to companies in the biotechnology and medical device industries including, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&amp;#x2019;s business through appropriate commercial strategies.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379843" unitRef="iso4217-usd">-119000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379844" unitRef="iso4217-usd">-1223000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379836" unitRef="iso4217-usd">-1917000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379837" unitRef="iso4217-usd">207000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379827" unitRef="iso4217-usd">8462000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379828" unitRef="iso4217-usd">9592000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379791" unitRef="iso4217-usd">4507000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379792" unitRef="iso4217-usd">-6686000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46380974" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c46380975" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46380976" unitRef="iso4217-usd">4507000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46380977" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46381016" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c46381017" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46381018" unitRef="iso4217-usd">-6686000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46381019" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OperatingIncomeLoss contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379680" unitRef="iso4217-usd">5482000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379681" unitRef="iso4217-usd">-7832000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseCost contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380180" unitRef="iso4217-usd">522000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseLiability contextRef="i_2019-03-31" decimals="-3" id="c46380195" unitRef="iso4217-usd">23307000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380156" unitRef="iso4217-usd">1075000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="i_2018-12-31" id="c46380157" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c46379629" unitRef="iso4217-usd">22232000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="i_2018-12-31" id="c46379630" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OperatingLeasePayments contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380185" unitRef="iso4217-usd">497000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="i_2019-03-31" decimals="-3" id="c46379607" unitRef="iso4217-usd">23748000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="i_2018-12-31" id="c46379608" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="i_2019-03-31" decimals="3" id="c46380187" unitRef="xbrli-pure">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2019-03-31" id="c46380186">P17Y219D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2019-03-31" decimals="-3" id="c46380158" unitRef="iso4217-usd">476000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c46380159" unitRef="iso4217-usd">349000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c46379609" unitRef="iso4217-usd">4003000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c46379610" unitRef="iso4217-usd">4897000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379702" unitRef="iso4217-usd">-315000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379703" unitRef="iso4217-usd">620000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46380980" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c46380981" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46380982" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46380983" unitRef="iso4217-usd">-315000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380984" unitRef="iso4217-usd">-315000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46381022" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c46381023" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46381024" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46381025" unitRef="iso4217-usd">620000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46381026" unitRef="iso4217-usd">620000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c46379625" unitRef="iso4217-usd">366000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c46379626" unitRef="iso4217-usd">550000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379839" unitRef="iso4217-usd">124000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379840" unitRef="iso4217-usd">1735000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379832" unitRef="iso4217-usd">58981000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379833" unitRef="iso4217-usd">12500000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379834" unitRef="iso4217-usd">1030000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379835" unitRef="iso4217-usd">2543000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2019-03-31" decimals="INF" id="c46379637" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-12-31" decimals="INF" id="c46379638" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2019-03-31" decimals="-3" id="c46379639" unitRef="xbrli-shares">1250000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-12-31" decimals="-3" id="c46379640" unitRef="xbrli-shares">1250000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2019-03-31" decimals="-3" id="c46379641" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2018-12-31" decimals="-3" id="c46379642" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2019-03-31" decimals="-3" id="c46379643" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2018-12-31" decimals="-3" id="c46379644" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2019-03-31" decimals="-3" id="c46379635" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2018-12-31" decimals="-3" id="c46379636" unitRef="iso4217-usd">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2019-03-31" decimals="-3" id="c46379601" unitRef="iso4217-usd">2077000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2018-12-31" decimals="-3" id="c46379602" unitRef="iso4217-usd">1854000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379830" unitRef="iso4217-usd">58094000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379831" unitRef="iso4217-usd">15250000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379841" unitRef="iso4217-usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379842" unitRef="iso4217-usd">512000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProductWarrantyAccrual contextRef="i_2019-03-31" decimals="-3" id="c46380199" unitRef="iso4217-usd">0</us-gaap:ProductWarrantyAccrual>
  <us-gaap:ProductWarrantyAccrual contextRef="i_2018-12-31" decimals="-3" id="c46380202" unitRef="iso4217-usd">0</us-gaap:ProductWarrantyAccrual>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2019-03-31" decimals="-3" id="c46379605" unitRef="iso4217-usd">53051000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2018-12-31" decimals="-3" id="c46379606" unitRef="iso4217-usd">54111000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379674" unitRef="iso4217-usd">4258000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379675" unitRef="iso4217-usd">5161000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2019-03-31" decimals="-3" id="c46379659" unitRef="iso4217-usd">222740000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2018-12-31" decimals="-3" id="c46379660" unitRef="iso4217-usd">218233000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ProductMember" decimals="-3" id="c46379665" unitRef="iso4217-usd">24717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ProductMember" decimals="-3" id="c46379666" unitRef="iso4217-usd">21258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ServiceMember" decimals="-3" id="c46379667" unitRef="iso4217-usd">6000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ServiceMember" decimals="-3" id="c46379668" unitRef="iso4217-usd">6000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379669" unitRef="iso4217-usd">24723000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379670" unitRef="iso4217-usd">21264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-OrthobiologicsMember" decimals="-3" id="c46379907" unitRef="iso4217-usd">21748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-SurgicalMember" decimals="-3" id="c46379909" unitRef="iso4217-usd">1392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-DermalMember" decimals="-3" id="c46379911" unitRef="iso4217-usd">129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ManufacturedProductOtherMember" decimals="-3" id="c46379913" unitRef="iso4217-usd">1448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-US" decimals="-3" id="c46379918" unitRef="iso4217-usd">20089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-US" decimals="-3" id="c46379920" unitRef="iso4217-usd">16910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c46379922" unitRef="iso4217-usd">2526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c46379924" unitRef="iso4217-usd">2391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2019-01-01_2019-03-31_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c46379926" unitRef="iso4217-usd">2108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="d_2018-01-01_2018-03-31_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c46379928" unitRef="iso4217-usd">1963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2019-01-01_2019-03-31" id="s1184324">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&amp;#x2019;s right to consideration is unconditional. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;deferred revenue was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$67&lt;/div&gt; thousand.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (&amp;#x201c;Mitek&amp;#x201d;) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;72%&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;76%&lt;/div&gt; of total Company revenues for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;respectively. The Company has agreements with other customers that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;include the delivery of a license and supply of product.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following tables provide the disaggregated revenue by major product group and primary geographical market. Product revenue by product group was as follows:&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Orthobiologics&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,748&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,489&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Surgical&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,392&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dermal&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(539&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,448&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,063&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Product Revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,717&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,258&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Total revenue by geographic location was as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage of&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;br /&gt; Revenue&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage of&lt;br /&gt; Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 52%; text-align: left; padding-left: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,089&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,910&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt"&gt;Europe&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,526&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,391&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,108&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,963&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"&gt;Total Revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,723&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,264&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2, 2018, &lt;/div&gt;the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that the products were at risk of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; maintaining certain measures throughout their entire shelf life. While there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;the Company recorded a revenue reserve for this voluntary recall of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.9&lt;/div&gt; million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46381033" unitRef="iso4217-usd">24110</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="d_2018-01-01_2018-03-31" id="c46381034" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;br /&gt; 2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Compensation and related expenses&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,563&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,446&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,810&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,989&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Research grants&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;392&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Clinical trial costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;419&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;577&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Income taxes payable&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,296&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;385&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Lease liability - current&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,075&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;476&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,031&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,146&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Shares used in the calculation of basic earnings per share&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Effect of dilutive securities:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Stock options, SARs, RSAs, RSUs and PSUs&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Diluted shares used in the calculation of earnings per share&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,314&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Cost of product revenue&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(216&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Research&amp;nbsp;&amp;amp; development&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;177&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;210&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling, general&amp;nbsp;&amp;amp; administrative&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,117&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,571&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,386&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,565&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 82%"&gt;Balance at January 1, 2019&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,851&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Effect of foreign currency adjustments&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(156&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,695&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;March 31,&lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;br /&gt; 2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Raw materials&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,751&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 14%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,688&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Work-in-process&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,972&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,626&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,536&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,819&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,259&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,133&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Inventories&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,617&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Other long-term assets&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,642&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,833&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-15">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Orthobiologics&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,748&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,489&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Surgical&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,392&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dermal&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(539&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,448&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,063&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Product Revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,717&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,258&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2019-01-01_2019-03-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended March 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.44%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.54%&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.15%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.37%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44.34%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44.41%&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;38.74%&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; - &lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40.81%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; text-align: left"&gt;Expected life (years)&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 5%; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 5%; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.00%&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.00%&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379676" unitRef="iso4217-usd">7672000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379677" unitRef="iso4217-usd">16090000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2019-01-01_2019-03-31" decimals="INF" id="c46379802" unitRef="iso4217-usd">1386000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2018-01-01_2018-03-31" decimals="INF" id="c46379803" unitRef="iso4217-usd">7565000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" id="c46379974">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" id="c46379981">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockMember" id="c46380028" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c46380029" unitRef="xbrli-shares">64578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" decimals="INF" id="c46380030" unitRef="xbrli-shares">165507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" decimals="INF" id="c46380031" unitRef="xbrli-shares">8130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-PerformanceRestrictedStockUnitsMember" decimals="INF" id="c46380032" unitRef="xbrli-shares">114500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-PerformanceRestrictedStockUnitsMember" id="c46380033" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2019-01-01_2019-03-31" decimals="4" id="c46380012" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2019-01-01_2019-03-31_RangeAxis-MaximumMember" id="c46380013" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2018-01-01_2018-03-31" decimals="4" id="c46380015" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2019-01-01_2019-03-31_RangeAxis-MinimumMember" decimals="4" id="c46379999" unitRef="xbrli-pure">0.4434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2019-01-01_2019-03-31_RangeAxis-MaximumMember" decimals="4" id="c46380001" unitRef="xbrli-pure">0.4441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-03-31_RangeAxis-MinimumMember" decimals="4" id="c46380002" unitRef="xbrli-pure">0.3874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-03-31_RangeAxis-MaximumMember" decimals="4" id="c46380004" unitRef="xbrli-pure">0.4081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2019-01-01_2019-03-31_RangeAxis-MinimumMember" decimals="4" id="c46379993" unitRef="xbrli-pure">0.0244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2019-01-01_2019-03-31_RangeAxis-MaximumMember" decimals="4" id="c46379995" unitRef="xbrli-pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-03-31_RangeAxis-MinimumMember" decimals="4" id="c46379996" unitRef="xbrli-pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-03-31_RangeAxis-MaximumMember" decimals="4" id="c46379998" unitRef="xbrli-pure">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-StockAppreciationRightsSARSMember" id="c46380037" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-StockAppreciationRightsSARSMember" id="c46380038" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c46380026" unitRef="xbrli-shares">104292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c46380027" unitRef="xbrli-shares">192300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2019-01-01_2019-03-31_RangeAxis-MinimumMember" id="c46380005" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2019-01-01_2019-03-31" id="c46380006">P3Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2019-01-01_2019-03-31_RangeAxis-MaximumMember" id="c46380007" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-03-31" id="c46380009">P4Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380949" unitRef="xbrli-shares">14210000</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380985" unitRef="xbrli-shares">14214000</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380991" unitRef="xbrli-shares">14688000</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46381027" unitRef="xbrli-shares">14745000</us-gaap:SharesOutstanding>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380961" unitRef="xbrli-shares">3000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46381003" unitRef="xbrli-shares">32000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:ShortTermLeaseCost contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380181" unitRef="iso4217-usd">2000</us-gaap:ShortTermLeaseCost>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380955" unitRef="xbrli-shares">7000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380997" unitRef="xbrli-shares">89000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2019-01-01_2019-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c46380035" unitRef="xbrli-shares">500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2018-01-01_2018-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c46380036" unitRef="xbrli-shares">11425</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" id="c46380956" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380957" unitRef="iso4217-usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46380958" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46380959" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380960" unitRef="iso4217-usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380998" unitRef="iso4217-usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380999" unitRef="iso4217-usd">511000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c46381000" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" id="c46381001" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46381002" unitRef="iso4217-usd">512000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockholdersEquity contextRef="i_2019-03-31" decimals="-3" id="c46379661" unitRef="iso4217-usd">269071000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31" decimals="-3" id="c46379662" unitRef="iso4217-usd">263612000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380950" unitRef="iso4217-usd">142000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380951" unitRef="iso4217-usd">50763000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46380952" unitRef="iso4217-usd">218233000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46380953" unitRef="iso4217-usd">-5526000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380986" unitRef="iso4217-usd">142000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380987" unitRef="iso4217-usd">52030000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46380988" unitRef="iso4217-usd">222740000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46380989" unitRef="iso4217-usd">-5841000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46380992" unitRef="iso4217-usd">147000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46380993" unitRef="iso4217-usd">68617000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46380994" unitRef="iso4217-usd">199511000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46380995" unitRef="iso4217-usd">-4784000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31" decimals="-3" id="c46380996" unitRef="iso4217-usd">263491000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-03-31_StatementEquityComponentsAxis-CommonStockMember" decimals="-3" id="c46381028" unitRef="iso4217-usd">147000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c46381029" unitRef="iso4217-usd">74958000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c46381030" unitRef="iso4217-usd">192825000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="c46381031" unitRef="iso4217-usd">-4164000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-03-31" decimals="-3" id="c46381032" unitRef="iso4217-usd">263766000</us-gaap:StockholdersEquity>
  <us-gaap:VariableLeaseCost contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380182" unitRef="iso4217-usd">52000</us-gaap:VariableLeaseCost>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46380049" unitRef="xbrli-shares">129000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2018-01-01_2018-03-31" id="c46380050" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379698" unitRef="xbrli-shares">14314000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379699" unitRef="xbrli-shares">14679000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2019-01-01_2019-03-31" decimals="-3" id="c46379693" unitRef="xbrli-shares">14185000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2018-01-01_2018-03-31" decimals="-3" id="c46379694" unitRef="xbrli-shares">14679000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="utr-sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-PerformanceRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-StockAppreciationRightsSARSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_AwardTypeAxis-StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_CounterpartyNameAxis-DepuyMitekIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anik:DepuyMitekIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ManufacturedProductOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-ServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-03-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-08_2018-03-08_TitleOfIndividualAxis-FormerChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anik:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-08</xbrli:startDate>
      <xbrli:endDate>2018-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-PerformanceRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-RSUsGrantedToEmployeesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anik:RSUsGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-StockAppreciationRightsSARSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_AwardTypeAxis-StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_CounterpartyNameAxis-DepuyMitekIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anik:DepuyMitekIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-HYALOSPINEDevelopedTechnologyAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:HYALOSPINEDevelopedTechnologyAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ManufacturedProductOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ProductMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-ServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-03-31_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-11-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_InvestmentTypeAxis-USTreasuryBillSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FairValueByAssetClassAxis-USTreasurySecuritiesMember_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-MEROGELINJECTIBLEAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:MEROGELINJECTIBLEAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_InvestmentTypeAxis-USTreasuryBillSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_LeaseArrangementTypeAxis-AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">anik:AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_LeaseArrangementTypeAxis-OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">anik:OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-04-22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>anik-20190331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:55PM UTC 2019-05-03--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:anik="http://www.anikatherapeutics.com/20190331" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anikatherapeutics.com/20190331">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited-" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Nature of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation-" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-investments" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Equity Incentive Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Earnings Per Share ("EPS")</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Goodwill</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-operating-leases-" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Operating Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-commitments-and-contingencies" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 3 - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 5 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 6 - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 8 - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 9 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 10 - Goodwill (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 11 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-operating-leases-tables" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 12 - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 3 - Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-product-revenue-by-product-group-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 3 - Revenue - Product Revenue by Product Group (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-total-revenue-by-geographic-location-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 3 - Revenue - Total Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-investments-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 4 - Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 8 - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories-summary-of-inventories-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 9 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 10 - Goodwill (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 11 - Accrued Expenses (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-operating-leases-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 12 - Operating Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-operating-leases-lease-expense-and-other-information-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 12 - Operating Leases - Lease Expense and Other Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-commitments-and-contingencies-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-details-textual" roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 14 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="anik_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="anik_AccruedResearchGrantsCurrent" name="AccruedResearchGrantsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="anik_AccumulatedCurrencyTranslationAdjustment" name="AccumulatedCurrencyTranslationAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" name="AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_CashEquivalentsFairValueDisclosure" name="CashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_DepuyMitekIncMember" name="DepuyMitekIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_DermalMember" name="DermalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_ElevessTradeNameMember" name="ElevessTradeNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_FormerChiefExecutiveOfficerMember" name="FormerChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_HYALOSPINEDevelopedTechnologyAssetMember" name="HYALOSPINEDevelopedTechnologyAssetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" name="InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_MEROGELINJECTIBLEAssetsMember" name="MEROGELINJECTIBLEAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" name="OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_OrthobiologicsMember" name="OrthobiologicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_OtherLocationMember" name="OtherLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_PercentageOfNetRevenue" name="PercentageOfNetRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" name="PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" name="PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_PerformanceRestrictedStockUnitsMember" name="PerformanceRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_RSUsGrantedToEmployeesMember" name="RSUsGrantedToEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_RevenueFromContractWithCustomerPercentage" name="RevenueFromContractWithCustomerPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" name="RevenuesFromAgreementsAsPercentOfTotalRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" name="ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" name="ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_SeveranceBenefitFollowingRetirement" name="SeveranceBenefitFollowingRetirement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="anik_SeveranceBenefitFollowingRetirementTerm" name="SeveranceBenefitFollowingRetirementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" name="StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" name="statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-10-goodwill-tables" name="statement-statement-note-10-goodwill-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" name="statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-11-accrued-expenses-tables" name="statement-statement-note-11-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" name="statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" name="statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-12-operating-leases-tables" name="statement-statement-note-12-operating-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" name="statement-statement-note-3-revenue-product-revenue-by-product-group-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-3-revenue-tables" name="statement-statement-note-3-revenue-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" name="statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" name="statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-5-fair-value-measurements-tables" name="statement-statement-note-5-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" name="statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" name="statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-equity-incentive-plan-tables" name="statement-statement-note-6-equity-incentive-plan-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" name="statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" name="statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-7-earnings-per-share-eps-tables" name="statement-statement-note-7-earnings-per-share-eps-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-8-inventories-summary-of-inventories-details" name="statement-statement-note-8-inventories-summary-of-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-8-inventories-tables" name="statement-statement-note-8-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" name="statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-9-intangible-assets-tables" name="statement-statement-note-9-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>anik-20190331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:56PM UTC 2019-05-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:href="anik-20190331.xsd#statement-note-8-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="anik_AccruedResearchGrantsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="anik_AccruedClinicalTrialCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_IncreaseDecreaseInLeaseLiabilities" xlink:label="anik_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="anik_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>anik-20190331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:55PM UTC 2019-05-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-" xlink:href="anik-20190331.xsd#statement-note-2-basis-of-presentation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business" xlink:href="anik-20190331.xsd#statement-note-1-nature-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information" xlink:href="anik-20190331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue" xlink:href="anik-20190331.xsd#statement-note-3-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DepuyMitekIncMember" xlink:label="anik_DepuyMitekIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="anik_DepuyMitekIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments" xlink:href="anik-20190331.xsd#statement-note-4-investments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_RSUsGrantedToEmployeesMember" xlink:label="anik_RSUsGrantedToEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_RSUsGrantedToEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories" xlink:href="anik-20190331.xsd#statement-note-8-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_MEROGELINJECTIBLEAssetsMember" xlink:label="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill" xlink:href="anik-20190331.xsd#statement-note-10-goodwill" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_FormerChiefExecutiveOfficerMember" xlink:label="anik_FormerChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_FormerChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies" xlink:href="anik-20190331.xsd#statement-note-13-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes" xlink:href="anik-20190331.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables" xlink:href="anik-20190331.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables" xlink:href="anik-20190331.xsd#statement-note-8-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual" xlink:href="anik-20190331.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DepuyMitekIncMember" xlink:label="anik_DepuyMitekIncMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRecallExpense" xlink:label="us-gaap_InventoryRecallExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="anik_DepuyMitekIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRecallExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual" xlink:href="anik-20190331.xsd#statement-note-4-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RSUsGrantedToEmployeesMember" xlink:label="anik_RSUsGrantedToEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_RSUsGrantedToEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual" xlink:href="anik-20190331.xsd#statement-note-8-inventories-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_MEROGELINJECTIBLEAssetsMember" xlink:label="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_FormerChiefExecutiveOfficerMember" xlink:label="anik_FormerChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirement" xlink:label="anik_SeveranceBenefitFollowingRetirement" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirementTerm" xlink:label="anik_SeveranceBenefitFollowingRetirementTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_FormerChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_SeveranceBenefitFollowingRetirement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_SeveranceBenefitFollowingRetirementTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:href="anik-20190331.xsd#statement-note-13-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProductWarrantyAccrual" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual" xlink:href="anik-20190331.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:href="anik-20190331.xsd#statement-note-8-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedResearchGrantsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedClinicalTrialCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_IncreaseDecreaseInLeaseLiabilities" xlink:label="anik_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="anik_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details" xlink:href="anik-20190331.xsd#statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenueFromContractWithCustomerPercentage" xlink:label="anik_RevenueFromContractWithCustomerPercentage" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="anik_OrthobiologicsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="anik_SurgicalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="anik_DermalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ManufacturedProductOtherMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_RevenueFromContractWithCustomerPercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:href="anik-20190331.xsd#statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_ElevessTradeNameMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_CashEquivalentsFairValueDisclosure" xlink:label="anik_CashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_CashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceRestrictedStockUnitsMember" xlink:label="anik_PerformanceRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="us-gaap_StockAppreciationRightsSARSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="anik_PerformanceRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:href="anik-20190331.xsd#statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="anik_OtherLocationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PercentageOfNetRevenue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>anik-20190331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:55PM UTC 2019-05-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DocumentAndEntityInformation" xlink:label="anik_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="anik_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DocumentAndEntityInformation" xlink:to="anik_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="anik_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="anik_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-tables" xlink:label="anik_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-3-revenue-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-3-revenue-tables" xlink:to="anik_statement-statement-note-3-revenue-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-5-fair-value-measurements-tables" xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:to="anik_statement-statement-note-5-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Equity Incentive Plan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:to="anik_statement-statement-note-6-equity-incentive-plan-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Earnings Per Share ("EPS")</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:to="anik_statement-statement-note-7-earnings-per-share-eps-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-8-inventories-tables" xlink:label="anik_statement-statement-note-8-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-8-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-8-inventories-tables" xlink:to="anik_statement-statement-note-8-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-9-intangible-assets-tables" xlink:label="anik_statement-statement-note-9-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-9-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-9-intangible-assets-tables" xlink:to="anik_statement-statement-note-9-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-10-goodwill-tables" xlink:label="anik_statement-statement-note-10-goodwill-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-10-goodwill-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-10-goodwill-tables" xlink:to="anik_statement-statement-note-10-goodwill-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-11-accrued-expenses-tables" xlink:label="anik_statement-statement-note-11-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-11-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-11-accrued-expenses-tables" xlink:to="anik_statement-statement-note-11-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-tables" xlink:label="anik_statement-statement-note-12-operating-leases-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-12-operating-leases-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-12-operating-leases-tables" xlink:to="anik_statement-statement-note-12-operating-leases-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:label="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Product Revenue by Product Group (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:to="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:label="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Total Revenue by Geographic Location (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:to="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:label="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:to="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:to="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 (remaining 9 months)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:to="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:to="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:to="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:label="anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-8-inventories-summary-of-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Inventories - Summary of Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:to="anik_statement-statement-note-8-inventories-summary-of-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:label="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:to="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:label="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:to="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:label="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:to="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:label="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Operating Leases - Lease Expense and Other Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:to="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:label="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:to="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatements" xlink:label="anik_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="anik_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NotesToFinancialStatements" xlink:to="anik_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="anik_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="anik_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member]</link:label>
    <link:label xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about stock options, PSUs and RSUs to employees and RSUs to non-employee directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:to="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceRestrictedStockUnitsMember" xlink:label="anik_PerformanceRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_PerformanceRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units [Member]</link:label>
    <link:label xlink:label="anik_PerformanceRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Performance Restricted Stock Units (PSUs).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PerformanceRestrictedStockUnitsMember" xlink:to="anik_PerformanceRestrictedStockUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear</link:label>
    <link:label xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company&#8217;s Operating Results in next Fiscal Year</link:label>
    <link:label xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance conditions based on company&#8217;s operating results in next fiscal year set as business target.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:to="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear</link:label>
    <link:label xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year</link:label>
    <link:label xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance conditions based on achievement in current fiscal year set as business target.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:to="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasurySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="locator"/>
    <link:label xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HYALOSPINE Developed Technology Asset [Member]</link:label>
    <link:label xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents HYALOSPINE developed technology asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:to="anik_HYALOSPINEDevelopedTechnologyAssetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Instruments Other than Options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock for minimum tax withholdings (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InventoryNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive Income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office, Research and Development, Training, and Warehousing Space in Padova, Italy [Member]</link:label>
    <link:label xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents office, research and development, training, and warehousing space in Padova, Italy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:to="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="locator"/>
    <link:label xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative, Research and Development, and Manufacturing Space in Bedford, MA [Member]</link:label>
    <link:label xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about administrative, research and development, and manufacturing space in Bedford, MA.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:to="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RSUsGrantedToEmployeesMember" xlink:label="anik_RSUsGrantedToEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="anik_RSUsGrantedToEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSUs Granted to Employees [Member]</link:label>
    <link:label xlink:label="anik_RSUsGrantedToEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about RSUs granted to employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_RSUsGrantedToEmployeesMember" xlink:to="anik_RSUsGrantedToEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.01 par value; 60,000 shares authorized, 14,214 and 14,210 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</link:label>
    <link:label xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfGoodwillTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedIncomeTaxesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_MEROGELINJECTIBLEAssetsMember" xlink:label="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_MEROGELINJECTIBLEAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MEROGEL INJECTIBLE Assets [Member]</link:label>
    <link:label xlink:label="anik_MEROGELINJECTIBLEAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MEROGEL INJECTIBLE Assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_MEROGELINJECTIBLEAssetsMember" xlink:to="anik_MEROGELINJECTIBLEAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_EuropeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DevelopedTechnologyRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DistributionRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of reserves of $1,210 and $1,525 at March 31, 2019 and December 31, 2018, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock for minimum tax withholdings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_FormerChiefExecutiveOfficerMember" xlink:label="anik_FormerChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="anik_FormerChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="anik_FormerChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the former highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_FormerChiefExecutiveOfficerMember" xlink:to="anik_FormerChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentIncomeAmortizationOfDiscount</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion to amortized cost of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="us-gaap_StockAppreciationRightsSARSMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockAppreciationRightsSARSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAppreciationRightsSARSMember" xlink:to="us-gaap_StockAppreciationRightsSARSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange rate impact on cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</link:label>
    <link:label xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_IncreaseDecreaseInLeaseLiabilities" xlink:label="anik_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator"/>
    <link:label xlink:label="anik_IncreaseDecreaseInLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_IncreaseDecreaseInLeaseLiabilities</link:label>
    <link:label xlink:label="anik_IncreaseDecreaseInLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label xlink:label="anik_IncreaseDecreaseInLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_IncreaseDecreaseInLeaseLiabilities" xlink:to="anik_IncreaseDecreaseInLeaseLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:type="locator"/>
    <link:label xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_RevenuesFromAgreementsAsPercentOfTotalRevenue</link:label>
    <link:label xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues From Agreements as Percent of Total Revenue</link:label>
    <link:label xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of total revenue that revenue from agreements comprises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:to="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for tax withheld on vested restricted stock awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductWarrantyAccrual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProductWarrantyAccrual</link:label>
    <link:label xlink:label="us-gaap_ProductWarrantyAccrual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirementTerm" xlink:label="anik_SeveranceBenefitFollowingRetirementTerm" xlink:type="locator"/>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_SeveranceBenefitFollowingRetirementTerm</link:label>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Benefit Following Retirement, Term</link:label>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time for the severance benefit to be paid following retirement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_SeveranceBenefitFollowingRetirementTerm" xlink:to="anik_SeveranceBenefitFollowingRetirementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirement" xlink:label="anik_SeveranceBenefitFollowingRetirement" xlink:type="locator"/>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_SeveranceBenefitFollowingRetirement</link:label>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Benefit Following Retirement</link:label>
    <link:label xlink:label="anik_SeveranceBenefitFollowingRetirement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of severance benefit provided following a person's retirement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_SeveranceBenefitFollowingRetirement" xlink:to="anik_SeveranceBenefitFollowingRetirement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:label xlink:label="anik_ElevessTradeNameMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elevess Trade Name [Member]</link:label>
    <link:label xlink:label="anik_ElevessTradeNameMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Elevess trade name.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ElevessTradeNameMember" xlink:to="anik_ElevessTradeNameMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:type="locator"/>
    <link:label xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal</link:label>
    <link:label xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:to="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of equity awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]</link:label>
    <link:label xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents schedule of revenue and operating income, by geographical areas.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OtherLocationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Location [Member]</link:label>
    <link:label xlink:label="anik_OtherLocationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents other location.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OtherLocationMember" xlink:to="anik_OtherLocationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue" xlink:type="locator"/>
    <link:label xlink:label="anik_PercentageOfNetRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Revenue</link:label>
    <link:label xlink:label="anik_PercentageOfNetRevenue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of net revenue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PercentageOfNetRevenue" xlink:to="anik_PercentageOfNetRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses, other current and long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ManufacturedProductOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturedProductOtherMember" xlink:to="us-gaap_ManufacturedProductOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</link:label>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseCost</link:label>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, other current and long-term assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_CashEquivalentsFairValueDisclosure" xlink:label="anik_CashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="anik_CashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label xlink:label="anik_CashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value disclosure for cash equivalents as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_CashEquivalentsFairValueDisclosure" xlink:to="anik_CashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ServiceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on impairment of intangible asset</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:label xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options, SARs, RSAs, RSUs and PSUs (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenueFromContractWithCustomerPercentage" xlink:label="anik_RevenueFromContractWithCustomerPercentage" xlink:type="locator"/>
    <link:label xlink:label="anik_RevenueFromContractWithCustomerPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Product Revenue</link:label>
    <link:label xlink:label="anik_RevenueFromContractWithCustomerPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of revenue from contract with customer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_RevenueFromContractWithCustomerPercentage" xlink:to="anik_RevenueFromContractWithCustomerPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted shares used in the calculation of earnings per share (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRecallExpense" xlink:label="us-gaap_InventoryRecallExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRecallExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryRecallExpense</link:label>
    <link:label xlink:label="us-gaap_InventoryRecallExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRecallExpense" xlink:to="us-gaap_InventoryRecallExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareDiluted</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="locator"/>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_AccumulatedCurrencyTranslationAdjustment</link:label>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Currency Translation Adjustment</link:label>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of the accumulated currency translation adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccumulatedCurrencyTranslationAdjustment" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted net income (loss) per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecurities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic net income (loss) per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="anik_AccruedClinicalTrialCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label xlink:label="anik_AccruedClinicalTrialCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued clinical trial costs current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccruedClinicalTrialCostsCurrent" xlink:to="anik_AccruedClinicalTrialCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:label xlink:label="anik_AccruedResearchGrantsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research grants</link:label>
    <link:label xlink:label="anik_AccruedResearchGrantsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued research grants current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccruedResearchGrantsCurrent" xlink:to="anik_AccruedResearchGrantsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasuryBillSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for equity awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general &amp; administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for equity awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OrthobiologicsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orthobiologics [Member]</link:label>
    <link:label xlink:label="anik_OrthobiologicsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Orthobiologics.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OrthobiologicsMember" xlink:to="anik_OrthobiologicsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:label xlink:label="anik_DermalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dermal [Member]</link:label>
    <link:label xlink:label="anik_DermalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Dermal.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DermalMember" xlink:to="anik_DermalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:label xlink:label="anik_SurgicalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [Member]</link:label>
    <link:label xlink:label="anik_SurgicalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Surgical.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_SurgicalMember" xlink:to="anik_SurgicalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:label xlink:label="country_US-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research &amp; development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_DepuyMitekIncMember" xlink:label="anik_DepuyMitekIncMember" xlink:type="locator"/>
    <link:label xlink:label="anik_DepuyMitekIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DePuy Mitek Inc [Member]</link:label>
    <link:label xlink:label="anik_DepuyMitekIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The DePuy Mitek Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DepuyMitekIncMember" xlink:to="anik_DepuyMitekIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liability - current</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion included in Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Present value adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>anik-20190331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:55PM UTC 2019-05-03--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-" xlink:href="anik-20190331.xsd#statement-note-2-basis-of-presentation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business" xlink:href="anik-20190331.xsd#statement-note-1-nature-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information" xlink:href="anik-20190331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue" xlink:href="anik-20190331.xsd#statement-note-3-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DepuyMitekIncMember" xlink:label="anik_DepuyMitekIncMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="anik_DepuyMitekIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments" xlink:href="anik-20190331.xsd#statement-note-4-investments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RSUsGrantedToEmployeesMember" xlink:label="anik_RSUsGrantedToEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="anik_RSUsGrantedToEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories" xlink:href="anik-20190331.xsd#statement-note-8-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_MEROGELINJECTIBLEAssetsMember" xlink:label="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill" xlink:href="anik-20190331.xsd#statement-note-10-goodwill" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_FormerChiefExecutiveOfficerMember" xlink:label="anik_FormerChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="anik_FormerChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies" xlink:href="anik-20190331.xsd#statement-note-13-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes" xlink:href="anik-20190331.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables" xlink:href="anik-20190331.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-tables" xlink:label="anik_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-3-revenue-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-5-fair-value-measurements-tables" xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables" xlink:href="anik-20190331.xsd#statement-note-8-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-8-inventories-tables" xlink:label="anik_statement-statement-note-8-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-8-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-9-intangible-assets-tables" xlink:label="anik_statement-statement-note-9-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-9-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-10-goodwill-tables" xlink:label="anik_statement-statement-note-10-goodwill-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-10-goodwill-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-11-accrued-expenses-tables" xlink:label="anik_statement-statement-note-11-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-11-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-tables" xlink:label="anik_statement-statement-note-12-operating-leases-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-12-operating-leases-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual" xlink:href="anik-20190331.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DepuyMitekIncMember" xlink:label="anik_DepuyMitekIncMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenuesFromAgreementsAsPercentOfTotalRevenue" xlink:label="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRecallExpense" xlink:label="us-gaap_InventoryRecallExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="anik_DepuyMitekIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_RevenuesFromAgreementsAsPercentOfTotalRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRecallExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual" xlink:href="anik-20190331.xsd#statement-note-4-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear" xlink:label="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear" xlink:label="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RSUsGrantedToEmployeesMember" xlink:label="anik_RSUsGrantedToEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:label="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="anik_RSUsGrantedToEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual" xlink:href="anik-20190331.xsd#statement-note-8-inventories-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual" xlink:href="anik-20190331.xsd#statement-note-9-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:label="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_MEROGELINJECTIBLEAssetsMember" xlink:label="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_HYALOSPINEDevelopedTechnologyAssetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_MEROGELINJECTIBLEAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_FormerChiefExecutiveOfficerMember" xlink:label="anik_FormerChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirement" xlink:label="anik_SeveranceBenefitFollowingRetirement-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SeveranceBenefitFollowingRetirementTerm" xlink:label="anik_SeveranceBenefitFollowingRetirementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="anik_FormerChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_SeveranceBenefitFollowingRetirement-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_SeveranceBenefitFollowingRetirementTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:label="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:label="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:href="anik-20190331.xsd#statement-note-13-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProductWarrantyAccrual-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual" xlink:href="anik-20190331.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:href="anik-20190331.xsd#statement-note-8-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal" xlink:label="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-3" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:label="anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-8-inventories-summary-of-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:href="anik-20190331.xsd#statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:label="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:href="anik-20190331.xsd#statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:label="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-11-accrued-expenses-summary-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedResearchGrantsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedClinicalTrialCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:label="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_IncreaseDecreaseInLeaseLiabilities" xlink:label="anik_IncreaseDecreaseInLeaseLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="anik_IncreaseDecreaseInLeaseLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details" xlink:href="anik-20190331.xsd#statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_RevenueFromContractWithCustomerPercentage" xlink:label="anik_RevenueFromContractWithCustomerPercentage" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:label="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-3-revenue-product-revenue-by-product-group-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="anik_OrthobiologicsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="anik_SurgicalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="anik_DermalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ManufacturedProductOtherMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_RevenueFromContractWithCustomerPercentage" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:href="anik-20190331.xsd#statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:href="anik-20190331.xsd#statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-n8" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:label="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_ElevessTradeNameMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:href="anik-20190331.xsd#statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:label="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-12-operating-leases-lease-expense-and-other-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:href="anik-20190331.xsd#statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_CashEquivalentsFairValueDisclosure" xlink:label="anik_CashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:label="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_CashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:href="anik-20190331.xsd#statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_PerformanceRestrictedStockUnitsMember" xlink:label="anik_PerformanceRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="us-gaap_StockAppreciationRightsSARSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="anik_PerformanceRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:href="anik-20190331.xsd#statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="anik-20190331.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue" xlink:type="locator"/>
    <link:loc xlink:href="anik-20190331.xsd#anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:label="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-3-revenue-total-revenue-by-geographic-location-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_EuropeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="anik_OtherLocationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PercentageOfNetRevenue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="anik-20190331.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769727632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 22, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Anika Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000898437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">anik<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,206,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772025904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 95,514,000<span></span>
</td>
<td class="nump">$ 89,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">71,222,000<span></span>
</td>
<td class="nump">69,972,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of reserves of $1,210 and $1,525 at March 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">18,265,000<span></span>
</td>
<td class="nump">20,775,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">22,617,000<span></span>
</td>
<td class="nump">21,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,077,000<span></span>
</td>
<td class="nump">1,854,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">209,695,000<span></span>
</td>
<td class="nump">202,943,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">53,051,000<span></span>
</td>
<td class="nump">54,111,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">23,748,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,003,000<span></span>
</td>
<td class="nump">4,897,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">8,467,000<span></span>
</td>
<td class="nump">9,191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,695,000<span></span>
</td>
<td class="nump">7,851,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">306,659,000<span></span>
</td>
<td class="nump">278,993,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,571,000<span></span>
</td>
<td class="nump">3,143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,031,000<span></span>
</td>
<td class="nump">8,146,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,602,000<span></span>
</td>
<td class="nump">11,289,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">3,388,000<span></span>
</td>
<td class="nump">3,542,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">22,232,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 60,000 shares authorized, 14,214 and 14,210 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">52,030,000<span></span>
</td>
<td class="nump">50,763,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,841,000)<span></span>
</td>
<td class="num">(5,526,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">222,740,000<span></span>
</td>
<td class="nump">218,233,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">269,071,000<span></span>
</td>
<td class="nump">263,612,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 306,659,000<span></span>
</td>
<td class="nump">$ 278,993,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6773264352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, reserves</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,214<span></span>
</td>
<td class="nump">14,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,214<span></span>
</td>
<td class="nump">14,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769882816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 24,723,000<span></span>
</td>
<td class="nump">$ 21,264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenue</a></td>
<td class="nump">7,311,000<span></span>
</td>
<td class="nump">7,845,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">4,258,000<span></span>
</td>
<td class="nump">5,161,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general &amp; administrative</a></td>
<td class="nump">7,672,000<span></span>
</td>
<td class="nump">16,090,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,241,000<span></span>
</td>
<td class="nump">29,096,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">5,482,000<span></span>
</td>
<td class="num">(7,832,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">498,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">5,980,000<span></span>
</td>
<td class="num">(7,737,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">1,473,000<span></span>
</td>
<td class="num">(1,051,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,507,000<span></span>
</td>
<td class="num">$ (6,686,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">14,185<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">14,314<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,507,000<span></span>
</td>
<td class="num">$ (6,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(315,000)<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">4,192,000<span></span>
</td>
<td class="num">(6,066,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">24,717,000<span></span>
</td>
<td class="nump">21,258,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6773515632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">14,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="nump">$ 68,617,000<span></span>
</td>
<td class="nump">$ 199,511,000<span></span>
</td>
<td class="num">$ (4,784,000)<span></span>
</td>
<td class="nump">$ 263,491,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for equity awards (in shares)</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for equity awards</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">511,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">512,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Retirement of common stock for minimum tax withholdings (in shares)</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Retirement of common stock for minimum tax withholdings</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(1,735,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,736,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,565,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,565,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,686,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">14,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="nump">74,958,000<span></span>
</td>
<td class="nump">192,825,000<span></span>
</td>
<td class="num">(4,164,000)<span></span>
</td>
<td class="nump">263,766,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">14,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">50,763,000<span></span>
</td>
<td class="nump">218,233,000<span></span>
</td>
<td class="num">(5,526,000)<span></span>
</td>
<td class="nump">263,612,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for equity awards (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for equity awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Retirement of common stock for minimum tax withholdings (in shares)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Retirement of common stock for minimum tax withholdings</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(124,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(124,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,386,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,386,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,507,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,507,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(315,000)<span></span>
</td>
<td class="num">(315,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">14,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 52,030,000<span></span>
</td>
<td class="nump">$ 222,740,000<span></span>
</td>
<td class="num">$ (5,841,000)<span></span>
</td>
<td class="nump">$ 269,071,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772856320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,507,000<span></span>
</td>
<td class="num">$ (6,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,477,000<span></span>
</td>
<td class="nump">1,473,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">297,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">721,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">281,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,386,000<span></span>
</td>
<td class="nump">7,565,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(124,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory</a></td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">3,246,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Accretion to amortized cost of investments</a></td>
<td class="num">(363,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,489,000<span></span>
</td>
<td class="nump">5,730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,617,000)<span></span>
</td>
<td class="num">(3,924,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current and long-term assets</a></td>
<td class="num">(182,000)<span></span>
</td>
<td class="nump">509,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">496,000<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(269,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses, other current and long-term liabilities</a></td>
<td class="num">(1,928,000)<span></span>
</td>
<td class="nump">3,270,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">910,000<span></span>
</td>
<td class="num">(1,478,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">8,462,000<span></span>
</td>
<td class="nump">9,592,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of investments</a></td>
<td class="nump">58,094,000<span></span>
</td>
<td class="nump">15,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(58,981,000)<span></span>
</td>
<td class="num">(12,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,030,000)<span></span>
</td>
<td class="num">(2,543,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,917,000)<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for tax withheld on vested restricted stock awards</a></td>
<td class="num">(124,000)<span></span>
</td>
<td class="num">(1,735,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of equity awards</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">512,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) financing activities</a></td>
<td class="num">(119,000)<span></span>
</td>
<td class="num">(1,223,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Exchange rate impact on cash</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">6,472,000<span></span>
</td>
<td class="nump">8,541,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">89,042,000<span></span>
</td>
<td class="nump">133,256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">95,514,000<span></span>
</td>
<td class="nump">141,797,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019</a></td>
<td class="nump">24,110<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762569792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Nature of Business</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Anika Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (&#x201c;HA&#x201d;) technology. The Company&#x2019;s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639681072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and in accordance with accounting principles generally accepted in the United States (&#x201c;US GAAP&#x201d;). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company&#x2019;s annual financial statements filed with its Annual Report on Form&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>The results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results to be expected for the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Leases</div> (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>), which, among other things, results in the recognition of lease assets and lease liabilities by lessees on the Company&#x2019;s balance sheets for virtually all leases. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> supersedes most previous lease accounting guidance and is effective for interim and annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>The Company adopted the new guidance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>using the modified retrospective adoption method in which it did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> restate prior periods. The adoption of this standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the condensed consolidated statement of operations. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> for further details.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div>&nbsp;<div style="display: inline; font-style: italic;">Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software&nbsp;(Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>)</div>, which amends ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">05,</div>&nbsp;Customers Accounting for Fees in a Cloud Computing Agreement,&nbsp;to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> is effective for fiscal years and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019. </div>Early adoption is permitted, including adoption in any interim period for all entities. The Company is assessing ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762616800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Revenue</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div>&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>deferred revenue was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$67</div> thousand.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (&#x201c;Mitek&#x201d;) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76%</div> of total Company revenues for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>respectively. The Company has agreements with other customers that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>include the delivery of a license and supply of product.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <!-- Field: Page; Sequence: 7; Value: 3 -->   <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables provide the disaggregated revenue by major product group and primary geographical market. Product revenue by product group was as follows:&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Orthobiologics</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,748</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,489</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Surgical</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,392</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,245</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dermal</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(539</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,448</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,063</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Product Revenue</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,717</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,258</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Total revenue by geographic location was as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,089</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,910</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,526</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,391</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,108</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,963</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,723</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,264</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2, 2018, </div>the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that the products were at risk of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> maintaining certain measures throughout their entire shelf life. While there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the Company recorded a revenue reserve for this voluntary recall of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.9</div> million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942529104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Investments</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All of the Company&#x2019;s investments are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held investments, including U.S. treasury bills totaling <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$71.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$70.0</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively. Unrealized gains and losses as well as the associated tax impact on the Company&#x2019;s available-for-sale securities were immaterial as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762689536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div></div></td> <td style="width: 7px">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company&#x2019;s investments are all classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity of these instruments, and therefore fair value information is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the table below.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy of the Company's cash equivalents and investments at fair value was as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br /> Active Markets<br /> &nbsp;for Identical Assets&nbsp;<br /> &nbsp;(Level 1)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br /> &nbsp;Observable Inputs&nbsp;<br /> &nbsp;(Level 2)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br /> &nbsp;Unobservable Inputs&nbsp;<br /> &nbsp;(Level 3)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br /> Active Markets<br /> &nbsp;for Identical Assets&nbsp;<br /> &nbsp;(Level 1)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br /> &nbsp;Observable Inputs&nbsp;<br /> &nbsp;(Level 2)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br /> &nbsp;Unobservable Inputs&nbsp;<br /> &nbsp;(Level 3)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639792336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></div></td> <td style="width: 7px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Equity Incentive Plan</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates the fair value of stock options and stock appreciation rights (&#x201c;SARs&#x201d;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) are measured by the grant-date price of the Company&#x2019;s shares. Fair value of performance restricted stock units (&#x201c;PSUs&#x201d;) is measured by the grant-date price of the Company&#x2019;s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> achieved, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation cost is recognized and any previously recognized compensation cost is reversed.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of each stock option award during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.44%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.54%</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.37%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.34%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.41%</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.74%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40.81%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Expected life (years)</td> <td style="width: 2%">&nbsp;</td> <td style="width: 4%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 2%">&nbsp;</td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.6</div> million of stock-based compensation expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. Upon the retirement of the Company&#x2019;s former Chief Executive Officer on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018, </div>all of his outstanding stock-based compensation awards vested in full and became exercisable in accordance with their terms, resulting in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million that was fully recognized during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Cost of product revenue</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(216</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research&nbsp;&amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">177</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general&nbsp;&amp; administrative</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,117</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,571</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,386</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,565</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth share information for stock-based compensation awards granted and exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grants:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-left: 10pt">Stock Options</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,292</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">192,300</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">RSAs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64,578</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">RSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">165,507</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,130</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">PSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercises:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock Options</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,425</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">SARs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the Company granted stock-based compensation awards in the form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable or vest ratably over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year period. The PSUs granted to employees contained performance conditions with business and financial targets. The business target, amounting to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div> of the total performance conditions, will be measured based on achievement in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> fiscal year, while the financial targets, amounting to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the total performance conditions, will ultimately be measured with respect to the Company&#x2019;s operating results in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021</div> fiscal year. The Company recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million of stock-based compensation expense associated with PSUs for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762556272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS")<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="text-align: justify; width: 47px"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div></td> <td style="width: 7px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Earnings Per Share (&#x201c;EPS&#x201d;)</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <!-- Field: Page; Sequence: 9; Value: 3 -->   <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; background-color: white">The following table provides share information used in the calculation of the Company's basic and diluted earnings (loss) per share (in thousands):</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,185</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,679</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options, SARs, RSAs, RSUs and PSUs</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted shares used in the calculation of earnings per share</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,314</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,679</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Stock options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div> million shares for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>were excluded from the computation of diluted EPS as their effect would have been anti-dilutive. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the net loss available to common stockholders is divided by the weighted average number of common shares outstanding during the period to calculate basic earnings per share. The assumed exercise of stock options at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>would have been anti-dilutive.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942587472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Inventories</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventories consist of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,751</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,688</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in-process</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,972</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,626</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,536</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,819</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,259</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,133</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventories</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,617</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other long-term assets</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,642</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other long-term assets include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.6</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million of inventory expected to remain on hand beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6640035088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Intangible Assets</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>consisted of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">March 31, 2019</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">December 31, 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Gross Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Currency <br /> Translation<br /> Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Impairment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Currency <br /> Translation<br /> Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">Useful Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 21%">Developed technology</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,929</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,927</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,963</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,824</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,672</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,604</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 6%; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">In-process research &amp; development</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,406</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,232</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,174</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,168</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,238</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Indefinite</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Distributor relationships</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,700</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Patents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(176</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(494</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(169</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(482</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Elevess trade name</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,206</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,752</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,706</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,467</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,576</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,439</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,191</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate amortization expense related to intangible assets was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3</div> million impairment charge for the HYALOSPINE developed technology asset in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>HYALOSPINE was an adhesion prevention gel for use after spinal surgery, and received initial CE Mark approval in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2015. </div>In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019, </div>the Company made the decision <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to renew the CE Mark as the product was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> aligned with the Company&#x2019;s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general &amp; administrative expenses on our condensed consolidated statements of operations.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>except as set forth in this paragraph, there have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639444736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="text-align: justify; width: 47px"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Goodwill</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company completed its annual impairment review as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 30, 2018 </div>and concluded that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment in the carrying value of goodwill exists as of that date. Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> events or changes in circumstances that indicate that the carrying value of goodwill <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Changes in the carrying value of goodwill were as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at January 1, 2019</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,851</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(156</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2019</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,695</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6926817120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Accrued Expenses</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Accrued expenses consist of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Compensation and related expenses</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,563</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,446</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,810</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,989</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research grants</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">392</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical trial costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">419</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income taxes payable</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,296</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability - current</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,075</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">476</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,031</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,146</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included in Compensation and related expenses as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>are the accrued and unpaid costs related to the retirement of the Company&#x2019;s former Chief Executive Officer as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018. </div>On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.7</div> million over the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div>-month period subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018, </div>among other benefits. The unpaid amounts under these agreements are included in accrued expenses. As more fully described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,</div> all of the former Chief Executive Officer&#x2019;s outstanding equity awards vested in full and became exercisable upon his retirement.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6668759024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="text-align: justify; width: 47px"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Operating Leases</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company adopted Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>using the modified retrospective adoption method, which did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require it to restate prior periods. The Company has elected the transition relief package of practical expedients permitted within Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842.</div> Accordingly, the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassessed the classification of its existing leases as of the transition date, whether existing contracts at the transition date contain a lease, or whether unamortized initial direct costs before the transition adjustments would have met the definition of initial direct costs at lease commencement. The Company also applied practical expedients to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> separate lease and nonlease components for all new leases as well as leases commencing before the effective date if certain criteria are met, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> record leases on its balance sheet with terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months or less. Lease expense associated with leases with terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months or less are immaterial and recognized as incurred. The Company has included options to extend in the terms of its leases where it is reasonably certain that it will exercise these options.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the expected lease terms. The interest rate implicit in lease contracts is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> depend on a rate or index are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the lease liability and are recognized as incurred. Certain adjustments to the right-of-use assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required for items such as initial direct costs paid or incentives received. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised inputs as of the reassessment date, and adjust the right-of-use asset.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company leases approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134,000</div> square feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts, and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,000</div> square feet of office, research and development, training, and warehousing space in Padova, Italy. The current term of the Bedford lease extends to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2022</div> with several extension options, and the current term of the Padova lease extends to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2026.</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company identified and assessed significant assumptions in recognizing the right-of-use asset and lease liability on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>as follows:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-style: italic;">Incremental borrowing rate</div>. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company&#x2019;s lease agreements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> provide implicit rates. As the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any external borrowings at the transition date with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-style: italic;"></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; font-style: italic;">Lease and nonlease components. </div>The Company is required to pay variable fees for operating expenses in addition to monthly base rent for certain operating leases. The amounts of additional rent associated with these fees are considered nonlease components. The Company has elected the practical expedient which allows nonlease components in a contract to be accounted for as part of a single lease component to which they relate. Any variable components of these operating costs are excluded from lease payments and are recognized in the period incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-style: italic;">Extension Options.</div> The terms of the Company&#x2019;s leases include options to extend the lease term. As of the transition date to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> the Company has included extension options reasonably certain to be exercised in the lease term.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <!-- Field: Page; Sequence: 11; Value: 3 -->   <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense and other information are as follows:&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ending <br /> March 31, 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Operating lease cost</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 20%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable Lease Cost</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">576</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term (in years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.1</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Future minimum commitments due under these lease agreements as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>are as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; padding-left: 10pt; text-indent: -10pt">Years ending December 31,</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Operating Lease Obligation</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left; padding-left: 10pt; text-indent: -10pt">2019 (remaining 9 months)</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,490</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,025</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,024</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Thereafter</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,530</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Present value adjustment</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,708</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Present value of lease payments</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,307</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Less current portion included in Accrued expenses and other current liabilities</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td> <td style="text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,075</div></td> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Lease liabilities</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,232</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942529104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>also warrant that the products it manufactures do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company&#x2019;s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div>accrued warranties as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>and has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> history of claims paid.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6611306368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 47px; text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The provision for income taxes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.5</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>based on an effective tax rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.6%.</div>&nbsp;The benefit from income taxes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>based on an effective tax benefit rate of (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.6%</div>). The net increase in the effective tax rate for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>as compared to the same period in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> was primarily due to the windfall tax benefit the Company realized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018 </div>due to limitations on the deductibility of executive compensation for accelerated stock vesting upon the retirement of its former Chief Executive Officer on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018. </div>The Company realized an immaterial shortfall for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.&nbsp; The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the preparation of the financial statements, the Company assesses whether it was more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> otherwise subject to a valuation allowance are realizable on a &#x201c;more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not&#x201d;</div> basis. As such, the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> </div>record a valuation allowance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942506224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Orthobiologics</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,748</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,489</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Surgical</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,392</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,245</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dermal</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(539</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,448</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,063</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Product Revenue</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,717</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,258</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock', window );">Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 52%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,089</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,910</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,526</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,391</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,108</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,963</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,723</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,264</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents schedule of revenue and operating income, by geographical areas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942538192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br /> Active Markets<br /> &nbsp;for Identical Assets&nbsp;<br /> &nbsp;(Level 1)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br /> &nbsp;Observable Inputs&nbsp;<br /> &nbsp;(Level 2)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br /> &nbsp;Unobservable Inputs&nbsp;<br /> &nbsp;(Level 3)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,147</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,221</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices in<br /> Active Markets<br /> &nbsp;for Identical Assets&nbsp;<br /> &nbsp;(Level 1)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant Other<br /> &nbsp;Observable Inputs&nbsp;<br /> &nbsp;(Level 2)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant&nbsp;<br /> &nbsp;Unobservable Inputs&nbsp;<br /> &nbsp;(Level 3)</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized Cost</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">&#x2013;</td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">U.S. treasury bills</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#x2013;</td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6925897904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.44%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.54%</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.37%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.34%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.41%</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.74%</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> - </div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40.81%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Expected life (years)</td> <td style="width: 2%">&nbsp;</td> <td style="width: 4%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 2%">&nbsp;</td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Cost of product revenue</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(216</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research&nbsp;&amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">177</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general&nbsp;&amp; administrative</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,117</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,571</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,386</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,565</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grants:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 68%; text-align: left; padding-left: 10pt">Stock Options</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,292</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">192,300</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">RSAs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64,578</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">RSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">165,507</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,130</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">PSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercises:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock Options</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,425</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">SARs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942671280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS") (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,185</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,679</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options, SARs, RSAs, RSUs and PSUs</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted shares used in the calculation of earnings per share</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,314</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,679</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942606688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,751</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,688</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in-process</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,972</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,626</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,536</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,819</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,259</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,133</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventories</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,617</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other long-term assets</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,642</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6926817120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock', window );">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">March 31, 2019</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">December 31, 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; white-space: nowrap">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Gross Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Currency <br /> Translation<br /> Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Impairment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Currency <br /> Translation<br /> Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated <br /> Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Book <br /> Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap">Useful Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 21%">Developed technology</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,929</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,927</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,963</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,824</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,672</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 6%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,604</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 6%; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">In-process research &amp; development</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,406</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,232</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,174</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,168</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,238</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Indefinite</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Distributor relationships</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,700</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Patents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(176</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(494</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(169</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(482</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Elevess trade name</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,206</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,752</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,706</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,467</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,576</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,439</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,191</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6933038560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance at January 1, 2019</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,851</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(156</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2019</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,695</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6638921968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Compensation and related expenses</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,563</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 14%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,446</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,810</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,989</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research grants</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">392</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical trial costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">419</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income taxes payable</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,296</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability - current</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,075</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">476</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,031</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,146</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754352704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ending <br /> March 31, 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Operating lease cost</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 20%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable Lease Cost</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">576</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term (in years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.1</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; padding-left: 10pt; text-indent: -10pt">Years ending December 31,</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Operating Lease Obligation</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left; padding-left: 10pt; text-indent: -10pt">2019 (remaining 9 months)</td> <td style="width: 2%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,490</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,025</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,024</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Thereafter</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,530</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Present value adjustment</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,708</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Present value of lease payments</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,307</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Less current portion included in Accrued expenses and other current liabilities</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td> <td style="text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,075</div></td> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Lease liabilities</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,232</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6923768240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRecallExpense', window );">Inventory Recall Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anik_DepuyMitekIncMember', window );">DePuy Mitek Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenuesFromAgreementsAsPercentOfTotalRevenue', window );">Revenues From Agreements as Percent of Total Revenue</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_RevenuesFromAgreementsAsPercentOfTotalRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of total revenue that revenue from agreements comprises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_RevenuesFromAgreementsAsPercentOfTotalRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRecallExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRecallExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anik_DepuyMitekIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anik_DepuyMitekIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760955920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue - Product Revenue by Product Group (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 24,723<span></span>
</td>
<td class="nump">$ 21,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anik_OrthobiologicsMember', window );">Orthobiologics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">21,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenueFromContractWithCustomerPercentage', window );">Percentage of Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19489.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anik_SurgicalMember', window );">Surgical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenueFromContractWithCustomerPercentage', window );">Percentage of Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1245.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anik_DermalMember', window );">Dermal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenueFromContractWithCustomerPercentage', window );">Percentage of Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(539.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Manufactured Product, Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenueFromContractWithCustomerPercentage', window );">Percentage of Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1063.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 24,717<span></span>
</td>
<td class="nump">$ 21,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_RevenueFromContractWithCustomerPercentage', window );">Percentage of Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21258.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_RevenueFromContractWithCustomerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_RevenueFromContractWithCustomerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anik_OrthobiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anik_OrthobiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anik_SurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anik_SurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anik_DermalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anik_DermalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772137872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue - Total Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 24,723<span></span>
</td>
<td class="nump">$ 21,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 20,089<span></span>
</td>
<td class="nump">$ 16,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,526<span></span>
</td>
<td class="nump">$ 2,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=anik_OtherLocationMember', window );">Other Location [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,108<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_PercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_PercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=anik_OtherLocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=anik_OtherLocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6616057200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Investments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Total</a></td>
<td class="nump">$ 71.2<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761032608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">$ 71,222<span></span>
</td>
<td class="nump">$ 69,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">71,221<span></span>
</td>
<td class="nump">69,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">71,221<span></span>
</td>
<td class="nump">69,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">$ 71,221<span></span>
</td>
<td class="nump">$ 69,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_CashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value disclosure for cash equivalents as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_CashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6917643504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 7,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember', window );">Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anik_RSUsGrantedToEmployeesMember', window );">RSUs Granted to Employees [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear', window );">Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear', window );">Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company&#8217;s Operating Results in next Fiscal Year</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance conditions based on achievement in current fiscal year set as business target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance conditions based on company&#8217;s operating results in next fiscal year set as business target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anik_StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=anik_RSUsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=anik_RSUsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772339488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years) (Year)</a></td>
<td class="text">3 years 182 days<span></span>
</td>
<td class="text">4 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.44%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">44.34%<span></span>
</td>
<td class="nump">38.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years) (Year)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">44.41%<span></span>
</td>
<td class="nump">40.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years) (Year)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6923227488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 7,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 7,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6944117984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options (in shares)</a></td>
<td class="nump">104,292<span></span>
</td>
<td class="nump">192,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">11,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity Instruments Other than Options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity Instruments Other than Options (in shares)</a></td>
<td class="nump">165,507<span></span>
</td>
<td class="nump">8,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anik_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity Instruments Other than Options (in shares)</a></td>
<td class="nump">114,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">SARs (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anik_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anik_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6609019056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS") (Details Textual)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942529392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">14,185<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Stock options, SARs, RSAs, RSUs and PSUs (in shares)</a></td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares used in the calculation of earnings per share (in shares)</a></td>
<td class="nump">14,314<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942550592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Inventories (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent, Total</a></td>
<td class="nump">$ 3,642<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6918390512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Inventories - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 12,751<span></span>
</td>
<td class="nump">$ 13,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">5,972<span></span>
</td>
<td class="nump">4,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,536<span></span>
</td>
<td class="nump">6,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal', window );">Total</a></td>
<td class="nump">26,259<span></span>
</td>
<td class="nump">25,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">22,617<span></span>
</td>
<td class="nump">21,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent, Total</a></td>
<td class="nump">$ 3,642<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6941203952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets, Total</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="nump">281,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill), Total</a></td>
<td class="nump">8,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,191,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_HYALOSPINEDevelopedTechnologyAssetMember', window );">HYALOSPINE Developed Technology Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_MEROGELINJECTIBLEAssetsMember', window );">MEROGEL INJECTIBLE Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill), Total</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_HYALOSPINEDevelopedTechnologyAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_HYALOSPINEDevelopedTechnologyAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_MEROGELINJECTIBLEAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_MEROGELINJECTIBLEAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772286592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">$ 28,206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="num">(4,752,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,576,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment</a></td>
<td class="num">(281,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(14,706,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,439,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">8,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,191,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">4,406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="num">(1,232,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,168,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,238,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="num">(2,929,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,824,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment</a></td>
<td class="num">(281,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,927,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,672,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 4,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="num">(415,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,285,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,285,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="num">(176,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(494,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember', window );">Elevess Trade Name [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccumulatedCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the accumulated currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccumulatedCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6640727488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Goodwill (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6640819680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 7,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Effect of foreign currency adjustments</a></td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 7,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942662304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses (Details Textual) - Former Chief Executive Officer [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 08, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_SeveranceBenefitFollowingRetirement', window );">Severance Benefit Following Retirement</a></td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_SeveranceBenefitFollowingRetirementTerm', window );">Severance Benefit Following Retirement, Term</a></td>
<td class="text">1 year 180 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_SeveranceBenefitFollowingRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of severance benefit provided following a person's retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_SeveranceBenefitFollowingRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_SeveranceBenefitFollowingRetirementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time for the severance benefit to be paid following retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_SeveranceBenefitFollowingRetirementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=anik_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=anik_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6922915888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">$ 2,563<span></span>
</td>
<td class="nump">$ 4,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccruedResearchGrantsCurrent', window );">Research grants</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccruedClinicalTrialCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 8,031<span></span>
</td>
<td class="nump">$ 8,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued clinical trial costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccruedResearchGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research grants current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccruedResearchGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769757648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Operating Leases (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember', window );">Administrative, Research and Development, and Manufacturing Space in Bedford, MA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property</a></td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember', window );">Office, Research and Development, Training, and Warehousing Space in Padova, Italy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property</a></td>
<td class="nump">33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=anik_AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=anik_OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6925813296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Operating Leases - Lease Expense and Other Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease Cost</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years) (Year)</a></td>
<td class="text">17 years 219 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6925329168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining 9 months)</a></td>
<td class="nump">$ 1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">23,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(9,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">23,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion included in Accrued expenses and other current liabilities</a></td>
<td class="num">(1,075)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 22,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762725344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6942595504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 1,473<span></span>
</td>
<td class="num">$ (1,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent, Total</a></td>
<td class="nump">24.60%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +"8HTX?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ L)BC3B?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V'?6;=W_]CX*JAJ^'47Z@M02P,$%     @ L)BC3IE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<VAE970Q+GAM;'U6VX[;(!#]%<L?L!@<Y[)R+"6IJE9JI6BKML\D(;&UV+A
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MYK)_T_N%%NW0KZ"Q:2K^ %!+ P04    " "PF*-.D&XU9>@#  "X$@  &
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M\VW%)S_1DRL.MYW*'8=Q,_/;W?5=RG5G:,_S>Z+T]K)J^Q]02P,$%     @
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MWFN^O>,INP:A"7,:,7R)F1',J\\A^%J($_^/SM?IN]4,=Y&^6T9/#NL"R:I
M$@62#R7N/I6XADD^!6&+GFHP=9PF2PKLVSC)"^\\L/<\OLD[?)SVG\+4LK7D
M@LZ_;.Q_A>C I[*Y\2/4^ \V&PHJ%XYW_FS&,1L-A]WT@]C\C?-_4$L#!!0
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MX\O&_C?&>,!4=G<X0AU^L,60T/AP/.#93F,V&=[T\P]BRS<N_P!02P,$%
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M7S;VO]':@4\EN?(CU/D/MA@"&A>.M_YLIC&;#*?[^0>1Y1N7?P%02P,$%
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M_UNM'?A4#C=^A'K_P59#0.O"\;,_FWG,9L/I8?E!9/W&U3]02P,$%     @
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MW%Z/ S,&5G736T#F!RG_ U!+ P04    " "PF*-.4D@.!K@!  #2 P  &0
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M+9[M.&:CX4TW_2 V?^/\+U!+ P04    " "PF*-.F(PZK+8!  #2 P  &0
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M.X!08XZW^-7QR)O6>@<ILIXU\ OL[_ZHG446EHI+Z Q7'=)0Y_AVNS^D'A\
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M:U"IABZ,R\J[3,4M#8U_@T\C]9/IAG<&G91USR<TN5;*@DME<^5R:=T4+X:
MVOKM%[?7TUN>#*OZ>4S)\J\H_@-02P,$%     @ L)BC3EI8"A\3 @  R04
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M&<OFN-!,M*C;HU#4G<?F_P!02P,$%     @ L)BC3K8[JA=W @  N@@  !D
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M@\ZXZ<;.5;ADH3!RB.\'3X^X_@=02P,$%     @ L)BC3E2@?79( @  ;@@
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M 6/'P(ES1;7$X$FWD%)_&8P'1D_*;&.]%_UX[ ^*M\/H1^/W1_8/4$L#!!0
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MG4R1X>!DI^%DB!V4$N;O$22..4WI-?#8-:T+ 59DO6C@%[C?_<EXCRTL5:=
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M";4+YB=OFVG-)L=A/[\@MCSCXA]02P,$%     @ L)BC3B\N68;[ 0  .04
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MOH\E$# XO[W%O8E3$@.GI_0 Z/(*V_]02P,$%     @ L)BC3AZ0!D4A @
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M"/LA7SA75 >,7G1=M;[:YP6C%V6FF9Z+\8(;%XKWT]T-YC^0ZA]02P,$%
M  @ L)BC3EU(O[8U @  P@8  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&ULC57K;ILP%'X5Q /4X1XB@M0DJC9IDZ).VWX[Y"2@&DQM)W1O/U\HI>!$
MS8]@F^]V3L(AZRA[X26 <-YJTO"U6PK1KA#B10DUY@^TA4;>.5%68R&W[(QX
MRP ?-:DFR%\L8E3CJG'S3)_M69[1BR!5 WOF\$M=8_9O X1V:]=SWP^>JW,I
MU '*LQ:?X1>(W^V>R1T:5(Y5#0VO:.,P.*W=1V^U2Q5> _Y4T/'1VE&5'"A]
M49OOQ[6[4(& 0"&4 I:7*VR!$"4D8[SVFNY@J8CC];OZDZY=UG+ '+:4_*V.
MHER[2]<YP@E?B'BFW3?HZXE<IR_^!UR!2+A*(CT*2KC^=HH+%[3N5624&K^9
M:]7H:V?N1%%/LQ/\GN /!.\^(>@)P0<AO$L(>T(X(2!3BN[-#@N<9XQV#C._
M;HO5G\A;A;+[A3K4S=;W9'NX/+WF@>]GZ*J$>LS&8/P1QAL02*H/%K[-8N//
MZ!.#[1R1!)\ANSDDN!$BL-89:'[XJ<Z)Q\9@8HUI#&:A/G:?T.H36GS"B8_!
M1",??^F-?4Q7YE+AC9(C:Y3($B6:1(EF499AG,RR[*)9:U(O]6[V)K8&BBV!
M8KM 8A5(OM#<9%;1O1]Q:?596GP2NT!J%4B_T/ITUE+/%A2-GN0:V%E/2>X4
M]-((]4",3H=!_.BK23 YWWBKK9FG'S)FNO_$[%PUW#E0(>>,G@8G2@7(E(L'
MV<E2OE"&#8&34,M$KID9JV8C:-N_,=#PVLK_ U!+ P04    " "PF*-.6NK<
M;0<$   9%   &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R5F%MOVS@0
MA?^*H/=4XI"Z!;:!V$&Q"VR!H(NVSXI-7U!)]$ITW/[[U2VN)!ZZZDML*6=F
M#LG19XJ+JRJ_5T<IM?,CSXIJZ1ZU/C]Z7K4]RCRM/JBS+.K_[%69I[J^+ ]>
M=2YENFN#\LPCWP^]/#T5[FK1WGLI5PMUT=FID"^E4UWR/"U_KF6FKDN7N>\W
M/I\.1]W<\%:+<WJ0_TK]Y?Q2UE?>+<ONE,NB.JG"*>5^Z3ZQQV<>-@&MXNM)
M7JO!=Z<9RJM2WYN+OW=+UV\<R4QN=9,BK3_>Y$9F69.I]O%?G]2]U6P"A]_?
MLW]L!U\/YC6MY$9EWTX[?5RZL>OLY#Z]9/JSNOXE^P$%KM./_A_Y)K-:WCBI
M:VQ55K5_G>VETBKOL]16\O1']WDJVL]KG_\]# =0'T"W@+KVO0#>!_!? >)N
M@.@#Q"3 ZX;2SLUSJM/5HE17I^R6]YPV7<0>13W[V^9F.]GM_^KIJ>J[;RM.
M\<)[:Q+UFG6GH8&&W11>G?U6@E")-1GA-"ZP,141'TN>30FWF.!PG+R-%Z-Q
M)I-Q=IJPU12=T9C\T/=]7$G 2L*LQ/U)I4X3#"H]B"B@8:5NV,*P]"""R&XI
M@)8"8(E-+ 6F)8J9X6ACYA*6A0BAEQ!XF?3#.C2],!&-5Z*;'Z@4/+%.4 1-
M1>:@)@VXCHQ*L0@CTY&I2UC"K'YBZ"<&D\1Q@@0F2&:T>V(X%>).MS,? \2?
MT>^]:+Q.Q$'#0R4+8[LM"]?8[Y>TUPQK<18)8 H(B=_Q!$'XQ A,E;"DP!AC
M<SC6BX9V6=2TH-4O)AF;@S(&6$8))6 6D3(F8;>%:<;FX(S]GF?C6IA6; ZN
M&*!0G!"  U2&$=EM85ZQ&<#J-</?#I&$')@RD16$_IUEP<QB"%K!U!02A98Z
M&&T,L(U'E@T)9A8!9AE/42\:S5]TYR$B#"(R060^1&0"YD&PP%RK&<*Q*4PB
M0B2:MG4O&M>B&+F:H1S;PG0CDVY&6R,-F_JYJQD[P>@CA+YI,T-1;*F#64:(
M98DE!484 429S1P:S=S](-@6"'.'3.Z 9C9Y\L BL'F#PM"^=R,,'D),,9HY
M!BV:@-]Z*(SMA"9,*3(I9;9R8BP*YSZP9.[4N+!/$\?0XVBC-FUI)!*V.AAX
M' #/]O1QC"<.\&2^K=&?M32WO!B"'971TD!D0.>^9FP%0X<CGDP;F8-=U'3<
MO:$9RK$MS"@.7OFFK8PTQ@3-?W7D&'4<[<:,%@8B09,ZWN!\))?EH3U[JIRM
MNA2Z.688W+V=;SU1<[XRN;]FCYONE.I7FN[0[%-:'DY%Y;PJK57>GK'LE=*R
M]NA_J*?B*-/=[2*3>]U\C>KO97=8U5UH=>X/XKS;:>#J?U!+ P04    " "P
MF*-.95ZF^(T!   7 P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6QM
M4]M.XS 0_17+'X!3T[*H2B)1$ *)E2I6P+.;3!H+7X+M-O#W.[9#5"I>,A>?
M.3-G[)2C=>^^!PCD4ROC*]J',*P9\TT/6O@+.X#!D\XZ+0*&;L_\X$"TJ4@K
MQHOBBFDA#:W+E-NZNK2'H*2!K2/^H+5P7QM0=JSH@GXGGN6^#S'!ZG(0>_@'
MX678.HS8S-)*#<9+:XB#KJ(WB_6&1WP"O$H8_8E/HI*=M>\Q>&PK6L2!0$$3
M(H- <X1;4"H2X1@?$R>=6\;"4_^;_3YI1RT[X>'6JC?9AKZBUY2TT(F#"L]V
M?(!)SXJ22?P3'$$A/$Z"/1JK?/J2YN"#U1,+CJ+%9[;2)#OFDQ6?RGXOX%,!
MGPMXUI(;I<GO1!!UZ>Q(7-[](.(5+]8<=]/$9%I%.L/A/6:/]>7RLF3'2#1A
M-AG#?V"6,X8A_]R$_]J$)X+E#X+569.,N4H8DS#%60MVHBD^F;_"[:7Q9&<#
MKB>)Z*P-@&S%!=Y#CZ]T#A1T(;I_T'?YKG(0[# ]0S;_"_5_4$L#!!0    (
M +"8HT[X.CCTU@$  & $   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;(U4VXZ;,!#]%<OO70<")!L!TF9752NU4K15VV<'AHO6QM0V8?OW]850FJ72
MOF#/<.:<,\9#.@KYHAH C5XYZU2&&ZW[ R&J:(!3=2=ZZ,R;2DA.M0EE350O
M@9:NB#,2;C8)X;3M<)ZZW$GFJ1@T:SLX2:0&SJG\?00FQ@P'^)IX;NM&VP3)
MTY[6\ WT]_XD341FEK+ET*E6=$A"E>&'X'",+=X!?K0PJL4>V4[.0KS8X'.9
MX8TU! P*;1FH62[P"(Q9(F/CU\2)9TE;N-Q?V3^ZWDTO9ZK@4;"?;:F;#.\Q
M*J&B ]//8OP$4S\Q1E/S7^ "S,"M$Z-1"*;<$Q6#TH)/+,8*IZ]^;3NWCA/_
MM6R]()P*PKD@]+UX(>?\B6J:IU*,2/JS[ZG]Q,$A-&=3V*0["O?.F%<F>\FW
M49*2BR6:,$>/"1>88$80PSY+A&L2Q_!-^3;:K1-L5SUN'4'T#\'^QJ/') [3
M.<QN'__'9K2J$JVHW-^H>$R\4/D0Q,FZ2KRJ$K^CE_AM+\E]?*-"%E^8@ZS=
MW5:H$$/GYFJ1G<?G(70WY"_<S]Y7*NNV4^@LM+EG[C940F@P7C9WQDQCQGT.
M&%3:;G=F+_VE]X$6_33/9/ZIY'\ 4$L#!!0    ( +"8HTX6W!?BG@$  'X#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;&U3VV[;, S]%4$?$-ER
MNQ:!;6#I4'3 !@0=MCXK-AT+U<63E+C[^U&R8Z2!7R22.CR'I*1RM.[=]P"!
M?&AE?$7[$(8M8[[I00N_L0,8/.FLTR*@ZX[,#PY$FY*T8CS+OC MI*%UF6)[
M5Y?V%)0TL'?$G[06[M\.E!TKFM-+X%4>^Q #K"X'<81?$'X/>X<>6UA:J<%X
M:0UQT%7T:[[=%1&? '\DC/[*)K&3@[7OT?G>5C2+!8&")D0&@=L9GD"I2(1E
M_)TYZ2(9$Z_M"_MSZAU[.0@/3U:]R3;T%7VDI(5.G%1XM>,+S/W<4S(W_P/.
MH! >*T&-QBJ?5M*<?+!Z9L%2M/B8=FG2/L[\E[3U!#XG\"6!3[U,0JGR;R*(
MNG1V)&Z:_2#B%>=;CK-I8C"-(IUA\1ZCY[JXSTIVCD0S9C=A^"=,OF 8\B\B
M?%6$)X*[3P3\1F3"/":,29A\\[ N4JR*%"LBQ8W(&N;N1H1=C2Z^S)_"':7Q
MY& #WD*:56=M .3+-GC=/7Z&Q5'0A6@^H.VF)S$YP0[S:V?+EZO_ U!+ P04
M    " "PF*-.C1Z8R$,"  !4!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q]E=N.VR 0AE_%\@,LML&GR+'4N*I:J96BK;J])@F)K<7&!1)OW[Z
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MRKJ?(5Q9KY0%1TSN'&QP;W(-./363[=NKN<_<PZL&I='1]:7W_P'4$L#!!0
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M&59]RVBG $'J1] DX%_9__#[=KL!_#>;ST;#:?O-=>H'8;QAR_O=;1*UW_H
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M<?))O-2J+F0M+UUGP#>[YKV"RAV/#NY.V>(G&HP]F*'^!4HVNQ!4]J)2\LH
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M\X2=U^=AE:<?D[A7GI1E9V$*/F^2V@70,<'SSMBY(T/H?Y%7"U\:+Z,="H=
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MKB729]M9><J[#&I=B4/[E]4O2"2IG>&.%UK6J@R]H3<P/-.NG\%R#<.SH48
M50&'+A;-A1S=[;1R#EW*?=>R#O->'CSA_2WY$+S.#U,&(M0$AE]09]91P*"2
MN!?+P%\O.Q?U.1:[PWS$]YN\V>HT<!42E.K<YAT)VT?Y/5SL?(5B]TK^JFHH
M#T7*X+QE'#SQ:\A[#TU/JQ\DQ;E*CT@YJH-V!^)+F^I%EN6O_Q]02P,$%
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M1&#,D?$3/(-J(* Z):A.(U 52'6KGL$Z7SN\I^F0&JZ'$=A&R';#A6$/7#;
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M.!\4Z4&K^: 5/>AV/NB6'G0W'W1'#[J?#[JG!\D2R+CD)R&L^5H+X%KX7@L
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MS.9C/NO_&[!X U!+ 0(4 Q0    ( +"8HTX?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +"8HTXGZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ L)BC3LAJG-OO    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ L)BC3IE<G",0!@  G"<  !,
M         ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "P
MF*-.[.!9AWP"  ! "0  &               @ 'X"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ L)BC3I!N-67H P  N!(  !@
M         ( !J@L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( +"8HT[?Y /!00(  -X'   8              "  <@/  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "PF*-.[QUOY)D#  "U#P
M&               @ $_$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ L)BC3F?$48(O!   =A4  !@              ( !#A8  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +"8HT[WGO$]@@0
M &X6   8              "  7,:  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "PF*-.'/=N=K<!  #2 P  &               @ $K
M'P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ L)BC3I()
M,,"U 0  T@,  !@              ( !&"$  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( +"8HTY3B!*"MP$  -(#   8
M  "  0,C  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "P
MF*-.,)<!BK8!  #2 P  &0              @ 'P)   >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +"8HTXLN*ZOM@$  -(#   9
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M970Q-2YX;6Q02P$"% ,4    " "PF*-.?)Z"3K<!  #2 P  &0
M    @ %^,   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M +"8HTX YP".N $  -(#   9              "  6PR  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ L)BC3NT=JP:U 0  T@,  !D
M             ( !6S0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "PF*-.I/+Q+K<!  #2 P  &0              @ %'-@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +"8HTZ>[T,[MP$
M -(#   9              "  34X  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ L)BC3JP5:G;  0  -P0  !D              ( !
M(SH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "PF*-.
MMW^B6;<!  #2 P  &0              @ $:/   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( +"8HT[^\H"DS0$  )P$   9
M      "  0@^  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ L)BC3E)(#@:X 0  T@,  !D              ( !#$   'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "PF*-.F(PZK+8!  #2 P
M&0              @ '[00  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( +"8HTXQ]B<9LP$  -(#   9              "  >A#  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ L)BC3L+4MV"V
M 0  T@,  !D              ( !TD4  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "PF*-.,;*]@;@!  #2 P  &0
M@ &_1P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +"8
MHT[!X9@VQ0$  #<$   9              "  :Y)  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ L)BC3EI8"A\3 @  R04  !D
M         ( !JDL  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " "PF*-.1VXV\94"  ";"0  &0              @ 'T30  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( +"8HTZV.ZH7=P(  +H(
M   9              "  <!0  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ L)BC3FY6<0>P 0  T ,  !D              ( !;E,
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "PF*-.5*!]
M=D@"  !N"   &0              @ %550  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( +"8HTX)4'7D+@(  *,&   9
M  "  =17  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
ML)BC3I"@5X1: @  BP@  !D              ( !.5H  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " "PF*-.^KU:$RX"  "#!@  &0
M            @ '*7   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( +"8HTYA'Z'#; (  "T(   9              "  2]?  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ L)BC3JM_0 BV 0
MT@,  !D              ( !TF$  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " "PF*-.+RY9AOL!   Y!0  &0              @ &_
M8P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +"8HTXT
M(;/WI0$  )$#   9              "  ?%E  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ L)BC3AZ0!D4A @  3 8  !D
M     ( !S6<  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M" "PF*-.74B_MC4"  #"!@  &0              @ $E:@  >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( +"8HTY:ZMQM!P0  !D4   9
M              "  9%L  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!
M A0#%     @ L)BC3F5>IOB- 0  %P,  !D              ( !SW   'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "PF*-.^#HX]-8!
M  !@!   &0              @ &3<@  >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;%!+ 0(4 Q0    ( +"8HTX6W!?BG@$  'X#   9              "
M :!T  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ L)BC
M3HT>F,A# @  5 <  !D              ( !=78  'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " "PF*-.+O@[M;,!   %!   &0
M        @ 'O>   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( +"8HTX]G=YH"0(  .X%   9              "  =EZ  !X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ L)BC3N2, R5! @  50<
M !D              ( !&7T  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " "PF*-.[2!*XJ(!  "+ P  &0              @ &1?P
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( +"8HTX^CT\Y
M! (  (8%   9              "  6J!  !X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ L)BC3M[<SGE0(   AXP  !0
M ( !I8,  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ L)BC3JLO
M-AXW @  UPD   T              ( !)Z0  'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    " "PF*-.7ZR!9FT$  #!(P  #P              @ &)I@  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ L)BC3AHKVS'N 0  5"   !H
M         ( !(ZL  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ L)BC3HRC=%'1 0  (R   !,              ( !2:T  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #X /@#D$   2Z\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>111</ContextCount>
  <ElementCount>187</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited-</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-1-nature-of-business</Role>
      <ShortName>Note 1 - Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-2-basis-of-presentation-</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue</Role>
      <ShortName>Note 3 - Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments</Role>
      <ShortName>Note 4 - Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements</Role>
      <ShortName>Note 5 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan</Role>
      <ShortName>Note 6 - Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Earnings Per Share ("EPS")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories</Role>
      <ShortName>Note 8 - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets</Role>
      <ShortName>Note 9 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill</Role>
      <ShortName>Note 10 - Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses</Role>
      <ShortName>Note 11 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-</Role>
      <ShortName>Note 12 - Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies</Role>
      <ShortName>Note 13 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes</Role>
      <ShortName>Note 14 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables</Role>
      <ShortName>Note 3 - Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 5 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-tables</Role>
      <ShortName>Note 5 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 6 - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables</Role>
      <ShortName>Note 6 - Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS") (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 8 - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables</Role>
      <ShortName>Note 8 - Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 9 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables</Role>
      <ShortName>Note 9 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 10 - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables</Role>
      <ShortName>Note 10 - Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 11 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables</Role>
      <ShortName>Note 11 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 12 - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables</Role>
      <ShortName>Note 12 - Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 3 - Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-details-textual</Role>
      <ShortName>Note 3 - Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 3 - Revenue - Product Revenue by Product Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-product-revenue-by-product-group-details</Role>
      <ShortName>Note 3 - Revenue - Product Revenue by Product Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 3 - Revenue - Total Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-3-revenue-total-revenue-by-geographic-location-details</Role>
      <ShortName>Note 3 - Revenue - Total Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 4 - Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments-details-textual</Role>
      <ShortName>Note 4 - Investments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-4-investments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details</Role>
      <ShortName>Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-details-textual</Role>
      <ShortName>Note 6 - Equity Incentive Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details</Role>
      <ShortName>Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details</Role>
      <ShortName>Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details</Role>
      <ShortName>Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-details-textual</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS") (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-7-earnings-per-share-eps-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 8 - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-details-textual</Role>
      <ShortName>Note 8 - Inventories (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-8-inventories-summary-of-inventories-details</Role>
      <ShortName>Note 8 - Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 9 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-details-textual</Role>
      <ShortName>Note 9 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-9-intangible-assets-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-9-acquired-intangible-assets-net-summary-of-intangible-assets-details</Role>
      <ShortName>Note 9 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 10 - Goodwill (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-details-textual</Role>
      <ShortName>Note 10 - Goodwill (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details</Role>
      <ShortName>Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 11 - Accrued Expenses (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-details-textual</Role>
      <ShortName>Note 11 - Accrued Expenses (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 12 - Operating Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-details-textual</Role>
      <ShortName>Note 12 - Operating Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 12 - Operating Leases - Lease Expense and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-lease-expense-and-other-information-details</Role>
      <ShortName>Note 12 - Operating Leases - Lease Expense and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details</Role>
      <ShortName>Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 13 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-13-commitments-and-contingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="anik-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 14 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes-details-textual</Role>
      <ShortName>Note 14 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anikatherapeutics.com/20190331/role/statement-note-14-income-taxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>anik-20190331.xml</File>
    <File>anik-20190331.xsd</File>
    <File>anik-20190331_cal.xml</File>
    <File>anik-20190331_def.xml</File>
    <File>anik-20190331_lab.xml</File>
    <File>anik-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001171843-19-002946-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-19-002946-xbrl.zip
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MUY:RQ)ZY\]P1A%V@AKJMC$B>XA7E^/'EGS4&VT^%/,U,OL:P4JE'S2JR2:X
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MG?;&@'UCM@\?^TK\S>G6'7:%U5L#K=?-A2]O[2I0KB5B=]@30:FU^OT*4*+
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MB6NC(WGM>JQ*\B.$?68JY"]0-?8G:R&-K[]B[BC^WG5P-59XG0!KN= :#*D
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MYR,Q1ZX'7RV3:]$:FR=.I0X" ]]KTK]'/@8AF<M: 5X[PYY[X_E8/WBZA9R
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M8) K!:+EJP*[WC?1A*:JW<TX)V6!A7T7<WAXV45R+$9%X] ?BN>S=S)3CU9
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MY"SL%!%-&\GM!Q$.20=$H\GI-;)'4T7LX4JPC_XLK?,T4&4:I.B4NCBW*&(
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MP=+,&XP7+,42<Z4Y:WV/9<#.PQ]/"7#1/-^_A!^2MBU!\!_-IG*-,V_?*7?
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M^!&?6&]AFAX0#[_V MUNA,.M/&^.^>+ZE/]&G\T\]\6:8OIX I5'8N@!'ZF
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M9R!ACCN%O1/W*XMM10U<%C6-AHZ BVTA<*'(RQ[!=II668_,,-"&90( %U\
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M.(D[ 6(#GEJ6'^0NCVV]HJP:-@/<\'FKMK#+#SPR01 ?R=RM!5+72?7)XBV
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M[D0^DG@;PTV*_QPYH?-C/8!*MYEP 8\L>!\C/K6FE@WRQR@.'A$[! 6?^N\
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MSG61F#BN44:XZ(;UZ?)0FRGCT@3;>I"[G'F$04/JE^0^]730'F!?3WGEF)!
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MFS!%5YKIKF-\H-YZ3FB4)8C?@C)E'\)<FY.J2D:VL#>GMO3TZWPN0/P.-2/
MKCO"I^2%=X"?;>*>:]<6S.:L5R=*>^F7X7W%;\=133/'8'V8@]J#]47#EG#]
M:,YR93+3Z$-?<]SUM6]APM$VU)6,;$%O3GB5)#@;5RC-1-IVA HVMMS G <K
MS'LV3E">G[3M!55\;+F!.5]6G@YM?,&0P;3M ,;&;:%NSJ3ELJ0-S(4I3=M@
ME["P!;DYU69,GC; O\AXV@;<T+0MH LR;]F<:@-P80+4.M#%+&P!7I"&,Z5:
M&^"+TZ*V@2]F80OX@AR<*?_: )]/J'@DP-0'3,AS$&)[K\F*.=B"W9R36\C=
M7$2L43]BW:">8#(5W O=(/U_,$N+1H*'TP2T-;A#;=:6_.2@.L?GH+M(@K1D
M,$N+OBFA4E=J7"C-Q/( ^UD41X2/P"/&U'7\^"2)-;K14NQMN9(Y9[CH2GTE
M6-:1OJ6"H>2$C<:=3'N4US86E7.QY1SF3&)N9W0S)M7.]V?*^= !Z3%S*8Z.
M[1+A I9O\/9A&6EL>90Y*5GVBF+A"1^BRT1.\,%4SB;Z5+QB6%<<JLO/EO^8
MTYLE[S::V%0++RQE.)DJKM)1S& RXD" IQ.@S@4*_<TUK("CRFH?2E2"IR \
M=$P]31%T-%Y#,'LG\6UYKSE36^R]CDK;)HJA[Z 8"CCJQHKE J/^X!S=QI75
M]IRHY#2C&+K7BC7ALNJ-K)Z*:\=0V$4G6Q F(^^(TWUOYMW+26/+6<W9YC)G
MC=8)VNL<+:@^9",1-$E5-LY7 3<LK9@Z;T ?._9,A$LE\0KAQT]8>&\7:5\E
MG"W7-.?%RUSS6R2V#HO=1.QB5SW5<C>>6K5E85W3RMH,;7F4.>%>M5FBF5S6
M0TT=K^#JD.%1/U3APU#1=@2S(XTM!S.G]BL<+#H?PM51ZR*2U5B]"5.&C37K
MBDWE7"SYRR=SBO_%/IXF I5@ TNG"18SM>HS0+8FAZA@:LL_S'G[O'\XZ"$2
M1RT038ZSZPYCVIZUKL!1AY<M]S!G[@OVA#5!)(<3=F$9(6!B\!(P1H+%+EZ
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MFZ:H_NT#*KT'9@JC/8FQ<[&])Z&P"X"%H>R?%-@MO$TM!/^V_^X=8AMD\4\
M[%QXU>Z-*9 /3H$TFX0VQ%=)F&6'WBQ+(_HDTXQ1V>;A?)JZ$MN:6SBK/LV;
M&23;Q)M/RLD,H:WOYY.Z,IS#)NEAG[28&=SR+)I/4L4X=<"-Q*UW(J8./KL4
MHD_BI@Y:T^"L3T*G%DZ[M(9/0J<.W*I0W N^3[W7\*[Q\YO4*#*>0/!K0 M7
M'_$$&7ZQ"/AXX^M(J<1X98Y55R76[KK=.L2&;)I5'FZ/D_KF)<)R1YYND"%!
M22R_<_'CBJ&K'()4J^LS951.(%*^3*Z/[T""F,,#1Z/K5=QWW]TZ+ W0,J@K
MJ[*@= AK?4ZL4%42.@2UL;BL4%53^I6HV/L&VQ5P-1T4'^RZ5@;$<.W[8/FU
M,AZF$LZ=3='O!R0/[P20Y^HV].K6LWKF1<.W.+ T]L)Q(Z.CB+H-L"5%G ]J
M;0ZXU%4K6-'8J*!R]M1ZQM4[^2((,V&MM+VSXPEY( 7=UJIZM<KV?Y^PV#\T
M%,5C%,59)/,S&$Y1!5'[8"Y1>O$%H/#.HGG&!9[&=*ZK"E>1@7(\9D2NZ@JW
M-D0%&",BOTSC>IN?UUZ1/EB_M3%;ZBX?+-O&\VLC07T*;C8%7*75?8IL-EK(
MAO:A5[4#=>?61D*; O[9:\ 6^M6)WZDY4;YJ()6#%1(Y"<8Q?Y+[/&IO\0XO
M3ME;\]LPS!T*M68N(/][Q3:6T+8;84GER['4V^R2@M=\:RR\.EVX._.Y4F%%
MX?4Y,!AK2^<-J5S F0D(:2YW670VY2*A?V4?M5 J*1RX?.,QA,EP?/D<3@A[
MA#O<S4.V>T7IO+\:7;0/]#-EZC:07?6O!G-G2>W@ #*A3%79#-D]CO1PO%$?
MNRJ.U:"S(W:0')K."!6*A^'X=:&LBE\G$-,Y:A1-@LB.VD7NZ[5Z>E6DJ<U\
M&=+Y!.GEO(8UJFU23X"]\LQJS%IY#Q[!K [8VI#Z .SJI2[#&-$.&A^@%"?:
MEC;3SI-MQAAM.G-9+R!0@%_P)YWFUC=TP[1,E";*]_JZZ3 <7U"9R;D2(.;$
M[8-3Q^_0V$/;84[1O3M?H(&$,BVWG-#7/PL3.B\3'/8=> ,RGYL&($LZ\ ;D
M*FI3%V1)!TY OM2FZW%LMW%P@)XLL@!+D<QXX&@C?*?)1%6 XFA^YN)^0@2<
MH]B.5/$]RNDR7Z9I=^X&X(&?A>B-"-AU2K8"K1&M!]"T!QM-\55VX.0&B! @
MDI\%GRH/$[FZ(8D:^\5P;#.7=?MQ#%F5:P]G:@_)RV<0(95:9]68SL%-$39"
MIKX(J<PV!V^6T*BAMW@S \VGQ'-S]&5V=HVTL[\3;>P/UL@]OQ_457$9GY+1
M;X5]9Z2F1E;Z_<RZ?5S IYQUL]$H<0A,0?[B/4C[ )XI]E^]Q5XK36P*^\1;
MV-:I26-[I8WJP#=:YE5Q>.,QZ/LOWNMD_HSQMU%!V Q^K;2N,?XV"@J;X3?Q
MTHSAO@,SKDXFV!A_&S6&3<6\13&-3S=9U(B:;]X5UB1L5,-';UW<FXY$S6#A
M>W#>ZP[!_A: PYU0EB33[83JZ.)[6/FFR/>2]/!I)=2J^N2-5(EW(<LW&H/*
ME+-/9VB:CD']\DV?#M:\T4JHS,O[>SR!YQL9&P2$J99KM[(%-+, W^[<0KV7
M>WB@H0F0-G]*<,>E>Q6_ZF9 X>*7K"2RD-U%H6[# C&G(<A[5-):%%4$;D H
M;@KO2I?-UC5S4DE8Q+2583C@#"5>BD)ON%K\YS#F M8B8Y?/B2 HWU%3BL45
M;ICL;CFDQ$V&_#VB>PT"1:<&>PMO=#6,IB=;O#O1LAS G+&"*QQCOK0(RWYA
MRYST[U*O$E97UG<EPR4M'5U,L$.AH%N%AA_+#W:&BP=!T*T*BRQ#]JDP%J/_
MIGGIQ%(%W:KH*SY($D%':>:>/_!;4G7/0=L\N/@1FOR$/S)_ 7.(>1:N*;:<
M9FB,:%Q F0-+8:D!!,Z*<LD'. TX;V)U_[T*T.)_D=Z6:="3@SHJR/15_KOL
ML4JW15-U"5>B]O,<RJ?2CMC/6SVTA@^OM62]"D@80#,U6;T*,AC@JK,T?0JH
ME6E4OD=9XU54U1!TN:_BTRRVX5GP)I:O3^*JY<&JM%EK+*0W33B4;XJ]IE%;
MJO U0=2"6^Z3Q# )A+V^K<>-G^'36K(<-:/*R;9OEOTE@.)760)<X(%4&<
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MUO+,JM6.1B'[)/B1.,2>3XLZ!V9M>0LJY/A^S["N].?5E@>/"GA4P*/BL.O
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MI; 7HT=]4%Y<VP(&KQ($(#= [E>+0H?IM)B@1YW4[/55 $X#G 8X#7 :X#3
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MJ+]K-W";=6XH=M)GQSJI@M)6U.B+8QKI4]SU00CY<_E_<K"()_\?4$L#!!0
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MKM.!6&E+S?YN2OZQ9?BG$6,!,S-?R'3#. Y1LGJ@!E6Q[2B=*-C?,05[)8A
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MQX>@/U<4YFF9A/3Y%X8=BO=$^/&&J*6"ZK-J1$Z\,I7MD:QQQ NJW2^NHRS
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M5;_\CXBD/!!UUWH) L'H>U[HX+*]76LF:859R.W=["]^+SBP)6DZ6,SY[$F
M;Y+--L]N>0/8LU9?BL:(OL)Y"MF=*$Z0Q#Y! C\Z\^LBT>%VD]QUL="_E'TP
MEK(/UJ3L@V\I^S ^*3OF=H>4-;+P*ZER)O[O+R3CL:0/)(UH>*802QLH7%<Q
M:R!E]%7+&FAV6J5L$)Y!JI*)QY=G3@XZ* I>HYEWZ:I_5]"-!,T3^1]4T(XD
M\5]7<;.VO3-$,;/.Q?7F9SJ],0I=J^=NTAC<W^O4@L2O^3 */Y3.$C2[H[3Y
MZJ?CC7E[&WN];'PVKAECBQK#?C0C:SY32TKD!29X4,**QB$[.F6IR8Z$+=/A
MT/)^FFBL%_J[F9W?W-[,;ZZ>T.SN$CW-[R_^ZS_N;R^O'I]^^YL?/YS]\ =T
M]7\_W\S_ZJ?:G^EJT+XL]B:L14B7OG@J!O07R"/ UGO52'0HWE/@IS^L!F^;
MQ:N58:X;TK!#GFY(."?!*J$Q7>X>H^5*49/0<!2X$4TK=-OR5:%'>_Q($N#7
M::++=0IDI>MX4%'5J3TROND;<'1G#9:K0EM>Y:69>U2+)8ZCST7\A4((#O\(
MC2870)QUUQ'80*UT@'3FO%&4F:M'])9"6(-46]'MAPM+V[G@V+6[W6QBX<3!
M,6^]?AW3+S?)@J9KZ>1IOW49CH8Z9/6P6"\F5R,#A7O[E"[V?550M*?+SV7-
M=$EH3SX[OL95;+]?=+HE,Y5?LLNU8@D+])HX+#76KY4'.T/'SYZU.MK'TAG6
MEE!01ROM.LHNYS2VWWJ;O@''RM5@6;_U2F2>;[V-W*-:+'$=ULXNX ')LD>2
M$>YRGR5A8;!QH6V5$:.QX-!U#1SV@]51004JR2BJ*U:$^)4WLY6@O=CK5C[O
M2,ZO.XS*ER@DX?GN<\:#YJO.*#->R5+Z2]NOPW! 0,DU1VC=::GL,(@K6OQ<
MC'LL#AV.XXZMNZH]?5'"Z)%L>)Y^LJS=Z]D]0OZQZUK<$QK4^H-AM6X-%F2)
M2Z[$C2K*4(VTB;C=%E^,Y"[;=R7IP,OCW(C,T^AYRRG3>03H^!QNUC6"=6"?
M57C'X>[OXB\U99IC)5N6$[R-$G+#?E0Y>-4?0E7C"4 7#16*_':.$PFDGG28
MFIM4GT6._?\QNQEA-K5KFE[2[7.^V,9E'Z%'$I#H1:/C$P0&]#7!!)>S_E!I
MA5E4FB?IBZ^R-:"EH(/PUWG9I".B^$58JS-9VQ!XR20E:"]2F)"<WP-+8>0_
M_\O9Y,/9>V'"LQ^___#]5]0]06OI&EJA=:^'O]>"NA?UD<0\&?2"9GEVXD/M
M;&\[$-0!7@, V*U?$)K<^+60>N_!G$.MGL)MWWM)'(?$]RZ> X  #8X?3]$<
M2<KT5E$PAQG\];HB/D/F^]7. ;-\-%)L4#,'"&5X:?91*Z==HL=6)P>Z5'JB
M/;;Z..S6^"O)^;7JB03;5*,GE,8(H-BV0'91K3G+Q=GI1>ATF$H!G/+U)'"U
MWL1T1TC1:U01<! +$6$_W2_8]9XN$UYX7B;SB8N-_J.!)7R]GQ4&ILOS#7N"
MKF0S2=F^KVC0*!O\S=;<3!O?(X0MR6A\IK"ZW(Z],F$8Y:+V,>^Q>9,4B\TF
MLJ:)2.Q1^6:T!T(]-)T(K/MI*@K0AC<@94=X((GPXU+1YSB%L]&Y4W"[W@H;
M5W0_Y!LH)2NVA]BMZB8)Z+J]>+#Q>+B[4 ^/=9F\O[A!LUR^8 D=G%.FPU/O
ML3WF*T%[L]>UJOS[MK@\%FZ9.9WCUY^C?,63'Z-D>4W3YK- J4-[0P0K5S!F
M9XDA<!)!V21..-*GE. CR:.BGB?/%Q *7!:^1PMF6*^9-;K>KE&.7]&7/=6>
MGK4&D&QJ87%</^L;9LA;RXGWEP5?QUQFO1-!@:?D%J-$]Z%3VW$2_2JDY?UW
MA:SPW_R-2>^:G7JKB"RN7IFISQ_N[A<+9ENDC=<?LT&&,J,'W+HW41" ! 6H
M(@$5-&C>==Q,+*3L]L)3GDX/YE9UON&/O?P=F%UYN KG\UU%RQ7)<L2,\5]Y
M%""I9DXED1/T9471"F=H&Q<=)-8XP4MF5S([A;_[4G9K$NGS.W$N<. ,2U34
MG>6C4Q%?E_&K(__K,^4Y,NQ,"=GY$C 9R;YUNC4-I9G"5M*MZC_?9E%"LNR2
M9$$:;81#( E%]>K[Q8-<>"$O7<XO."#@46&.T+8J*"E"-9*$+,NRYDQPZV3Y
M?Q_NL61TN'4867U'9:Z93#ACQ++9\?K1G8]L-E'9JO<((,FZ)T%D1G+4?A_B
MK"ZG20G"WFO4:\=I=<_5OR%J?FTH[QU0K6<&];H,#BR_NARFAFSS44Y$KT!6
MZ[>]BHUX*HLE"WKXL4/;F7E2X&-$=; :VKAU/N%JC>E;\;0)ML-"IS7T_N^@
M>@QOJF_:S47'&JHZ?=41A(W?0#52'9;+2YB_$+]F]E$MGCC/LY;/0;<T4PE#
MXS?P[.@]+-O"P)"A2&!#;]D.S#K:U5JA&% <RY!L>[G9#:M.M1@SFE#3VCOH
M;,U38/^G[?D0#FCX@%,%0E>/A>:40?:6U?GW>1JL84?ZDW0?6=LEEGK!M5J\
M=EV?I@PLE3JF3M?]@E^I>-B<8A^;#097J-%!XFJ_ZE$#V:.#S[/GODR)<$KG
M%&%)"=NB <W$&W[D.1S94/!H/RZ[WI&'2H,=_U>O0;SEP0)E>7WE?M0?"MZ-
MW2CL!\-7*1JX2-%("'#/V9@-H"5/0]8)OYV^K:A!)3G?3) HZNIIWQD(&.W#
M9P_Q+K/-)B5!A/?U-9YFCT^M49S:X_I$O[3!=Q($@^H4E&53WC(BLF_\AF[J
ML_\X,D:?IVX%\9'P&B\!.Z\%F9_953)[?/K<*H1:8X "V K;MO#MD2,IAP(]
M>LL(\"UY>CRG($:.H@ @LV)P$AP4=5-[K0P!#%OPKP&1*V- GR*@0\S:?('>
M,E'K^^V6)UA%R3=H49)2*W XIOJ&;3+87=>PD]%>CP:3(\'&4>#I"!B3UM?6
M]OZU/,^:BJ3!/DO""YKP(H6$2;=2K6N,  I2"V3K[^=[U"(.+Z@C1V_O:$[0
MV7=^W@%T&$X!7'0K:%4QV,[7KI8O@8+5 -'53: !->3('V0&@+/]IOX*=E"\
MF"9^3O0VZ: &#',K_55^-=?Z]R+TM?6<[OP>N!.4<+TGZ$MB_![CW5RGQJP<
MA='64(G;S&AK 6"]2KMGHZV!H@&-MD'FV\=HVQ0$\?I<377IQV2VM4DAJ!R]
MUV8P*>$U&(K").RJ)O+$#V(C%7O48"1P<VI@L-Y.1I* B*1!7LLI)P,%!\&N
MGKHKZB\![<'749P>\FFTQ^G1 F#8TZ,!D>?3HX&B 4^/0>8[C,NO?HY$)5DC
M/4?:Y+'['.EDNF/38K$@07Z_N'H-5OPZ_8AS<I]PPKGYS_[#L[Q?<,P= BIK
M P ":H 8H+*]=4L:4,ISCJ/UADDK8C8(EVP_]@=D'>@0S'4KLN7+_C5-2;1,
MY,D7[.;,',QBX5OXB*.DQ45D#@ HKOJ(7)TS^A1!SAF;\P5$OTB!YH%E"TE0
M<?<+=@CO"ZAXV:L $:3]^>SX<:!1<\B"?S=)D!*<D4LB_ZMZ+0" @#X?&*!R
MM5M-:(+L5[MSACF,!3)V!Y0W1/&:PG\@>_K\/*- ))$.P6K'V65)'H51+))R
M]T5V950=":\93WBV^#8O(ENO<)KPHEIL(C)7?-<,H"U7S3Y&:.:;/<JLY]'5
M,*,]:J])=0[6F7I8O#'LS\X:(;K#!MTI#FMW-(O[9 1U];4YWRF[XZB<STLU
MWR_X#90'"!05G[,G&H?*B(^N >" #Q5@^_$>,E]ED])PRRR,E+R09-MQ!;,6
MW]')7FK.,P>E6WA"#$DW.,UW7+(;;@A=GT&*M32 LR\M>YR%0G)_"G?RDNHR
MR+YH/)(-8^6*W81GRY2(%_YCLAH/.]!8@!!IX_ @63Z..AC?:2]FND]G39A\
M['YF1S&CYXOJGJ7^L$>:ZB% ^T^G]"7*>#0-KY89E?B])60JV$GU>=2S&.VQ
M>7Z3W/+_W$985!4]?<\T' 4I1]L-W;:8:))A7(_6QLP OF.!%,4CFPBLLNY\
MQ1UJA6?M;5C0\PT*F6&1+$7)V[3L,(\VPB7%'7#\]_$Q&SQ4PC78213(>]<F
M5"**EO%R[1?;+*=KDI:D[916E,88L"'5 MN9K[N-")!S>]A9 71(28%H/X!*
M&B:HHL)GSK6>0%$0/T>3A+*OW=95D \&9/A4E09DKK-7#NBI5?'S7\0/N$AZ
MZ2V=G'<=X,GC:?,=+[";,UKYJ]&&$WY'U)&=W4/ (9UJT X,$H%;""<I$6L4
MY[ 6O:G!9@KAG9\XFHXHF8%B8&Q+28FG3]R*.8WRMOR4XS0WNQN<8_;/ /1J
MWY?:J\2P:I,6K98#9=K"8 :U]A^E+S_C+X251RJ;\8?!@/UTOQ!7MN*K)L,?
M! #B S!"Y,0=8$21L4%M>;Z "WY)$>(DH3U-"&>HH(H_$PFZT$BG#7<I;/8S
M%*$^Y3,8RE>X>A.369]XSYJ MS*,,B^>!-C6I/T7PO'5469(#M65L2\XZ)43
MB-:5PP)*'^3(=\"+/F4=+T0J(,^W$@VVRH:+) YY0#S/=R A;\55UMR031HQ
M+Z+M*0&KKTC3H=?&N7') Q=^QCR'.M_QLIQ;K#($VC^&&Y0-0)WMW4;LH)TY
MT#P MP]F=20A+Y?/[>*KUYPD/(&J( B5%*&"I EB]W[NX/=YF^\0)6K&5_>!
M3]QI5*1?J@O<-'_6(\BI#LZ=._X0+\P#WY=V0 BYO&SO<]&)U@0L!F<U"@/5
MY5)/:_:)W493OMW/24(647Y-XYA^87S9-T^>DW3=9,<:#H58L)HHG-BNFK08
MFV_6Y@@Y,4I:4$$,JJA!>W(F:%P3[66A\K=L;J!&:U)U?\TJ-CP7;,@I^[&\
MP98<22NZ/9BJIKN/]ED%^TH&J& L*Y>Q*!8;>VU$"F4<TX.K$;SF 8E<C9QJ
MCJIPP5YO8*YW,IK\:S9Z%0)1'U]'B9&.UHUP0-9+CCAK^LB=-@NVNIGTT3:5
MW?#3"K+'XH#J;_1K(JDX%*]BMI6R;)[BD/ @YL:"?1I?0HZ^9HC6"V)(K$B@
M+<+1M>KQ69P!3.D_DHWL)YZA<E*YF%3"2/&@R3LDA!HPS75QZ1Q'"0G+[,J.
MZM)M'X/+2S<!M5]?6F)%)5K?!:9;.4O-V.6X0-%18FY7(%_G]]#20RJXUM5J
M*4(,,Q*H_0?B=3.9&G.N=Y9&D03RB+]\PLR6B7"<_4S37V\2=@4(F%Z<)2%O
MHI>M2"@2(-D%X7[QR/1\^D*$U[#I<!X0+"S/HS=Z1XD@O>D$)%AXX W4(_UU
MS*Z'C;Q<IN+I& 4X37?"C!!FLXC3Y+;S"XZWLM53*FF4T<:U2DP3'C?#G74,
MWK-\I4)L=FQXR &SOZ3X"UJ7S)B@+XP=/%-E(QDBX"T*EJ EYXF7=)7A- :U
M)0S.GYL#0D(1.5,K>)U=O9(TB)A9IGYYUAL'?X1NA^\@M%D0("UP4J#EDL[C
MG'G(L\<8"6WF4S!'75LC(C1+UGXY36:I6@?RBKKL?^$<ORI-%3 DL!UCC-&^
MD>.OZD6?!: #<M5^,81YE,?D?G&3A-%+%&YQS D4L49\7ZVBS9Q>)3G3%<J2
M"$ (@,((AIAL"Z@@ARO3/4'^"B1 5X$.P%H/4JHHY]+ZW1 2YZ*@2Z-<^2GI
MTLY/E>SX+F)VFIXMXKNX>YZWVV%:EF0/>(>?8U5A4  $< $.;4RVY:YHIY1S
ME)[*<9ASG0[ RK[Q"0&SBK9\"Q3G/6^=<-CAZ7SWD=!EBC>K*&#[@Y,WYW2H
MO(V#PP5%. R WWKGIH)&KBX+*H697M&)"JE^WJ$ZJ4C0BGX1U")M?^=HN-3[
MX2FK,2ZM,6X?V1@)VB><<\LZYS"GWT>\P9#;@5I;O9[*1/1<N>7[5-6%K>LS
MR%9O &=[YPJ4J,0)?\H=A/3>VTGV_HD+,CSLCC:!H+JLZBF[1:8:7K+M=$?R
MEB36]B\A$MP,T;J#K<):.X",17@HVGM+<;Y/NRRFQ)WKQ?'@0:@[Q(0:\,]Q
M&>4PC/@BX/@!1^S^>8$W48[CUO@$K3'0 LIML*U73ZZ0(XY]&B6HP.\W;$&/
MX13$1?<EBFC2W6!=^5V/0D,'\%S4$F*7A1$T55>SDFKSQ[E71%K!1290$8*K
M]H"T?0WW=C1!=5MS]&T97,U7])O"SM%Q>UB>$R! OC!N&7)48$=O"_S?^*S^
MUB4]U)!](_$?JFNR0H8.[3%T6)VUP%AE/TZ.FY\F(3.&DN64R?1:O\RI:[^B
MHL8GG--NY?2)W?1%SL25>,WGV?\T$45#U.UPM,8 );,5MO4X1AG1L$?JLQF-
M'I<IB'6.XV,/Z6GM M/Z+30NM@FF:UGRV^*EG:W4B%<C.$AYU![D^:UIW)!'
M:!V^N8"]D/29FE[?2JQH(]$"KY]#S\5LLV@3,IZSOU&4N@Y^-4]]V'&\^V89
M5Q0EVRA9%L\6-,G."6](6GOUO'K-4TS3,$IPNKMA!TUVQSC'(Y)H'(N'#G9/
M(UF[+6@58R][T@IE#K>-K2G K=F1<!36XI-;Q&]C-H-OT+.@U<#$MVH/V]U!
M)S:U@T5TJ_D^X62[P$&^34E8%' 23UJM/D^]04#]TP[<M@JI8R\+<TV0?%CU
MZAS5Y#F%,=*Q;[VQL^XLORCR4/Z"XY,W3M!8J ]>!X>39'_S9LI.9P2NI:V<
M',(Y.V&64<+S#T7#1H%B=',VKLC=.F.2A+ISM?7V8K2M.KMDMW+9\;MQ+/8_
M"9MK>A8N<M4#LM%@Z$NR%A)']K-X69L^<R)$X>>2BM(O#=F)MB8(LP[TJ!G3
M/"%EGC@%Q3(6Y6[1C!?F7!8%X[2F:2M*P&Q7T7X<'E7&6E<M!-/A=G+3G,4:
ME_'%(IFRN?F6_]()QFNBGZXV0-^BK)39C 3?+NG+NY!$7%Q_Y#]P*?VQ)J7L
M5W^;,040<B5P'>/ED1@J_VXH9R=PK+^>EL@0Q^943-0\HYV,<'P5DAY7=BM[
MH'$4=-=<ZQX O?(H 3MX9B\PHQ(U^J5$[BEHKIO+U)QUSL/E-BE9L=,W>BE\
M8**>@3HA6V,$/(1.!=E=+6XE";"RW /.". !/L!?NGZE/]A7I&"G[%  ^QS'
MFA#A!OY($I+BF!G1LW#-"X+DW*'\0LKJXJVN6! ,:"R*"2[K66J2F DJR!&^
ME4."2AO'<RDWV!+10?CN5J _XBCA+R3WR1/F^5\';12K'HH*238;#!1A/22N
M3@D]:D -!X>>9Y]>0YP0WE4HC+(-S7BKAP5:1*\D1#C+2)=#V]*N-!0WVH^W
MC@\6[AS)[K=YQOO-,-6A.CQ4WT$/B&-XKC;2"6+(GAF ^KZ]1=';*$&9H*/C
M8F5Y"M"&H_H3L'78*D6::K/)6Z*1[K[5&=(__<CY;BXRD42KN4DA18CN\7L7
M+BV^-^<JC4KD'A@LDJ8D-)(ZS5'@PGZMT.VG,Q7H1RQ^N@M @5RUZG6^D&DL
MUU$6X/BO!*?LB+ED=\D&!W37IP!?M JD=956).](Q(ACYDW]$,?MW$G=R5=J
MPBS7IV26WR_XA;O='Z+\#GP>'L&S?PAFHO:N0.D['U?%2ZK-(+=2\A><1CR6
M_)9'F'/*%%*B_ XH)2?P;$M)B1 )C(BC]"(B:D92;>ZX%9$NT1A*))R)P@E"
MB.'8@UIPP\]8B&[@2W1;178\HEH+VIDS["UIJ%V?]Q'D!K"VY5IJMH.8)8[:
M9PIJ)X>/):B3;?X%JC7[M'O @$+E)@]5*58^TU$U^-PA6F-,3&7&)^_/>EF8
MH,4[%:\&R-,09L+WKQ"\?L &2V'50>HO%U2'NF'27P?F0Y_'I((4S3(9'A^8
M>HIP:^JL^7JX#H+-",/%$P,NR0N)J7@2*\CLZ"BG/1(<^MJ)P7[4JR1!"&N-
MB*K@D.?6<_I+0'OPU:U(5A5HQ>GY,XF6*Z9[9KQW[I)<1ID(JGMD^JBH?*B0
M3R@8H+":HK,MN24%4RQ)X&_Z@@:4NO9H]EX1.A2;>Y9X/4J=NL91*I*F.-Z8
M9MNTL=RK_BA(Z==NZ$[2'X%9C]:F,$@UV 6C1+16D[M'TB*JZ)VF!K8T5_-0
M.]9 YBAP%:R^05T6RR=?-AY$I,,U^]VQ%:+U+> 52@G3]F8J$9?O4!(U$KB=
M/T-U<Y8:L<OG/:+%D:S^<)"[@ O7\K[C@V=?;0LOE:=X/^]M3]W"7TWU-,O)
ME[WU2@71M581K]MCT"FG/&W4* I&N8[5I&D^)^FZ2Y^H/P1':QX#M!ZSSS$6
M]4O]*I069E)]#GEZN6QM<Z3Y==]73;<MB03:B7CF-NXO9/OY4-T-QXAI3@ZG
MAS*X5Q%YU?I=CX/I )ZS8ZFXY7J+MVKG)M5FD6/?+7=^W"\^9T3XD>^?<QPE
MO.';U6NPXD].US0]O&F5I9MW*I]N?XA07R\<LW4?,"=M2A?3+3L'Y3,%H@5]
MO$$Z*2@4C@%Z=!&O5?\N? 3_B9,M3G?H;(+XNOIQ' ^PSM3"XOFH)5H5GRY[
M0[4$;FB,Z%7+LQ&R;?DNBD96N&MMR?P%<.AP^J3FHP;[1B%AK9$<6F.&E3(W
M\1PM<N8SHD./W]VRYC^NH_5MY)%P\LH_<E/I#/)PU@+&QL-9 SKG#V=I24-Q
MI NKF&>8[ A.LV_06^Z=\)-G EXJW1>U3OY;-89DT_6K-4F7/*L^I5_R%:\0
M@9/C"ZSFUP##J 6J]48, C4J<2.)'!78G1M).OREADQS8DOSJ+L6$[K^YQZ6
M,P?CS&#FR+Q9R0<,HUU<<* AGM8XCL^W&3,ZLB8_?LM78(UP ,V1)A X48G4
MDP)H9B/5Y(V3#7^3,%-\+6YEMXP&4="]10&T?=Y#(32!=:8@:LC1+QP]$OC=
M7K&UF4Q-.>=:C.8-_7IT/AU&?.8N.MDTBXY /0JIF1_WJ]%GEO/:C4=M\LIP
MW^X.BD9CX14=NW$X*.YXT$-1!-@>QH=K-TYT.DUH$IVO>I4&XD1[,<]U1;[T
M)0K:(]0;OP%7U*O!LE\Q3R#S70ROB7M4BR6.%6Y*\/WBD>#X*N->N;+,ETK'
M=GP.5:L*L,Z*Y2OP@W3G8',!%,3GR/E#&4>/)'ZD-QE;6K1+8*@IYQS8Q-=1
M3-(+1L&2IFIO6>-78)OX )HCFUC@1"523S9Q,QNI)F\<2$-1*.:1;&C*?;W\
M]:(QY%'G<[!\-(-U)"AE@9\*.Y+H/8E,!XNI*=\</VRN-SA*N>5UO[A)<L;N
MB%E=,IWQ.DJBG,31"PE53YQFHZ&/G7I8K$?$%355HXH<?KA%%4$RI 24_6MK
M@H!#^^9@=GMJD"1G@B1!4T'1.";;)[=Y3XV?-VO##41[\K%GWMQ3L"+AEE?@
MK6%@!N5-$I+%_C?'Y)SO/N&_T_0B9CND-9+6+A)(5M[@Q%@W.0N"^>XMMNHM
MIU#X9?94%[\\V=_H>8<$Z4C0;ASZ.TX6PI((&=9MC--ZRJ HH[W7?X*IT9ZI
M\I?'1X)@ZEHP->"S\9!&:&]/43>K[/96=!0\<;?EGI'+*-Z6;=#J%3UGX=^W
M6=Y29K\G-."M"8C5NG[B55$1W8C^S1/T-'MD___X-!/__UFZCQ_X#[Y+O_9=
M-3KP4O0\NCNZHA59]HRZIB/9>##DJ-5&8KTP<86)Z_NBCS,JR#,^_BQ.:Y#<
M^,W!;--Z=\#@H#M@4%#LX?@RES_:C_N._=Y)'H5<'; 3\HD$VU2\RER]!O$V
M)*&D?;W9RG6^7USAE$?R98QXH3UF:UXK0^4D'Q(VU*,^! W.W.]#$ ORU?OA
M$L2Q7Z,4[4E%):UE;]&*6JY92GIYCA@2%$^0#K-LO04,NB^HU64<P>7W?J&Z
MKYA<>KNA#'G956.S'H(C\:(O!5FH#$$/BGX;/3H=>&( (%RBY$(QVVTFT^SX
MI2/ <<!LZU(WD%(WL,N(_'R<UW\-^>VZ]NNNB>]*HD7/T^R1!"1Z:8B:@PP=
MK$KH*0I_-4%/:1FF FBO.?;QB9>(F3&@-R-GY3Q;)*NU>&<7*QU?]RL+/YO3
M61A&7 WB^ %'X4UR@3<1T[1".SPSXD-^6R!))G3E(Z]4ED4Y*4)V9 8[FQ5=
M)@***/2EL@0<H84:"9;)<^+8F@KB^#%?45=&1OJYY;I:<^IK(5W$7!#N.(BY
M)_OUOX@Z!D?Q'3S*XA">J_ *B56\%;TBAM=77(6"FU2;16ZU^B5WJP613%=/
M0F;'I7GT/P>NN2.-IS$"J$M;(%LW?6JHA3,?UY![T8$Z;*8 WCG0/(]D*7I.
M)_D=7C>EK;1]!M8[A^ <J9T]4L2Q>E(Z"DY27?:XMMI>F/ZC*2.)&=1Q4?A;
M::>U?0RVS)J NK/%FK##K*]AY@$)N"I1(XD;:4W#FLG5*B34C&,.-&1C!1;5
MG\$:T4U=E4(3>BFBHF09[>*#6Y575;,^WXD $A$XTE+HJ?-[H.)3PK6>;\>Q
ME<%9_LHZ=?.5&C/+JKJX)4L<2REN$)>6+P!*XPB2_5*=2YY@4V@/]S+1QCRJ
MP1%/&D0&H'TBF$?VA??)(W^L2Z-D>8ZS*/N<T.>,I,)9>)-LMCEW0R1!%$O+
MH"[)K57 ;*/KJ[\&)LNI^O-9;<SZNC;I3ZN+Y3COMRR[UE21H?TC:.;O 3#[
M[N"R.IZ/T@L=#*1Z7/$D$2*$&#/!Q?$#S83C=_:<B=BM+CG1&-I7>EI0N),I
M&=POJ4 E&>SL+PCQ+&PZJ] D@MJL=2N8QR$ZQ0.^0A8[O@:*GP*J*T^+ CW$
MU3+83 "^ECMV=XAD]=*W,<UXS<<H02&-8YS6@D_\1)QT"0XUY&'/@/%9$&S7
M/$:'A#)M-=C-4YQD,FI'F?0 &@L)%]?%87N+&!%C'#UN898]0T-*<E!)#ZH1
MA,8UU2'CY+$(S"R;P^$:(X*2$7F-$;BBUT.\O/'^H[W68!3QJ2?Q=-PF"A2'
M- C&L+&IS;AL:RN!Q$I<JMLXS(Z5ZH["U&&_X["PVDOS:4JW*JA+:Q T)*L5
MN+.$C%8J0)D6 \\+DD)1(T%1:,%CM3D]H:(PCCHOXBA"/Q_PCCLX>$3'24F\
M?6?4KA9?/:'!"SU"L#HH_2CCA NZ1+A/60^R1AK:TX9^\=U$K.\*TH&7912N
MC [WFN:H85T;KIQJ999*<N(;J/P!OQ^3/Z#-DV;$2L>2MUB0@.?$R:XK<_S*
MF[OSG-PHV3*:B^X5-%'==,P!0.51&Y$S[YLV12"'G,7Y FY&%3FHZ#/$"$*<
M(G3XG#5!1?*VSYL20"AI?\X[OD&]X"CF!]PU39]P7$MJ55V2.@= [T%*P,YL
M$24%(#MDP/E ;) 2_71!TVG&"*@E<WNU/[H%B)IST>]-J\T;U?KM0+<J)]ZE
M5N1#/!8!9_'/_E2D='YI\&\$V\+0_&@<,^0V<65Z2&?LZ V/9GYW2=D8C(Y:
M9,$%SE;7,?V2Z8>2*(?T#R$Y >TT=(1C1P+]B$)&U-QN#A7I8*&+O%#Q:"+R
M?KNJHI@-@F>,M@!WE3XJ7Y($#1-9YR=#]R-X4#)< @KCJS?])HA;T3AD5YVK
M?VQYH+6VHNL>VU_CJ7$X57UU,OX524)&I 0U5J)9&^JRMW]0$'=P7[ OHP#'
M\S3"\07-\JRH;*\(!M(: PP":H5M6[9*Q"CGF%' 44,"7P:>1.^ %UR\X@0-
M\RO[>OF):]$3)0IBK?.:2_7VXQWJNN-K>&6E)JBVM\U)!WG/&KB+N>JF\3:U
M["/;C S&ZB//-=?0L*W?]]"NC7!MBTB)%"T%5JA2'8CVP11J>C@M_[JT76BH
M,3<=7X"KJO.G3^^MG2;@ *!786U$+CM$-$5KF+9\L'4K-E\9VI_=;L7W\],\
M%<E\N_,HCO</%ZW=,/4& <6T';AMT?S\A$KTB..O%Q?VVD-3D^<4QDCW56-D
M%/><X2TZV16Q>ZV"IS^P1S69=@3V+Z8E!9[3BPUX3>$,]%UDMBPBHXXET!HS
M6%G9&FQ_]61K1 Q32!8VJUY=U72G8,^>TY":UI*Q2J99?5B8IYC[E)]VZV<:
M'VT)Y=\!SP4'<&R+>H$,26S.G?[-/*.=C/!Y*K=4-%)_.,BIZZ)@S1XCXBA]
MUC%JX:;R7/5=P>8.Y]N463:=(;/J#X&B<@K0MJA(C-Q4W>/TGT30PEBJSRW'
M=8]$:05RRX^W1YX2=[_XG,D$'8U:M8:CH56)]+!83VPY2LY*.2E3NIANL[*E
MHY^:0X:+0'MRUO5C-MO/-UFV)>'EEA<UDN6_Y8.[^..][!IX]4K2(,J4%3C@
M@,#/W*8(75D7YI1!3 X7\P>$<,I6DP5J[XG,/:22#L=JMUM:RP4_J)O=K2N]
M&2MD"_6E&Q+A3'.2(8'8SW'6[<4?CZ>^?=\50:^'W2Q IU,K)"O'4R/&<9Q/
MC:0-?T -Q %([6]&$K^6\4MF68)#'%H+FB(B@]/P%YR&8S^^VL56^_S26 G'
MVY[$#.;R(TF8"1?S#.]P'26B_#_/VVNON&\V&+JYM9!8?U.65$S04M*!?HO7
MFS\@?$"+'[DU6P3:C[.C+&7<=0&#@K%;>MC9)8[3@P1!DZ+V"BII0DPA5U0A
M0=98PB/ BV9>5WC,%S!!_A#W+PU PUZ_6A!:][]K7SO&=-706:'NFX8VVQW[
M]$G.$YH>4OH2A20\WWUFQ-TD13W<9#GC=0)$ $E'G# <$/1-P!BA]:!\GMZV
M$.EMHA'YHB0%X8H6/YF5/1:'#L=QQXJ[<:_-TI0MF0BA/M_M/WG .Q%5S95/
MX<B2L:8WB=R^'U.:J9Z[+&*"JO[A*7)FF0]/.LAR'P,'OW[?L\6=01TNEEO-
M=9^O2%J+&[YCC&Y,PM ? -0C:L"VU8' C&*:+*=L%ZQ1O"?"BR1KL)B:\ZUG
MOLY]FJ_H<T1CNHR"YN#MSN\@^3E-\*P+Q %.S:AL:[3WSLLY),-#&DZK3%!M
M9O64X$NVMW&LEMRFOT,DM@['>F%'@0LNH?UH[2V9$KT'B6Q<:]K)E)X2^+1-
MESQ%5RV#S5] I/ 0DG7?>($-+HE]Z>TMBR4!'J11L>I4@S7N WAE0US\Y1-F
MEZ4(QQDSU>\7/&LR?6E)<= =V"/ MQV!]61>_ 6M2\R>&QMW,KFQR;$>Y]Q*
M7.UB.TO"TPH@"GG3'0:4MB[PKAP8771 O!'#SRWG13;-7 NB+F?=$!-UU[,:
M,;_]S8\?SG[X0^'*][+?M(6,0KGK=J]=D@5AAF,XQZ\F'@'=8<"]U@7>_A5;
MXD<Y?JTDTH_ :7.:0MGGZ3IQS6,.5B3\2&EH=I_H'MGW0J'&8/W1OL",EARU
MWRN%!I^;[A2ZS/,D=S_3]->;Y"&E <G,Y*Y[9%^Y4V.P+7<<\S1*IAN)VZ_@
M:3"Z2?!TN=<KTU6T1DEW7/!^*/_!9>Z'FLP5O_X;8^SA@I_^P5!B]@"LEZRX
MNYE?7:*G^6Q^]>14'!J81-4S=ZM%'DF.HX2$967@6E]!=NA&0:2Z,.D/!.J0
M;@3V*UM)"A I2/"B1 P83>'<<RUULCP5LQXNR0N)Z89[O=J#=+7&@&6M!;:S
M FHR%#?<$^!)WG3X3$',<RME-9D7[XO\K3LE*T96U<GEEA8'*[,L%'('A *4
M1$-LUA-L:]USJ7AA#NH$H;@S6L22E$)7A0[$ZM[/>)OM[E.4$W:_"]I>\Y2?
MP1[U3L#9=SP\;'=(X.1MHOH\\@U .^Q]9;XBZ&@>7E[[U+) =9GD5@%_H@G9
M?<+IKR2_WB9A>[6\]H^!ZK09J&VA%UB11(L$7K]%\3I82\WXY;L665&E(UE>
MX$V4X[B['K,A@,&JE*D068^K7O$XO@Q%":(E"44Y#/$$47N2\!->#5B3UAI@
M>HSVD >C\\PW^,.>OZ>\81[OO#[709_G[$UE(Q-O<YSF9A,ZQS%/'O)+]U5B
M6))0BVJ;"4V=SY\C>_ \;5S=<2)JC( ^<ZHANU)!+21 -L*@,P+7_L@I*I*&
MF(:J6AKXL;QUI(<"&.CI]:REA;SJ4:NMZWS/][+.+O06<DQ+W&B/W'_A/BUF
M-[V9=7+0<6I*>3,5!=W*X(5==X:*[CAHHDH7?-MB)_#ZSU+19C,%\\ZQV5'U
M4ZBV1-'^P[#-AMYPJ(FBB<9EBXV*D@DJ:!E+"0GC16GLKV'":=>F<G&CN8AQ
MEA4]\EHJ*W=^#S:<%7"M.VPXOJKKH<\RR]VL;6IKV,XO7PJPN=MQ$EY&\3;G
MP81&^A $K;=Z-,+J4EN6A"%&F>P>.T&R33;W,!;DC4^!PE:Q49_V6)I1W$'-
M;IYV[INV)?9!)D:A%UY,AHMM+*Z=&YG2/JH[I\%-<X3"U-STT&S0L*+EJ/WA
MH1VS0].R4R#$VS385/KTA+DE6=7N$&UXR7&:H"@)XFW(-'J45+WHB SQD6]*
M171(,6RD=EU#UT0(Z]WN.%Y"B!TK_#_<V\Q4&5==^GXKX_' ?:B-QTE9*2Z3
MXH<:+:/R<)DO"^W-:]<^UIPM2\2N0;)LH:@3<_7*%0DOUTEI^"6*8X74F@T&
M^UUUD-B65X%5%K;TY&LU8C7MQS^?UY6CAAI:MQ7%F$$N*T>PK4<:CZ0]BAZ#
ME8=S*]<<9W:SNQ(ABKO#YR1D"IFG>9"0;0KVZ6S-_Z40NUZPH#G@$)S.$L,A
MQ(&RQ2USH<]M_-""Q>'?M[*_F9]D\5XB2@?EN)^T<AD7/L>O17[#.4G(0IDD
MI3FJ9U*Y KJSG/)(X.>IY9ZL/5TV-V24:_%N1&=*48PQN]R2OQ*<SAEB5<(4
M&(Z-LZ0)GVT!_?#^P]GXU&0KYW559#<[QRNSUVR]!A#9.A@'$LO1.1#8#Z,7
MV .^ ^7UE)DC%M?H90@-6P?C0EP9.@?B^MWXQ;7.=ZBXGC!SG.(Z6^0D'4AF
M&V%9%MP#G+:E=[XB*<$<XZAEN'D= (+<PMQC::XSY);]Q'Y9_HK]WS-#P'[S
M_P%02P,$%     @ L)BC3D'UE^A#-0  <<,$ !4   !A;FEK+3(P,3DP,S,Q
M7W!R92YX;6SM?6MSVS:W[O<S<_Y#3O9G-G'2M$GG[=XCW_)J;]ORV$J[^ZD#
MDY"$AB)4D%2L_OH#D+K%)@B -Y#PFNDTE@2 :RWBLIYG+0#_^J_'9?AJC5E,
M:/3KZY,?WKY^A2.?!B2:__KZR[TWNC\;CU^_BA,4!2BD$?[U=41?_]=__M__
M\Z__YWF?<8092G#PZF'S:KI(HP"S<[K$K_[W].[JE??J[:=?/GRXO7[U97KV
MZMW;DT_>VP_>V_>>]Y__"DGT]1?QOP<4XU=<B"C./O[Z>I$DJU_>O/GV[=L/
MCP\L_(&R^9MW;]^^?[,K_7I;7/P:)/L*QX4_O,E_W!=]UO2W]UG9DT^?/KW)
M?MT7C4E10=[HR9O_O;ZZ]Q=XB3P2"8OX0I:8_!)G7UY1'R69&94JO)*6$)^\
M73%/?.6=O//>G_SP& >ON=5?O<I-QVB([_#LE?CWR]WXNV>BB'Q%R8*_F15.
M$^+'/_AT^4;8_^W[]R=O1)4W7/P$+W&4>!%-L/?!FR'"O#4*4^PM,8I3EOT:
M<P6SYRT8GOWZ6K3L[1H2(OV':3O)9L6[4$R6JQ"_?G.DT(KAF!?,+'C%O]B6
M%\*VKEPN%'Y,,._ 6S/OY JIKS"!^.;/&_Z@>$HO2<2[!4'A_4Z$>/00)PSY
MR>YA(7K 8=Z.0:U<Q%!T,<JVAI.)**P5[T9$C/T?YG3])L!$6.FC^$/(_]%[
M>[+M5__!O_KS(DI(LN&#%Y'HB:BRGUN7Z0K/49@_>?1(X@*Q)"5,)=L)-D/Q
M0S86T]B;([3*^M4;'";Q[ALOG\;V8FZ__O.<Q'Y(1<^:\GYTRA_R5?+B#6H,
M7 WOG3U%+OF(_TT,^(-\\5Y B2I:=;I793\I\&D1C_F?3P>"NJ!%H:?H(<0J
M@;\K5";L\2HQ8OXKRKC'\>MK[K7P7V:8,1Q<Y<^0KK#9"I$)PA^8>0F_B)>-
M@U]?)RS=2X&8_VSM^;ZA;8DW*\3$4N,O2!CL:L\879K/\53/-/S!+9DEX8X@
MONK$-AJ=EE::9=JS3C>=IFQ9HZK%>.C**[H_U5CUM4UP,E03Z,[WKG0&'4^)
M5EK&#Q;ZUYM"%-(>XGKG<81'8H_.O..'>H: 2]6,#;RE)Q/ +8!;E=W+TS3F
M<UX<G^/89V25S6=1<"JZW61V>]3I5#Y_]88&#LX<4<,FQ@1@-E3/ H 9 #,
M9@#, )AU"<SJ^EH6T=J)%Z&$ZRDPS<-6#4.D5M:$#92FE@<0&B"T?GCYCJAA
M$ZS<9(-],INL1,8&GTYD8$5>$! 6("Q 6("P &$!P@*$U4>$I5J[[2"H@/II
M]@>* @]G?=<CT8RR9?9<?1REV5#':,I(*CU,50D<C+@0@1#D,D3S FA0^'OK
MD.4L9:*37_*.C,(_,&(747#.35<@H*IHZ[*>;]]D+L$M9H0&E_R[(J"E+-NQ
MM,)>>K(^*]F9I./#J) Y]+K%;<A<Y,_K%.U,UKP7R@=8:;G.I)SR!Y4(=_QS
M1R3/&7\L0^&83\R/_X,W4K9'4JXK*>ER2:/[A/L ]PON.<23-,GV99"H:+K7
MK]25_/GT?H=7E"7\\<*'*YRN=(J_2/HO?^C%$K,Y-\AG1K\E"_Z"5RB2]]G2
MTAU)?$E"S,[X7#.G3"YI8:F.)+S#<R+<ZBBY0<NBV:FL6$<RWB]1&)X^8>J?
MB5A8RAUBVEBR*4-BKKO?+!]H6"!7X>_N\' OFE+1<LY> K%B8@A][]O1[E'(
MQNJM 8[V$X5%2MUB;9.\<\,D)>N)MBG>NV$*/3Y'VRH_NF$5I;.K;9 /+AE$
M!^YI6^8GERRC@>"T#?.S2X8I@3K:!OGHDD'TR1YM^WQRPSYR<E'?97/$B]4@
M@?5MXH@?JQ4@T;>*(ZZL9HA+WRZ.^+4E@50[ 7:?<N@5<=N(OV(:DD"<R>0]
MH%"<4>3%"XR3V/-S#\M;92_22R.4!D24RRVSP/PY*#1(:V[EL1T'[UO4H<50
M?Q^#$P/*31Z%(?TFWN\E9><T?4AF:3CR?9I&27R'?4S6@AC;(I(GBM1JHWM5
MCUS"6\0F+$N<"K+M\7Q"S[Q$B8(&-:VJE7NZHS194$;^P8%:'5F-'J@QCN-4
M7X7O2_= ?'E$VJ1*]XK<[KR2*@/%K+)MY32'BUZE?BA3.FC4%?JAA'KH:-:"
M71IF0D]F^_T)MS0F&68IW^%C4A6VG_0CDUSG55G?@P(I =UWC)>7# "[+*IM
MQ*J!^)SK,J6&JN(0#SU-H(Z%RKWKH6<-U+=,D;L^]*R!^E:I']OK:?Z F6F,
M::JA)Q%4-D]#TTQ/4PAJFJ76'-/3)(*:)M&88#H_A^>]Q_ :1P<[:1Z^\ZR>
MC1-W)$+4.F;G'*_2S35)\-=QY%_CY0-F3R"_JI@)0P%G_;R$>%K,DB.ZB7]Z
M2C7QK_ATP7$/9GSV238B$;I 1E6Q;@2]XUV?^0L4X]&<X:R#/16J\,57JCOP
M XH<4</F.4MW^11_R5?@,QIEXOQ.DL59&B=TB9GJ/&+3ZL#V RD.9S+!F4P0
M+6A#>:4'0VOY"4,WCSJ2H.<"#IT>U^DF>C!LZ);H,KPVE$C BP^O&1YB5LT%
MMDA*_>B1:(WC)/.B#(FIPKHVR*D20> <:."&JN>(HG@QB@+QS\7?*5FC4+S%
M@BE! LJ,ZP^<NW!$#9L4S'@_D8GM?@4#1%W0MM#;G>'DGVRJ+^3US2L"5V23
M*VI'V"_W4Y;=:+XY)6%XC_V4D83@N+3+Z%4"X@N(+R"^7B;QI;%"TNI+D"O6
M44-\E8?A"M^CUT],UAU7+ -,&#!A59FPBMC7(A7VDX>YH-D!^#[_DJRQMPJ1
MP1'_.JW8H,>T1'*&*).(>'?_)?XL3C[$P91><//3#99 #>WR#8B5Y2Q.LOL$
MXUO^2#YDQ)./'BF^B5/^S0V-\/;+<\*PSY]9(G^C#0-1V<,DM@7!LXM'[HB(
M$3V9S8B/66%_T"S=C=A3DH3\^>,H(&L2I"B4)-^5EK,DJ@CEW.$POYUF059\
M,,G[;8T6+)PJ\@VQ0,$X%I:Q2?5.9N) 01S%F3DSL^+@C,9)G"6!GR+N#]VB
M3;:BJ*CZAEH=.//MB!IV<RBY#,1/MON=OD0DB?G"6\II:M6Q0";O^_OQB!@Q
M[A7-<S_M=/-L3&2SQ&&JB();[FI*$Y6[>!2$#B#-%-AV8-N!;6^S5Q1[A[3+
M*7[HIE3#'MH K!BZE?02=S7@X]!9>NWNHHW]AVX1?=*^!,NZ8@3IA-P6/>A*
MR$>YDAG M:';1&N.,>3+AVZ3+J.C0SD7!Z*C9M'11NE&BS'3GSV,6$2B>2S.
M%_=B(;*'5Z8["53-V(B:ZLGD3-@4PG86HBY<AH"$F5M^R"BZ>/3#E'>I?!/1
M<I7FW7LRN]CVQ]W94*>;X@;*8CCM/[$O9E1RSKK5!AX,<40-FS&=I\- %4Q4
MEK>@PM8C/\)]I2$I97F(JD!4!:(J$%6!J$JK7%0'_AJMZA*Y8F0-NK@KM]D9
M\KG;?JOIK;AB7=B7 <QC5>91$YM8Y!0_9J=Y1-SIY2/>D$@LK&N#/2P1!"A#
MH S[P:DXHH;M\SK$*-_HGPJC4P78%6!7@%T!=@78E:'CJ,%"2<!1I3A*?Q6W
M"*4^<122H&A.^+OU4!QCXS,>2UJP :N4XM0"5__^8W0UN;\=WUR<XS4.Z0H'
M4^PO(AK2^68DGB;?;VU:MX&]X]<7=Y//%U?CF_^^.)N.3Z\NLL>4[ G7JM"
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M[>%5[#UDV__$?3'!=E-20<%J)&ZCS[1!XK:@0#LD;J.":I&X+9@&2-R^DKA
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M(G.E(S5KJD(:SD%3J1<V79C<7KY07R:DYK(LAY(F!%F6ZJWGIKD#KBQ->ME
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MXG]B.N/?_']02P$"% ,4    " "PF*-.G<PY]"!_  "A1P< $0
M    @ $     86YI:RTR,#$Y,#,S,2YX;6Q02P$"% ,4    " "PF*-.,86\
M/*4/  !;N0  $0              @ %/?P  86YI:RTR,#$Y,#,S,2YX<V10
M2P$"% ,4    " "PF*-.P0CXRV,+   >EP  %0              @ $CCP
M86YI:RTR,#$Y,#,S,5]C86PN>&UL4$L! A0#%     @ L)BC3B7I/BPQ,@
M&E\$ !4              ( !N9H  &%N:6LM,C Q.3 S,S%?9&5F+GAM;%!+
M 0(4 Q0    ( +"8HT[]!P<YKT,  ."> P 5              "  1W-  !A
M;FEK+3(P,3DP,S,Q7VQA8BYX;6Q02P$"% ,4    " "PF*-.0?67Z$,U  !Q
MPP0 %0              @ '_$ $ 86YI:RTR,#$Y,#,S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  '5& 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
